



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/86, A61K 38/00, C07K 16/00, 14/03, A61K 39/00		A3	(11) International Publication Number: WO 99/53047 (43) International Publication Date: 21 October 1999 (21.10.99)
<p>(21) International Application Number: PCT/US99/08220</p> <p>(22) International Filing Date: 15 April 1999 (15.04.99)</p> <p>(30) Priority Data: 60/081,882 15 April 1998 (15.04.98) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): UNIVERSITY OF SASKATCHEWAN [CA/CA]; 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): REDDY, Police, Seshidhar [CA/US]; Apartment #1, 722 Clopper Road, Gaithersburg, MD 20878 (US). TIKOO, Suresh, Kumar [CA/CA]; 302 102 Edinburgh Place, Saskatoon, Saskatchewan S7H 5J7 (CA). BABIUK, Lorne, A. [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA).</p> <p>(74) Agents: BRENNAN, Sean, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 13 January 2000 (13.01.00)</p>	
<p>(54) Title: PORCINE ADENOVIRUS TYPE 3 GENOME</p>			
<p>(57) Abstract</p> <p>The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in prokaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int. Application No PCT/US 99/08220
--

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/86 A61K38/00 C07K16/00 C07K14/03 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	<p>WO 99 08706 A (HAMMOND JEFFREY MICHAEL ; JOHNSON MICHAEL ANTHONY (AU); COMMW SCIEN) 25 February 1999 (1999-02-25) abstract page 5, line 18 - line 23 page 6, line 16 -page 7, line 3 page 7, line 23 -page 8, line 18 page 15, line 12 - line 16 page 26, line 1 -page 23, line 30 claims and figures</p> <p style="text-align: center;">-/-</p>	1-13, 20-118

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "8" document member of the same patent family

Date of the actual completion of the International search

16 November 1999

Date of mailing of the International search report

03/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5018 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 51 651 epo nl.
Fax: (+31-70) 340-3018

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 99/08220

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	REDDY P.S. ET AL.: "Development of porcine adenovirus-3 as an expression vector" JOURNAL OF GENERAL VIROLOGY, vol. 80, no. 3, March 1999 (1999-03), pages 563-570, XP002120921 READING GB the whole document	1-13, 20-118
X,P	REDDY P.S. ET AL.: "Sequence and transcription map analysis of early region-1 of porcine adenovirus type-3" VIRUS RESEARCH, vol. 58, no. 1-2, November 1998 (1998-11), pages 97-106, XP002120922 the whole document	1-13, 20-118
X,P	REDDY P.S. ET AL.: "Nucleotide sequence and transcription map of porcine adenovirus type-3" VIROLOGY, vol. 251, no. 2, 25 November 1998 (1998-11-25), pages 414-426, XP002120923 ORLANDO US the whole document	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112
X,P	DATABASE BIOSIS 'Online' BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US biosis no.: 199800510266, 1998 PARK JONG-HYEON ET AL.: XP002122737 abstract	1-13, 20-118
X,P	& PARK J-H ET AL.: "Sequence analysis of the early region 1 B (EB1B) of porcine adenovirus type 3" RDA JOURNAL OF VETERINARY SCIENCE, vol. 40, no. 1, June 1998 (1998-06), pages 19-25,	1-13, 20-118
X	REDDY P.S. ET AL.: "Characterization of the early region 4 of porcine adenovirus type-3" VIRUS GENES, vol. 15, no. 1, 1997, pages 87-90, XP002120925 the whole document	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/08220

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	REDDY P.S. ET AL.: "Porcine adenoviruses types 1, 2 and 3 have short and simple early E-3 regions" VIRUS RESEARCH, vol. 43, no. 2, 1996, pages 99-109, XP002120926 the whole document	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112
X	TUBOLY T. ET AL.: "Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs" RESEARCH IN VETERINARY SCIENCE, vol. 54, no. 3, 1993, pages 345-350, XP002120927 the whole document	1-13, 20-118
X	REDDY P.S. ET AL.: "Restriction endonuclease analysis and molecular cloning of porcine adenovirus type-3" INTERVIROLOGY, vol. 36, no. 3, 1993, pages 161-168, XP002120928 the whole document	1-13, 20-77, 111-118
X	REDDY P.S. ET AL.: "Sequence analysis of putative pVIII, E3 and fibre regions of porcine adenovirus type 3" VIRUS RESEARCH, vol. 36, no. 1, April 1995 (1995-04), pages 97-106, XP002120929 the whole document	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112
A	KLEIBOEKER S.B. ET AL.: "Genomic cloning and restriction site mapping of a porcine adenovirus isolate: demonstration of genomic stability in porcine adenovirus" ARCHIVES OF VIROLOGY, vol. 133, no. 3-4, 1993, pages 357-368, XP002120930 the whole document	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112
X	REDDY P.S. ET AL.: "Comparison of the inverted terminal repetition sequences from five porcine adenovirus serotypes" VIROLOGY, vol. 212, no. 1, 1995, pages 237-239, XP002120931 ORLANDO US the whole document	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/08220

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Insofar as claims 50–53 57–59 68–74 may be intended as to be directed to a diagnostic method practised on the human/animal body, then objection arises under Rule 39.1.iv PCT (subject-matter under Art. 17.2.a.1), therefore the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 99–110 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/08220

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9908706 A	25-02-1999	AU 8720998 A	08-03-1999



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/00		A2	(11) International Publication Number: WO 99/53047
			(43) International Publication Date: 21 October 1999 (21.10.99)
<p>(21) International Application Number: PCT/US99/08220</p> <p>(22) International Filing Date: 15 April 1999 (15.04.99)</p> <p>(30) Priority Data: 60/081,882 15 April 1998 (15.04.98) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): UNIVERSITY OF SASKATCHEWAN [CA/CA]; 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): REDDY, Police, Seshidhar [CA/US]; Apartment #1, 722 Clopper Road, Gaithersburg, MD 20878 (US). TIKOO, Suresh, Kumar [CA/CA]; 302 102 Edinburgh Place, Saskatoon, Saskatchewan S7H 5J7 (CA). BABIUK, Lorne, A. [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA).</p> <p>(74) Agents: BRENNAN, Sean, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: PORCINE ADENOVIRUS TYPE 3 GENOME</p>			
<p>(57) Abstract</p> <p>The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in prokaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

5

PORCINE ADENOVIRUS TYPE 3 GENOME

TECHNICAL FIELD

The present invention is in the field of recombinant mammalian viral vectors. More particularly, it concerns recombinant porcine adenovirus vectors for diagnostic and therapeutic purposes, such as vaccines and expression systems.

BACKGROUND

Adenoviruses are double-stranded DNA viruses that have been isolated from a wide variety of avian and mammalian species, including swine. While the majority of adenovirus infections in swine are subclinical, porcine adenovirus (PAV) infection has been associated with encephalitis, pneumonia, kidney lesions and diarrhea. Derbyshire (1992) In: "Diseases of Swine" (ed. Leman *et al.*), 7th edition, Iowa State University Press, Ames, IA. pp. 225-227. Thus, there is a need for vaccines that will provide protection against PAV infection.

In addition to their potential ability to provide protection against PAV infection, PAVs could also be used as viral vaccine vectors, if insertion capacity can be determined, and appropriate insertion sites can be defined and characterized. It has been shown that PAV is capable of stimulating both humoral response and a mucosal antibody responses in the intestine of infected piglets.

Tuboly *et al.* (1993) *Res. in Vet. Sci.* 54:345-350. Thus, recombinant PAV vaccine vectors would be especially useful, as they would be likely to be capable of providing both systemic and mucosal immunity to antigens encoded by native and/or recombinant PAV genomes.

Cross-neutralization studies have indicated the existence of at least five serotypes of PAV. Derbyshire *et al.* (1975) *J. Comp. Pathol.* 85:437-443; and

Hirahara *et al.* (1990) *Jpn. J. Vet. Sci.* 52:407-409. Previous studies of the PAV genome have included the determination of restriction maps for PAV Type 3 (PAV-3) and cloning of restriction fragments representing the complete genome of PAV-3. Reddy *et al.* (1993) *Intervirology* 36:161-168. In addition, restriction 5 maps for PAV-1 and PAV-2 have been determined. Reddy *et al.* (1995b) *Arch. Virol.* 140:195-200.

Nucleotide sequences have been determined for segments of the genome of various PAV serotypes. Sequences of the E3, pVIII and fiber genes of PAV-3 were determined by Reddy *et al.* (1995a) *Virus Res.* 36:97-106. The E3, pVIII 10 and fiber genes of PAV-1 and PAV-2 were sequenced by Reddy *et al.* (1996) *Virus Res.* 43:99-109; while the PAV-4 E3, pVIII and fiber gene sequences were determined by Kleiboecker (1994) *Virus Res.* 31:17-25. The PAV-4 fiber gene sequence was determined by Kleiboecker (1995b) *Virus Res.* 39:299-309. Inverted terminal repeat (ITR) sequences for all five PAV serotypes (PAV-1 through PAV- 15 5) were determined by Reddy *et al.* (1995c) *Virology* 212:237-239. The PAV-3 penton sequence was determined by McCoy *et al.* (1996a) *Arch. Virol.* 141:1367- 1375. The nucleotide sequence of the E1 region of PAV-4 was determined by Kleiboecker (1995a) *Virus Res.* 36:259-268. The sequence of the protease (23K) 20 gene of PAV-3 was determined by McCoy *et al.* (1996b) *DNA Seq.* 6:251-254. The unpublished sequence of the PAV-3 hexon gene (and the 14 N-terminal codons of the 23K protease gene) has been deposited in the GenBank database under accession No. U34592. The unpublished sequence of the PAV-3 100K gene has been deposited in the GenBank database under accession No. U82628. The sequence of the PAV-3 E4 region has been determined by Reddy *et al.* (1997) 25 *Virus Genes* 15:87-90.

Adenoviruses have proven to be effective vectors for the delivery and expression of foreign genes in a number of specific applications, and have a number of advantages as potential gene transfer and vaccine vectors. See Gerard *et al* (1993) *Trends Cardiovasc. Med.* 3:171-177; Imler *et al.* (1995) *Hum. Gene Ther.* 6:711-721. The ability of these vectors to mediate the efficient expression 30

of candidate therapeutic or vaccine genes in a variety of cell types, including post mitotic cells, is considered an advantage over other gene transfer vectors.

Adenoviral vectors are divided into helper-independent and helper-dependent groups based on the region of the adenoviral genome used for the insertion of transgenes. Helper-dependent vectors are usually made by deletion of E1 sequences and substitution of foreign DNA, and are produced in complementing human cell lines that constitutively express E1 proteins. Graham *et al.* (1977) *J. Gen. Virol.* 36:59-74; Fallaux *et al.* (1996) *Hum. Gene Ther.* 7:215-222; Fallaux *et al.* (1998) *Hum. Gene Ther.* 9:1909-1917. However, porcine adenoviruses do not replicate in human cell lines; hence these lines are unsuitable for the propagation of E1-deleted PAV vectors.

Though E1-deleted viruses do not replicate in cells that do not express E1 proteins, the viruses can express foreign proteins in these cells, provided the genes are placed under the control of a constitutive promoter. Xiang *et al.* (1996) *Virology* 219:220-227. Vaccination of animals with adenovirus recombinants containing inserts in the E1 region induced a systemic immune response and provided protection against subsequent challenge. Imler *et al.* (1995) *Hum. Gene Ther.* 6:711-721; Imler *et al.* (1996) *Gene Therap* 3:75-84.. This type of expression vector provides a significant safety profile to the vaccine as it eliminates the potential for dissemination of the vector within the vaccinee and therefore, the spread of the vector to nonvaccinated contacts or to the general environment. However, the currently used human adenovirus (HAV) based vectors are endemic in most populations, which provides an opportunity for recombination between the helper-dependent viral vectors and wild type viruses.

To circumvent some of the problems associated with the use of human adenoviruses, non human adenoviruses have been explored as possible expression vectors. All vectors developed to date, except one (Klonjkowski *et al.* (1997) *Hum. Gene Ther.* 8:2103-2115), contain an intact E1 region. Use of such vectors for gene therapy in humans and vaccination in animals is unsafe because they

have the ability to replicate in normal cells, and they retain the oncogenic potential of the E1 region.

Recombinant PAV genomes containing heterologous nucleotide sequences have not yet been described. Similarly, sites where insertion of heterologous sequence would not interfere with the ability of a PAV vector to stimulate an immune response against a determinant encoded by an inserted sequence have not been identified. Consequently, the development of effective recombinant PAV vectors for use in immunization, expression systems and gene therapy, awaits resolution of these issues. Similarly, there is a need for improved adenoviral vectors lacking E1 replication and oncogenic functions, for expression of transgenes in mammalian cells.

SUMMARY OF THE INVENTION

The present invention provides the complete nucleotide sequence of the porcine adenovirus type 3 (PAV-3) genome. Nucleic acid sequences that are substantially homologous to those comprising a PAV genome are also encompassed by the invention. Substantially homologous sequences include those capable of duplex and/or triplex formation with a nucleic acid comprising all or part of a PAV genome (or with its complement). As is known to those of skill in the art, duplex formation is influenced by hybridization conditions, particularly hybridization stringency. Factors affecting hybridization stringency are well-known to those of skill in the art. *See, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual; Hames et al. 1985) Nucleic Acid Hybridisation: A Practical Approach, IRL Press Ltd., Oxford* Accordingly, it is within the skill of the art to identify a sequence that is substantially homologous to a sequence from a PAV genome.

In addition, novel porcine adenovirus (PAV) expression vector systems comprising PAV genome sequences are disclosed herein. The PAV-3 sequence includes regions into which heterologous sequences can be inserted including, but not limited to, the E1, E3 and E4 regions, and the region between E4 and the right

end of the genome. The invention also provides non-essential regions which can be deleted to increase the capacity of a PAV vector for inserted heterologous sequences. These include, but are not limited to, the E3 and E4 regions, and the region between E4 and the right end of the genome. Essential regions, such as E1, 5 can also be deleted, if virus bearing such deletions are propagated in helper cell lines supplying the deleted essential function. Thus, PAV genome sequences can be replaced by one or more foreign genes to generate recombinant PAV vectors expressing heterologous antigenic polypeptides (or antigenic fragments thereof) for the purposes of producing live recombinant virus, subunit vaccines, nucleic 10 acid immunization, or other types of therapy. Multiple heterologous sequences can be inserted into the same, or different, locations in the genome, limited only by the capacity of the virus to accept heterologous sequences. This capacity can be expanded by deletion of viral sequences.

In addition, the invention provides PAV transcriptional and translational 15 regulatory sequences which can be used for expression of heterologous genes that have been inserted into the vectors of the invention. Furthermore, the novel sequences of the present invention can be used for diagnostic purposes, to determine the presence of PAV antigens and/or PAV nucleic acids in a subject or biological sample.

20 In additional embodiments, the invention provides compositions providing immunity to PAV infection, through expression of antigenic PAV polypeptides. The invention also provides vectors comprising PAV genome sequences, including sequences encoding various PAV genes as well as PAV regulatory sequences, which are useful for controlling the expression of heterologous genes 25 inserted into PAV vectors.

The invention provides defective recombinant PAV vectors that are deleted in their E1 region, as well as helper cell lines providing E1 function, in which such defective vectors can be propagated. Because these defective vectors replicate inefficiently in cells other than the helper cells, they are less likely to 30 stimulate an immune response in a mammalian host. This makes them

particularly suitable for use as vaccine vectors. In addition, since the amount of nucleic acid that can be packaged into an adenovirus virion is limited, deletion of the E1 region expands the capacity of these defective vectors, enabling them to accept larger inserts of heterologous sequence. Additional deletions in other 5 regions of the genome can be used to expand the capacity of these defective vectors still further.

The invention further provides methods for obtaining recombinant PAV vectors. In a preferred embodiment, heterologous nucleotide sequences are introduced, through recombinant DNA techniques, into a bacterial plasmid 10 comprising a defined portion of the PAV genome. The recombinant plasmid, containing heterologous sequences flanked by PAV sequences, is introduced into a host cell in combination with a full-length PAV genome or a plasmid containing a full-length or nearly full-length PAV genome. Within the host cell, recombination between the plasmid and the PAV genome generates a recombinant 15 PAV genome. Alternatively, recombinant PAV genomes can be constructed *in vitro*, using standard techniques in molecular biology and biotechnology.

The invention also provides methods for preparing live recombinant virus and subunit vaccines for inducing protective immune responses to an infectious organism in a mammalian subject. Protective immune responses include humoral 20 (antibody) responses, cell-mediated responses, mucosal responses, or any combination of these. The methods involve insertion, into the porcine adenovirus genome, of heterologous nucleotide sequences encoding one or more protective antigenic determinants of a pathogen. The heterologous sequences are inserted in such a way as to come under the regulatory control of a PAV promoter, or the 25 heterologous sequences are inserted in operative linkage to a eukaryotic transcriptional regulatory sequence. Translation of transcribed heterologous sequences can be controlled by PAV translational regulatory elements, or the heterologous sequence can include non-PAV sequences which regulate its translation.

In another aspect, the invention includes the use of recombinant porcine adenoviruses and recombinant PAV vectors for the expression of a nucleotide or amino acid sequence of interest in a cell system, such as, for example, production of antigen to be used in the preparation of antibodies, or production of antisense RNA.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein heterologous nucleotide sequences are inserted. The inserted heterologous sequences can comprise one or more regulatory elements for transcription and/or translation, or can be inserted so as to come under the control of PAV regulatory elements. Inserted regulatory elements can be those that are normally associated with the heterologous sequence, or a heterologous sequence can be juxtaposed to and placed in operative linkage with a regulatory element with which it is not normally associated, using standard recombinant DNA techniques. Heterologous sequences can be inserted into a full-length PAV genome, or into a PAV genome which has been deleted in one or more regions. A deletion in the PAV genome can be made to provide a site for insertion of a heterologous sequence, or simply to increase the capacity of the PAV vector to accommodate heterologous sequences inserted at another location.

The invention also provides recombinant PAV polypeptides including, but not limited to, those encoded by the following genes: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K. Such recombinant PAV polypeptides are produced in any eukaryotic expression vector known in the art, into which is inserted a PAV nucleotide sequence according to the invention. Also provided are methods and compositions for recombinant production of heterologous polypeptides and RNAs in a PAV vector. Expression of heterologous polypeptides and RNAs in a PAV vector can be regulated by endogenous PAV regulatory sequences, or by non-PAV sequences. Non-PAV regulatory sequences can be those which normally regulate the heterologous sequence, or they can be sequences that are not normally associated with the heterologous sequence in a regulatory capacity.

Thus, in one embodiment, the invention includes an expression system in which one or more regions of the PAV genome are deleted and replaced with heterologous sequences. In another embodiment, the invention includes a PAV expression system in which heterologous sequences are introduced into the PAV genome without the removal of any PAV sequences. Intergenic regions of the PAV genome comprising regulatory sequences are useful in the practice of the invention for controlling the expression of homologous and heterologous sequences.

The invention also includes recombinant vector systems comprising two or more nucleic acid molecules. In one embodiment, the vector system comprises two plasmids, the first containing a full-length or nearly full-length PAV genome and the second containing a segment of the PAV genome, such as the left end (including the E1 region) or the right end (including the E3 and/or E4 regions). Introduction of heterologous nucleotide sequences into the second plasmid, followed by co-transfection of both plasmids into a suitable host cell, will allow homologous recombination between the two plasmids to generate a viral genome containing inserted heterologous sequences. In another embodiment, the vector system comprises a full-length or nearly full-length PAV genome and a plasmid containing a segment of the PAV genome. Insertion of heterologous sequences into the plasmid, followed by co-transfection and homologous recombination, will generate recombinant PAV genomes as above.

Additional aspects of the invention provide a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes an antigenic determinant of a disease-causing organism; and a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes a foreign gene or fragment thereof. In further embodiments, the invention provides pharmaceutical compositions comprising recombinant PAV for producing an immune response in a mammalian host, the recombinant PAV comprising a heterologous nucleotide sequence encoding a protective determinant of a pathogenic organism. The heterologous sequence is expressed in quantities

sufficient for induction of a protective immune response, either through operative linkage to one or more non-PAV regulatory sequences, or through control by endogenous PAV regulatory sequences. The protective immune response can be humoral, cell-mediated and/or mucosal.

5 The recombinant PAV vectors of the invention will also allow the expression of various therapeutic polypeptides in a wide range of mammalian hosts and are thus useful in the practices of nucleic acid immunization and gene therapy. Exemplary hosts include, but are not limited to, human, equine, bovine, porcine, ovine, caprine, avian, and murine. Those of skill in the art are aware of
10 various therapeutic polypeptides which can be usefully expressed in mammalian hosts. Such therapeutic polypeptides include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane
15 conductance regulator (CFTR) and immunogenic polypeptides.

The invention also provides diagnostic methods and compositions for the detection of PAV nucleic acids and proteins in a cell or biological sample. The PAV nucleotide sequences disclosed herein can be used as hybridization probes to detect PAV nucleic acids. In addition, the PAV nucleotide sequences disclosed
20 herein encode PAV polypeptides, which can be used for the production of antibodies reactive with various PAV antigens. Such antibodies can be used to detect PAV antigens by immunoassay. Alternatively, PAV polypeptides themselves can be used in competitive immunoassays to detect the presence of PAV antigens in a cell or biological sample. PAV polypeptides can be produced
25 by the PAV vectors of the invention, or can be produced in any mammalian expression vector known in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the complete nucleotide sequence of the PAV-3 genome
30 (SEQ ID NO: 1).

Figure 2 shows the transcriptional map of the PAV-3 genome derived from alignment of the sequences of cDNA clones with the genomic sequence, and nuclease protection mapping of viral transcripts. The PAV-3 genome is represented by the thick horizontal line, with the numbers below the line 5 representing PAV-3 map units (*i.e.*, percentage of genome length from the left end). Rightward-reading transcription units are depicted above the line and leftward-reading transcription units are shown below the line.

Figure 3 shows immunoprecipitation of E1A and E1B proteins from various cell lines.

10 In Figure 3A, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP11 monoclonal antibody, which recognizes the human adenovirus E1A protein. Lane 1: 293 cells (human cells transformed by HAV-5, which express adenovirus E1A and E1B); Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

15 In Figure 3B, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP17 monoclonal antibody, which recognizes the human adenovirus E1B protein. Lane 1: human 293 cells; Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

Figure 4 shows a map of the plasmid pPAV-101.

20 **Figure 5** shows a map of the plasmid pPAV-102.

Figure 6 shows a map of the plasmid pPAV-300.

Figure 7 shows proteins labeled after infection of VIDO R1 cells with a recombinant PAV containing the PRV gp50 gene inserted in the E3 region. Labeled proteins were separated by gel electrophoresis; an autoradiogram of the 25 gel is shown. Lane 1: Molecular weight markers of 30K, 46K, 69K and 96K, in order of increasing molecular weight. Lane 2: Mock-infected cells, 12 hours post-infection. Lane 3: PAV-3-infected cells, 12 hours post-infection. Lane 4: cells infected with a recombinant PAV containing the PRV gp50 gene, 12 hours post-infection. Lane 5: cells infected with a recombinant PAV containing the PRV

gp50 gene, 16 hours post-infection. Lane 6: cells infected with a recombinant PAV containing the PRV gp50 gene, 24 hours post-infection.

Figure 8 provides a schematic diagram of the construction of an E1- and E3-deleted PAV vector with a green fluorescent protein gene insertion.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the complete nucleotide sequence and transcriptional map of the porcine adenovirus type 3 (PAV-3) genome. The sequence comprises a linear, double-stranded DNA molecule of about 34,094 base pairs, as shown in Figure 1 (SEQ ID NO: 1). Previously-determined partial sequences can be aligned with the complete genomic sequence as shown in Table 1.

Table 1. Alignment of published PAV-3 sequences

GenBank Accession No.	PAV Gene(s) included within sequence	Reference	Genome coordinates
L43077	ITR	Reddy et al., 1995 <i>c</i>	1-144
U24432	penton	McCoy et al., 1996 <i>a</i>	13556-15283
U34592	hexon; N-terminal 14 codons of 23K (protease) gene	unpublished	19036-21896
U33016	protease (23K)	McCoy et al., 1996 <i>b</i>	21897-22676
U82628	100K	unpublished	24056-26572
U10433	E3, pVIII, fiber	Reddy et al., 1995 <i>a</i>	27089-31148
L43363	E4	Reddy et al., 1997	31064-34094

15 Knowledge of the PAV genome sequence is useful for both therapeutic and diagnostic procedures. Regions suitable for insertion and regulated expression of heterologous sequences have been identified. These regions include, but are not limited to the E1, E3 and E4 regions, and the region between the E4 region and the right end of the genome. A heterologous nucleotide

sequence, with respect to the PAV vectors of the invention, is one which is not normally associated with PAV sequences as part of the PAV genome.

Heterologous nucleotide sequences include synthetic sequences. Regions encoding immunogenic PAV polypeptides, for use in immunodiagnostic

5 procedures, have also been identified and are disclosed herein. These include the regions encoding the following PAV proteins: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, 33K, pVIII, hexon and fiber (see Table 2). Regions essential for viral replication, such as E1 and E2A, can be deleted to provide attenuated strains for use as vaccines. Nonessential regions,

10 such as parts of the E3 and E4 regions, can be deleted to provide insertion sites, or to provide additional capacity for insertion at a site other than the deleted region. Deletions of viral sequences can be obtained by any method known in the art, including but not limited to restriction enzyme digestion and ligation, oligonucleotide-mediated deletion mutagenesis, and the like.

15 The practice of the present invention employs, unless otherwise indicated, conventional microbiology, immunology, virology, molecular biology, and recombinant DNA techniques which are within the skill of the art. These techniques are fully explained in the literature. See, e.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual* (1982); *DNA Cloning: A Practical Approach*, vols. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed. 20 (1984)); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds. (1985)); *Transcription and Translation* (B. Hames & S. Higgins, eds. (1984)); *Animal Cell Culture* (R. Freshney, ed. (1986)); Perbal, *A Practical Guide to Molecular Cloning* (1984); Ausubel, et al., *Current Protocols In Molecular Biology*, John Wiley & Sons (1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996); 25 and Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition); vols. I, II & III (1989).

**Nucleotide Sequence, Genome Organization, and Transcription Map
of Porcine Adenovirus Type 3 (PAV-3).**

The complete nucleotide sequence of PAV-3 genome is 34,094 base pairs (bp) in length and has a base composition of 31.3% G, 32.5% C, 18.3% A, and 17.9% T. Thus, the sequence of the PAV-3 genome has a G+C content of 63.8%, which is unusually high when compared with the G+C content of many other animal adenoviruses. The genome termini share inverted terminal repeats (ITR) of 144 bp. Reddy *et al.*, 1995c, *supra*. The organization of the genome as determined by analysis of open reading frames (ORFs), nuclease protection mapping, and sequencing of cDNA clones, is summarized in Table 2 and Figure 2.

One important feature of PAV-3 genome is the presence of a short virion associated (VA) RNA gene between the splice acceptor sites of the precursor terminal protein (pTP) and 52 kDa protein genes (Figure 2). Expression of VA genes increases the kinetics of viral replication; thereby providing the potential for higher yields of recombinant gene products using the PAV vectors of the invention. The locations of the signature sequences present upstream and downstream of VA RNA genes indicate the VA RNA gene of PAV-3 is about 126 nucleotides (nt) in length. This is somewhat shorter than most VA RNAs, whose lengths are 163 ± 14 nts, however shorter VA RNAs have also been reported in HAV-10 and CELO virus. Ma *et al.* (1996) *J. Virol.* 70:5083-5099; and Chiocca *et al.* (1996) *J. Virol.* 70:2939-2949. The VA RNA genes were not found in the genomes of BAV-3, CAV-1, and OAV. Reddy *et al.* (1998) *J. Virol.* 72:1394-1402; Morrison *et al.* (1997) *J. Gen. Virol.* 78:873-878; and Vrati *et al.* (1996) *Virology* 220:186-199.

In PAV-3 the major late transcript initiates at 17.7 map units (m.u.: an adenovirus map unit is 1% of genome length, starting from the left end of the genome). There are six 3'-coterminal families of late mRNAs, denoted L1 to L6 (see Figure 2). All mRNAs produced from the major late promoter (MLP) contain a tripartite leader sequence (TPL). The first portion of the TPL lies next

to the MLP and is 61 nts long. The second portion lies within the gene coding for pol and is 68 nt in length. The third portion is 99 nts long and is located within the gene coding for pTP. Thus the TPL of PAV-3 is 228 nt long and is derived from three exons located at 17.7, 20.9, and 28.1 m.u.

- 5 The MLP and TPL sequences can be used for expression of a heterologous sequence in a recombinant PAV vector or in any other adenoviral expression system.

Table 2: Transcriptional and Translational Features of the PAV-3 Genome

Region	Gene	Transcription start site	ATG	Splice donor site	Splice acceptor site	Poly(A) signal	Poly(A) addition site
E1A	229R 214R	heterogeneous 533 533	1043	1140		1286 1286	1307 1307
E1B	202R 474R	1382 1382	1461 1829			4085 4085	4110, 4112 4110, 4112
pIX		3377	3394			4085	4110, 4112
E2A	DBP	1701c	24041c	26949c, 24714c	24793c, 24051c	22560c	22536c
E2B	pTP pol	1701c 1701c	13638c 13638c	24949c, 24714c 24949c, 24714c	24793c, 13772c 24793†c, 13772†c	4075c 4075c	4053c 4053c
IVa2	IVa2	5867c	5711c	5699c	5441c	4075c	4053c
E3		27473				28765	28793
E4		33730c				31189c	31170c
L1	52K III A	6064	10629	9684	10606	13601	13627
L2	pII pVII	6064	11719	9684	11715	13601	13627
L3	pV pX pVI	6064	13662	9684	13662	15698*	15735
L4	Hexon Protease	6064	15170	9684	15139	15698*	15735
L5		6064	15819	9684	15793	18992	19013
L6	Fiber	6064	17783 18076	9684 9684	17776 18063	18992 18992	19013 19013

Notes:

* TTGGTTT is present as a polyadenylation signal instead of AATAAA.

† The splice acceptor sites for the *pol* and protease genes were determined based on consensus splice acceptor sequences "c" refers to sequences on the complementary (leftward-reading) strand of the PAV genome.

Construction of recombinant PAV vectors

In one embodiment of the invention, a recombinant PAV vector is constructed by *in vivo* recombination between a plasmid and a PAV genome. Generally, heterologous sequences are inserted into a plasmid vector containing a portion of the PAV genome, which may or may not possess one or more deletions of PAV sequences. The heterologous sequences are inserted into the PAV insert portion of the plasmid vector, such that the heterologous sequences are flanked by PAV sequences that are adjacent on the PAV genome. The PAV sequences serve as "guide sequences," to direct insertion of the heterologous sequences to a particular site in the PAV genome; the insertion site being defined by the genomic location of the guide sequences.

The vector is generally a bacterial plasmid, allowing multiple copies of the cloned sequence to be produced. In one embodiment, the plasmid is co-transfected, into an appropriate host cell, with a PAV genome comprising a full-length or nearly full-length PAV genomic sequence. The PAV genome can be isolated from PAV virions, or can comprise a PAV genome that has been inserted into a plasmid, using standard techniques of molecular biology and biotechnology. Construction of a plasmid containing a PAV genome is described in Example 2, *infra*. Nearly full-length PAV genomic sequences can be deleted in regions such as E1, E3, E4 and the region between E4 and the right end of the genome, but will retain sequences required for replication and packaging. PAV genomes can be deleted in essential regions if the essential function can be supplied by a helper cell line.

Insertion of the cloned heterologous sequences into a viral genome occurs by *in vivo* recombination between a plasmid vector (containing heterologous sequences flanked by PAV guide sequences) and a PAV genome following co-transfection into a suitable host cell. The PAV genome contains inverted terminal repeat (ITR) sequences required for initiation of viral DNA replication (Reddy *et al.* (1995c), *supra*), and sequences involved in packaging of replicated viral genomes. Adenovirus packaging signals generally lie between the left ITR and

the E1A promoter. Incorporation of the cloned heterologous sequences into the PAV genome thus places the heterologous sequences into a DNA molecule containing viral replication and packaging signals, allowing generation of multiple copies of a recombinant PAV genome that can be packaged into infectious viral particles. Alternatively, incorporation of the cloned heterologous sequences into a PAV genome places these sequences into a DNA molecule that can be replicated and packaged in an appropriate helper cell line. Multiple copies of a single sequence can be inserted to improve yield of the heterologous gene product, or multiple heterologous sequences can be inserted so that the recombinant virus is capable of expressing more than one heterologous gene product. The heterologous sequences can contain additions, deletions and/or substitutions to enhance the expression and/or immunological effect of the expressed gene product(s).

Attachment of guide sequences to a heterologous sequence can also be accomplished by ligation *in vitro*. In this case, a nucleic acid comprising a heterologous sequence flanked by PAV guide sequences can be co-introduced into a host cell along with a PAV genome, and recombination can occur to generate a recombinant PAV vector. Introduction of nucleic acids into cells can be achieved by any method known in the art, including, but not limited to, microinjection, transfection, electroporation, CaPO₄ precipitation, DEAE-dextran, liposomes, particle bombardment, *etc.*

In one embodiment of the invention, a recombinant PAV expression cassette can be obtained by cleaving a wild-type PAV genome with an appropriate restriction enzyme to produce a PAV restriction fragment representing, for example, the left end or the right end of the genome comprising E1 or E3 gene region sequences, respectively. The PAV restriction fragment can be inserted into a cloning vehicle, such as a plasmid, and thereafter at least one heterologous sequence (which may or may not encode a foreign protein) can be inserted into the E1 or E3 region with or without an operatively-linked eukaryotic transcriptional regulatory sequence. The recombinant expression cassette is

contacted with a PAV genome and, through homologous recombination or other conventional genetic engineering methods, the desired recombinant is obtained. In the case wherein the expression cassette comprises the E1 region or some other essential region, recombination between the expression cassette and a PAV 5 genome can occur within an appropriate helper cell line such as, for example, an E1-transformed cell line. Restriction fragments of the PAV genome other than those comprising the E1 or E3 regions are also useful in the practice of the invention and can be inserted into a cloning vehicle such that heterologous sequences can be inserted into the PAV sequences. These DNA constructs can 10 then undergo recombination *in vitro* or *in vivo*, with a PAV genome either before or after transformation or transfection of an appropriate host cell.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein a heterologous nucleotide sequence, e.g. DNA, replaces part or all of the E3 region, part or all of the E1 region, part or all 15 of the E2 region, part or all of the E4 region, part or all of the late region and/or part or all of the regions occupied by the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes. The expression system can be used wherein the foreign nucleotide sequences, e.g. DNA, are optionally in operative linkage with a eukaryotic transcriptional regulatory sequence. PAV expression 20 vectors can also comprise inverted terminal repeat (ITR) sequences and packaging sequences.

The PAV E1A, E1B, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, 25 pX, pVI, and 33K genes are essential for viral replication. Therefore, PAV vectors comprising deletions in any of these genes, or which lack functions encoded by any of these genes, are grown in an appropriate complementing cell line (*i.e.*, a helper cell line). Most, if not all, of the open reading frames in the E3 and E4 regions of PAV-3 are non-essential for viral replication and, therefore, 30 deletions in these regions can be constructed for insertion or to increase vector capacity, without necessitating the use of a helper cell line for growth of the viral vector.

In another embodiment, the invention provides a method for constructing a full-length clone of a PAV genome by homologous recombination *in vivo*. In this embodiment, two or more plasmid clones, containing overlapping segments of the PAV genome and together covering the entire genome, are introduced into an appropriate bacterial host cell. Approximately 30 base pairs of overlap is required for homologous recombination in *E. coli*. Chartier *et al.* (1996) *J. Virol.* 70:4805-4810. Through *in vivo* homologous recombination, the PAV genome segments are joined to form a full-length PAV genome. In a further embodiment, a recombinant plasmid containing left-end sequences and right-end sequences of the PAV genome, separated by a unique restriction site, is constructed. This plasmid is digested with the restriction enzyme recognizing the unique restriction site, to generate a unit-length linear plasmid, which is introduced into a cell together with a full-length PAV genome. Homologous recombination within the cell will result in production of a recombinant plasmid containing a full-length PAV genome.

Recombinant plasmids will also generally contain sequences specifying replication in a host cell and one or more selective markers, such as, for example, antibiotic resistance.

Suitable host cells include any cell that will support recombination between a PAV genome and a plasmid containing PAV sequences, or between two or more plasmids, each containing PAV sequences. Recombination is generally performed in prokaryotic cells, such as *E. coli*, while transfection of a plasmid containing a viral genome, to generate virus particles, is conducted in eukaryotic cells, preferably mammalian cells, most preferably porcine cell cultures. The growth of bacterial cell cultures, as well as culture and maintenance of eukaryotic cells and mammalian cell lines are procedures which are well-known to those of skill in the art.

In one embodiment of the invention, a defective recombinant PAV vector is used for expression of heterologous sequences. The defective vector will be deleted in all or part of the E1 region. Construction of a deletion in the E1 region of PAV is described in Example 3, *infra*. Heterologous sequences can be inserted

so as to replace the deleted E1 region, and/or can be inserted at other sites in the PAV genome, preferably E3, E4 and/or the region between E4 and the right end of the genome. Defective vectors with E1 deletions are grown in helper cell lines, which provide E1 function.

- 5 Accordingly, in one embodiment of the invention, a number of recombinant helper cell lines are produced according to the present invention by constructing an expression cassette comprising an adenoviral E1 region and transforming host cells therewith to provide complementing cell lines or cultures providing E1 functions. The terms "complementing cell," "complementing cell 10 line," "helper cell" and "helper cell line" are used interchangeably herein to denote a cell line that provides a viral function that is deficient in a deleted PAV, preferably E1 function. These recombinant complementing cell lines are capable of allowing a defective recombinant PAV, having a deleted E1 gene region, wherein the deleted sequences are optionally replaced by heterologous nucleotide 15 sequences, to replicate and express one or more foreign genes or fragments thereof encoded by the heterologous nucleotide sequences. PAV vectors with E1 deletions, wherein heterologous sequences are inserted in regions other than E1, can also be propagated in these complementing cell lines, and will express the heterologous sequences if they are inserted downstream of a PAV promoter or are 20 inserted in operative linkage with a eukaryotic regulatory sequence. Preferred helper cell lines include VIDO R1 cells, as described in Example 1, *infra*. Briefly, the VIDO R1 cell line is a porcine retinal cell line that has been transfected with DNA from the human adenovirus type 5 (HAV-5) E1 region, and which supports the growth of PAV E1A deletions and HAV-5 E1 deletions.
- 25 Transformation of porcine cells with either PAV or HAV has not been reported due to the fact that exposure of permissive or semi-permissive cells to adenovirus normally leads to lysis of infected cells. Graham *et al.*, *supra*. The approach used in the present study to create a PAV E1-complementing cell line employing the E1 region of HAV-5 is novel as E1A proteins of HAV-5 have been 30 shown for the first time to complement PAV-3 E1 mutants. There are several

reasons that the E1 region of HAV-5 was used for transformation of porcine embryonic retinal cells. The E1 region of HAV-5 was shown to transform human retina cells very efficiently. Fallaux *et al.* (1998) *supra*. In contrast to the E1 region of PAV-3, the E1 region of HAV-5 has been thoroughly characterized and
5 the monoclonal antibodies against the E1 proteins are readily available from commercial sources. In addition, the E1A region of HAV-5 was shown to complement the E1A functions of several non-human adenoviruses. Ball *et al.* (1988) *J. Virol.* 62:3947-3957; Zheng *et al.* (1994) *Virus Res.* 31:163-186.

More generally, defective recombinant PAV vectors, lacking one or more
10 essential functions encoded by the PAV genome, can be propagated in appropriate complementing cell lines, wherein a particular complementing cell line provides a function or functions that is (are) lacking in a particular defective recombinant PAV vector. Complementing cell lines can provide viral functions through, for example, co-infection with a helper virus, or by integrating or otherwise
15 maintaining in stable form a fragment of a viral genome encoding a particular viral function.

In another embodiment of the invention, E1 function (or the function of any other viral region which may be mutated or deleted in any particular viral vector) can be supplied (to provide a complementing cell line) by co-infection of
20 cells with a virus which expresses the function that the vector lacks.

PAV expression systems

In one embodiment, the present invention identifies and provides means of deleting regions of the PAV genome, to provide sites into which heterologous or
25 homologous nucleotide sequences encoding foreign genes or fragments thereof can be inserted to generate porcine adenovirus recombinants. In preferred embodiments, deletions are made in part or all of the nucleotide sequences of the PAV E1, E3, or E4 regions and/or the region between E4 and the right end of genome. E1 deletion is described in Example 3; E3 deletion and insertion of
30 heterologous sequence in the E3 region are described in Example 4 and 5; and

insertion of a heterologous sequence between the E4 region and the right end of the PAV genome, as well as expression of the inserted sequence, is described in Example 6, *infra*.

In another embodiment, the invention identifies and provides additional regions of the PAV genome (and fragments thereof) suitable for insertion of heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof to generate PAV recombinants. These regions include nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,573-27,088; and 31,149-34,094 and comprise the E2 region, the late region, and genes encoding the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K proteins. These regions of the PAV genome can be used, among other things, for insertion of foreign sequences, for provision of DNA control sequences including transcriptional and translational regulatory sequences, or for diagnostic purposes to detect the presence, in a biological sample, of viral nucleic acids and/or proteins encoded by these regions. Example 7, *infra*, describes procedures for constructing insertions in these regions.

One or more heterologous sequences can be inserted into one or more regions of the PAV genome to generate a recombinant PAV vector, limited only by the insertion capacity of the PAV genome and ability of the recombinant PAV vector to express the inserted heterologous sequences. In general, adenovirus genomes can accept inserts of approximately 5% of genome length and remain capable of being packaged into virus particles. The insertion capacity can be increased by deletion of non-essential regions and/or deletion of essential regions whose function is provided by a helper cell line.

In one embodiment of the invention, insertion can be achieved by constructing a plasmid containing the region of the PAV genome into which insertion is desired. The plasmid is then digested with a restriction enzyme having a recognition sequence in the PAV portion of the plasmid, and a heterologous sequence is inserted at the site of restriction digestion. The plasmid, containing a portion of the PAV genome with an inserted heterologous sequence,

in co-transformed, along with a plasmid (such as pPAV-200) containing a full-length PAV genome, into a bacterial cell (such as, for example, *E. coli*), wherein homologous recombination between the plasmids generates a full-length PAV genome containing inserted heterologous sequences.

5 Deletion of PAV sequences, to provide a site for insertion of heterologous sequences or to provide additional capacity for insertion at a different site, can be accomplished by methods well-known to those of skill in the art. For example, for PAV sequences cloned in a plasmid, digestion with one or more restriction enzymes (with at least one recognition sequence in the PAV insert) followed by
10 ligation will, in some cases, result in deletion of sequences between the restriction enzyme recognition sites. Alternatively, digestion at a single restriction enzyme recognition site within the PAV insert, followed by exonuclease treatment, followed by ligation will result in deletion of PAV sequences adjacent to the restriction site. A plasmid containing one or more portions of the PAV genome
15 with one or more deletions, constructed as described above, can be co-transfected into a bacterial cell along with a plasmid containing a full-length PAV genome to generate, by homologous recombination, a plasmid containing a PAV genome with a deletion at a specific site. PAV virions containing the deletion can then be obtained by transfection of mammalian cells (such as ST or VIDO R1 cells) with
20 the plasmid containing a PAV genome with a deletion at a specific site.

Expression of an inserted sequence in a recombinant PAV vector will depend on the insertion site. Accordingly, preferred insertion sites are adjacent to and downstream (in the transcriptional sense) of PAV promoters. The transcriptional map of PAV, as disclosed herein, provides the locations of PAV
25 promoters. Locations of restriction enzyme recognition sequences downstream of PAV promoters, for use as insertion sites, can be easily determined by one of skill in the art from the PAV nucleotide sequence provided herein. Alternatively, various *in vitro* techniques can be used for insertion of a restriction enzyme recognition sequence at a particular site, or for insertion of heterologous
30 sequences at a site that does not contain a restriction enzyme recognition

sequence. Such methods include, but are not limited to, oligonucleotide-mediated heteroduplex formation for insertion of one or more restriction enzyme recognition sequences (see, for example, Zoller *et al.* (1982) *Nucleic Acids Res.* 10:6487-6500; Brennan *et al.* (1990) *Roux's Arch. Dev. Biol.* 199:89-96; and 5 Kunkel *et al.* (1987) *Meth. Enzymology* 154:367-382) and PCR-mediated methods for insertion of longer sequences. See, for example, Zheng *et al.* (1994) *Virus Research* 31:163-186.

It is also possible to obtain expression of a heterologous sequence inserted at a site that is not downstream from a PAV promoter, if the heterologous 10 sequence additionally comprises transcriptional regulatory sequences that are active in eukaryotic cells. Such transcriptional regulatory sequences can include cellular promoters such as, for example, the bovine hsp70 promoter and viral promoters such as, for example, herpesvirus, adenovirus and papovavirus promoters and DNA copies of retroviral long terminal repeat (LTR) sequences.

15 In another embodiment, homologous recombination in a prokaryotic cell can be used to generate a cloned PAV genome; and the cloned PAV-3 genome can be propagated as a plasmid. Infectious virus can be obtained by transfection of mammalian cells with the cloned PAV genome rescued from plasmid-containing cells. Example 2, *infra* describes construction of an infectious plasmid 20 containing a PAV-3 genome.

The invention provides PAV regulatory sequences which can be used to regulate the expression of heterologous genes. A regulatory sequence can be, for example, a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a 25 transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.

Therapeutic genes and polypeptides

The PAV vectors of the invention can be used for the expression of 30 therapeutic polypeptides in applications such as *in vitro* polypeptide production,

vaccine production, nucleic acid immunization and gene therapy, for example. Therapeutic polypeptides comprise any polypeptide sequence with therapeutic and/or diagnostic value and include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

In a preferred embodiment, PAV vectors will contain heterologous sequences encoding protective determinants of various pathogens of swine, for 10 use in subunit vaccines and nucleic acid immunization. Representative swine pathogen antigens include, but are not limited to, pseudorabies virus (PRV) gp50; transmissible gastroenteritis virus (TGEV) S gene; porcine rotavirus VP7 and VP8 genes; genes of porcine respiratory and reproductive syndrome virus (PRRS), in particular ORF 5; genes of porcine epidemic diarrhea virus; genes of 15 hog cholera virus, and genes of porcine parvovirus.

Various foreign genes or nucleotide sequences or coding sequences (prokaryotic, and eukaryotic) can be inserted into a PAV vector, in accordance with the present invention, particularly to provide protection against a wide range of diseases. Many such genes are already known in the art; the problem 20 heretofore having been to provide a safe, convenient and effective vaccine vector for the genes or sequences.

A heterologous (*i.e.*, foreign) nucleotide sequence can consist of one or more gene(s) of interest, and preferably of therapeutic interest. In the context of the present invention, a gene of interest can code either for an antisense RNA, a 25 ribozyme or for an mRNA which will then be translated into a protein of interest. A gene of interest can be of genomic type, of complementary DNA (cDNA) type or of mixed type (minigene, in which at least one intron is deleted). It can code for a mature protein, a precursor of a mature protein, in particular a precursor intended to be secreted and accordingly comprising a signal peptide, a chimeric 30 protein originating from the fusion of sequences of diverse origins, or a mutant of

a natural protein displaying improved or modified biological properties. Such a mutant can be obtained by deletion, substitution and/or addition of one or more nucleotide(s) of the gene coding for the natural protein, or any other type of change in the sequence encoding the natural protein, such as, for example, 5 transposition or inversion.

A gene of interest can be placed under the control of regulatory sequences suitable for its expression in a host cell. Suitable regulatory sequences are understood to mean the set of elements needed for transcription of a gene into RNA (ribozyme, antisense RNA or mRNA), for processing of RNA, and for the 10 translation of an mRNA into protein. Among the elements needed for transcription, the promoter assumes special importance. It can be a constitutive promoter or a regulatable promoter, and can be isolated from any gene of eukaryotic, prokaryotic or viral origin, and even adenoviral origin. Alternatively, it can be the natural promoter of the gene of interest. Generally speaking, a 15 promoter used in the present invention can be chosen to contain cell-specific regulatory sequences, or modified to contain such sequences. For example, a gene of interest for use in the present invention is placed under the control of an immunoglobulin gene promoter when it is desired to target its expression to lymphocytic host cells. There may also be mentioned the HSV-1 TK (herpesvirus 20 type 1 thymidine kinase) gene promoter, the adenoviral MLP (major late promoter), in particular of human adenovirus type 2, the RSV (Rous Sarcoma Virus) LTR (long terminal repeat), the CMV (Cytomegalovirus) early promoter, and the PGK (phosphoglycerate kinase) gene promoter, for example, permitting expression in a large number of cell types.

25 Alternatively, targeting of a recombinant PAV vector to a particular cell type can be achieved by constructing recombinant hexon and/or fiber genes. The protein products of these genes are involved in host cell recognition; therefore, the genes can be modified to contain peptide sequences that will allow the virus to recognize alternative host cells.

Among genes of interest which are useful in the context of the present invention, there may be mentioned:

- genes coding for cytokines such as interferons and interleukins;
- genes encoding lymphokines;
- 5 - genes coding for membrane receptors such as the receptors recognized by pathogenic organisms (viruses, bacteria or parasites), preferably by the HIV virus (human immunodeficiency virus);
 - genes coding for coagulation factors such as factor VIII and factor IX;
 - genes coding for dystrophins;
- 10 - genes coding for insulin;
 - genes coding for proteins participating directly or indirectly in cellular ion channels, such as the CFTR (cystic fibrosis transmembrane conductance regulator) protein;
 - genes coding for antisense RNAs, or proteins capable of inhibiting the activity of a protein produced by a pathogenic gene which is present in the genome of a pathogenic organism, or proteins (or genes encoding them) capable of inhibiting the activity of a cellular gene whose expression is deregulated, for example an oncogene;
 - genes coding for a protein inhibiting an enzyme activity, such as α_1 -antitrypsin or a viral protease inhibitor, for example;
 - genes coding for variants of pathogenic proteins which have been mutated so as to impair their biological function, such as, for example, trans-dominant variants of the *tat* protein of the HIV virus which are capable of competing with the natural protein for binding to the target sequence, thereby preventing the activation of HIV;
 - genes coding for antigenic epitopes in order to increase the host cell's immunity;
 - genes coding for major histocompatibility complex classes I and II proteins, as well as the genes coding for the proteins which are inducers of these genes;

- genes coding for antibodies;
- genes coding for immunotoxins;
- genes encoding toxins;
- genes encoding growth factors or growth hormones;
5 - genes encoding cell receptors and their ligands;
- genes encoding tumor suppressors;
- genes coding for cellular enzymes or those produced by pathogenic organisms; and
- suicide genes. The HSV-1 TK suicide gene may be mentioned as an example. This viral TK enzyme displays markedly greater affinity compared to the cellular TK enzyme for certain nucleoside analogues (such as acyclovir or gancyclovir). It converts them to monophosphorylated molecules, which can themselves be converted by cellular enzymes to nucleotide precursors, which are toxic. These nucleotide analogues can be incorporated into replicating DNA
10 molecules, hence incorporation occurs chiefly in the DNA of dividing cells. This incorporation can result in specific destruction of dividing cells such as cancer cells.

This list is not restrictive, and any other gene of interest can be used in the context of the present invention. In some cases the gene for a particular antigen
20 can contain a large number of introns or can be from an RNA virus, in these cases a complementary DNA copy (cDNA) can be used. It is also possible that only fragments of nucleotide sequences of genes can be used (where these are sufficient to generate a protective immune response or a specific biological effect) rather than the complete sequence as found in the wild-type organism. Where
25 available, synthetic genes or fragments thereof can also be used. However, the present invention can be used with a wide variety of genes, fragments and the like, and is not limited to those set out above.

Recombinant PAV vectors can be used to express antigens for provision of, for example, subunit vaccines. Antigens used in the present invention can be
30 either native or recombinant antigenic polypeptides or fragments. They can be

partial sequences, full-length sequences, or even fusions (e.g., having appropriate leader sequences for the recombinant host, or with an additional antigen sequence for another pathogen). The preferred antigenic polypeptide to be expressed by the virus systems of the present invention contain full-length (or near full-length) 5 sequences encoding antigens. Alternatively, shorter sequences that are antigenic (i.e., encode one or more epitopes) can be used. The shorter sequence can encode a "neutralizing epitope," which is defined as an epitope capable of eliciting antibodies that neutralize virus infectivity in an *in vitro* assay. Preferably the peptide should encode a "protective epitope" that is capable of raising in the host a 10 "protective immune response;" i.e., a humoral (i.e. antibody-mediated), cell-mediated, and/or mucosal immune response that protects an immunized host from infection.

The antigens used in the present invention, particularly when comprised of short oligopeptides, can be conjugated to a vaccine carrier. Vaccine carriers are 15 well known in the art: for example, bovine serum albumin (BSA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH). A preferred carrier protein, rotavirus VP6, is disclosed in EPO Pub. No. 0259149, the disclosure of which is incorporated by reference herein.

Genes for desired antigens or coding sequences thereof which can be 20 inserted include those of organisms which cause disease in mammals, particularly porcine pathogens such as pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), porcine rotavirus, porcine respiratory and reproductive syndrome virus (PRRS), porcine epidemic diarrhea virus (PEDV), hog cholera virus (HCV), porcine parvovirus and the like. Genes encoding antigens of human pathogens are 25 also useful in the practice of the invention.

Therapeutic applications

With the recombinant viruses of the present invention, it is possible to provide protection against a wide variety of diseases affecting swine, cattle, 30 humans and other mammals. Any of the recombinant antigenic determinants or

recombinant live viruses of the invention can be formulated and used in substantially the same manner as described for the antigenic determinant vaccines or live vaccine vectors.

The present invention also includes pharmaceutical compositions comprising a therapeutically effective amount of a recombinant vector, recombinant virus or recombinant protein, prepared according to the methods of the invention, in combination with a pharmaceutically acceptable vehicle and/or an adjuvant. Such a pharmaceutical composition can be prepared and dosages determined according to techniques that are well-known in the art. The pharmaceutical compositions of the invention can be administered by any known administration route including, but not limited to, systemically (for example, intravenously, intratracheally, intraperitoneally, intranasally, parenterally, enterically, intramuscularly, subcutaneously, intratumorally or intracranially) or by aerosolization or intrapulmonary instillation. Administration can take place in a single dose or in doses repeated one or more times after certain time intervals. The appropriate administration route and dosage will vary in accordance with the situation (for example, the individual being treated, the disorder to be treated or the gene or polypeptide of interest), but can be determined by one of skill in the art.

The vaccines of the invention carrying foreign genes or fragments can be orally administered in a suitable oral carrier, such as in an enteric-coated dosage form. Oral formulations include such normally-employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral vaccine compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, containing from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%. An oral vaccine may be preferable to raise mucosal immunity (which plays an important role in protection against pathogens infecting the gastrointestinal tract) in combination with systemic immunity.

In addition, the vaccine can be formulated into a suppository. For suppositories, the vaccine composition will include traditional binders and carriers, such as polyalkaline glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%.

Protocols for administering to animals the vaccine composition(s) of the present invention are within the skill of the art in view of the present disclosure. Those skilled in the art will select a concentration of the vaccine composition in a dose effective to elicit antibody, cell-mediated and/or mucosal immune responses to the antigenic fragment. Within wide limits, the dosage is not believed to be critical. Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 micrograms of the subunit antigen in a convenient volume of vehicle, e.g., about 1-10 ml. Preferably, the dosage in a single immunization will deliver from about 1 to about 500 micrograms of subunit antigen, more preferably about 5-10 to about 100-200 micrograms (e.g., 5-200 micrograms).

The timing of administration may also be important. For example, a primary inoculation preferably may be followed by subsequent booster inoculations, for example, several weeks to several months after the initial immunization, if needed. To insure sustained high levels of protection against disease, it may be helpful to readminister booster immunizations at regular intervals, for example once every several years. Alternatively, an initial dose may be administered orally followed by later inoculations, or vice versa. Preferred vaccination protocols can be established through routine vaccination protocol experiments.

The dosage for all routes of administration of *in vivo* recombinant virus vaccine depends on various factors including, the size of patient, nature of infection against which protection is needed, carrier and the like and can readily be determined by those of skill in the art. By way of non-limiting example, a dosage of between approximately 10^3 pfu and 10^8 pfu can be used. As with *in*

vitro subunit vaccines, additional dosages can be given as determined by the clinical factors involved.

A problem that has beset the use of adenovirus vectors for immunization and gene therapy in humans is the rapid development of an immunological response (or indeed in some cases existing immunity) to human adenoviruses (HAVs). Recombinant PAV vectors are likely to be less immunogenic in humans and, for this and other reasons, will be useful either as a substitute for HAV vectors or in combination with HAV vectors. For example, an initial immunization with a HAV vector can be followed by booster immunizations using PAV vectors; alternatively, initial immunization with a recombinant PAV vector can be followed by booster immunizations with HAV and/or PAV vectors.

The presence of low levels of helper-independent vectors in the batches of helper-dependent human adenoviruses that are grown in complementing human cell lines has been reported. Fallaux *et al.* (1998) *supra*. This occurs as a result of recombination events between the viral DNA and the integrated adenoviral sequences present in the complementing cell line. Hehir *et al.* (1996) *J. Virol.* 70:8459-8467. This type of contamination constitutes a safety risk, which could result in the replication and spread of the virus. Complete elimination of helper-dependent adenoviruses in the batches of helper-dependent vectors can be achieved using two approaches. The first is by developing new helper cell lines and matched vectors that do not share any common sequences. Fallaux *et al.* (1998) *supra*. The second approach is to take advantage of possible cross-complementation between two distantly related adenoviruses such as HAV-5 and PAV-3. VIDO R1 cells contain the E1 coding sequences of HAV-5. Although there is no significant homology between the E1 regions of HAV-5 and PAV-3 at the nucleotide sequence level, the proteins produced from the region can complement each others' function(s). Thus, the problem of helper-independent vector generation by homologous recombination is eliminated when VIDO R1 cells are used for the propagation of recombinant PAV-3.

The invention also encompasses a method of treatment, according to which a therapeutically effective amount of a PAV vector, recombinant PAV, or host cell of the invention is administered to a mammalian subject requiring treatment. The finding that PAV-3 was effective in entering canine, sheep and 5 bovine cells in which it does not replicate or replicates poorly is an important observation. *See Example 8, infra.* This may have implications in designing PAV-3 vectors for vaccination in these and other animal species.

PAV Expression Systems

10 Recombinant PAV vectors can be used for regulated expression of foreign polypeptides encoded by heterologous nucleotide sequences. Standard conditions of cell culture, such as are known to those of skill in the art, will allow maximal expression of recombinant polypeptides. They can be used, in addition, for regulated expression of RNAs encoded by heterologous nucleotide sequences, as 15 in, for example, antisense applications and expression of ribozymes.

When the heterologous sequences encode an antigenic polypeptide, PAV vectors comprising insertions of heterologous nucleotide sequences can be used to provide large quantities of antigen which are useful, in turn, for the preparation of antibodies. Methods for preparation of antibodies are well-known to those of skill 20 in the art. Briefly, an animal (such as a rabbit) is given an initial subcutaneous injection of antigen plus Freund's complete adjuvant. One to two subsequent injections of antigen plus Freund's incomplete adjuvant are given at approximately 3 week intervals. Approximately 10 days after the final injection, serum is collected and tested for the presence of specific antibody by ELISA, 25 Western Blot, immunoprecipitation, or any other immunological assay known to one of skill in the art.

Adenovirus E1 gene products transactivate many cellular genes; therefore, cell lines which constitutively express E1 proteins can express cellular polypeptides at a higher levels than other cell lines. The recombinant mammalian, 30 particularly porcine, cell lines of the invention can be used to prepare and isolate

polypeptides, including those such as (a) proteins associated with adenovirus E1A proteins: *e.g.* p300, retinoblastoma (Rb) protein, cyclins, kinases and the like; (b) proteins associated with adenovirus E1B protein: *e.g.* p53 and the like; growth factors, such as epidermal growth factor (EGF), transforming growth factor (TGF) and the like; (d) receptors such as epidermal growth factor receptor (EGF-R), fibroblast growth factor receptor (FGF-R), tumor necrosis factor receptor (TNF-R), insulin-like growth factor receptor (IGF-R), major histocompatibility complex class I receptor and the like; (e) proteins encoded by proto-oncogenes such as protein kinases (tyrosine-specific protein kinases and protein kinases specific for serine or threonine), p21 proteins (guanine nucleotide-binding proteins with GTPase activity) and the like; (f) other cellular proteins such as actins, collagens, fibronectins, integrins, phosphoproteins, proteoglycans, histones and the like, and (g) proteins involved in regulation of transcription such as TATA-box-binding protein (TBP), TBP-associated factors (TAFs), Sp1 binding protein and the like.

15

Gene Therapy

The invention also includes a method for providing gene therapy to a mammal, such as a porcine, human or other mammal in need thereof, to control a gene deficiency. In one embodiment, the method comprises administering to said 20 mammal a live recombinant porcine adenovirus containing a heterologous nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue. These kinds 25 of techniques are currently being used by those of skill in the art to replace a defective gene or portion thereof. Examples of foreign genes, heterologous nucleotide sequences, or portions thereof that can be incorporated for use in gene therapy include, but are not limited to, cystic fibrosis transmembrane conductance regulator gene, human minidystrophin gene, alpha-1-antitrypsin gene and the like.

In particular, the practice of the present invention in regard to gene therapy in humans is intended for the prevention or treatment of diseases including, but not limited to, genetic diseases (for example, hemophilia, thalassemias, emphysema, Gaucher's disease, cystic fibrosis, Duchenne muscular dystrophy, 5 Duchenne's or Becker's myopathy, etc.), cancers, viral diseases (for example, AIDS, herpesvirus infection, cytomegalovirus infection and papillomavirus infection) and the like. For the purposes of the present invention, the vectors, cells and viral particles prepared by the methods of the invention may be introduced into a subject either *ex vivo*, (i.e., in a cell or cells removed from the 10 patient) or directly *in vivo* into the body to be treated. Preferably, the host cell is a human cell and, more preferably, is a lung, fibroblast, muscle, liver or lymphocytic cell or a cell of the hematopoietic lineage.

Diagnostic applications

15 The PAV genome, or any subregion of the PAV genome, is suitable for use as a nucleic acid probe, to test for the presence of PAV nucleic acid in a subject or a biological sample. The presence of viral nucleic acids can be detected by techniques known to one of skill in the art including, but not limited to, hybridization assays, polymerase chain reaction, and other types of amplification reactions. Suitable labels and hybridization techniques are well-known to those of skill in the art. See, for example, Kessler (ed.), *Nonradioactive Labeling and Detection of Biomolecules*, Springer-Verlag, Berlin, 1992; Kricka (ed.) *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, 1992; Howard (ed.) *Methods in Nonradioactive Detection*, Appleton & Lange, Norwalk, 1993; 20 Ausubel *et al.*, *supra*; and Sambrook *et al.*, *supra*. Diagnostic kits comprising the nucleotide sequences of the invention can also contain reagents for cell disruption and nucleic acid purification, as well as buffers and solvents for the formation, selection and detection of hybrids.

25 Regions of the PAV genome can be inserted into any expression vector known in the art and expressed to provide, for example, vaccine formulations,

protein for immunization, *etc.* The amino acid sequence of any PAV protein can be determined by one of skill in the art from the nucleotide sequences disclosed herein. PAV proteins can be used for diagnostic purposes, for example, to detect the presence of PAV antigens. Methods for detection of proteins are well-known to those of skill in the art and include, but are not limited to, various types of direct and competitive immunoassays, ELISA, Western blotting, enzymatic assay, immunohistochemistry, *etc.* See, for example, Harlow & Lane (eds.): *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, New York, 1988. Diagnostic kits comprising PAV polypeptides or amino acid sequences can also comprise reagents for protein isolation and for the formation, isolation, purification and/or detection of immune complexes.

EXAMPLES

METHODS

15 **Virus and viral DNA.**

The 6618 strain of PAV-3 was propagated in the swine testis (ST) cell line and in E1-transformed porcine retinal cells (VIDO R1, see below). Porcine embryonic retinal cells were obtained from the eyeballs of piglets delivered by caesarian section two weeks before the parturition date. Uninfected cells were grown in MEM supplemented with 10% fetal bovine serum (FBS). MEM with 2% FBS was used for maintenance of infected cells. Viral DNA was extracted either from infected cell monolayers by the method of Hirt (1967) *J. Mol. Biol.* 26:365-369, or from purified virions as described by Graham *et al.* (1991) in "Methods in Molecular Biology" Vol. 7, Gene transfer and expression protocols, ed. E.J. Murray, Humana Press, Clifton, NJ, pp. 109-128.

Plasmids and genomic DNA sequencing.

Selected restriction enzyme fragments of PAV-3 DNA were cloned into pGEM-3Z and pGEM-7Zf(+) plasmids (Promega). Nucleotide sequences were determined on both strands of the genome by the dideoxy chain-termination

method using Sequenase® enzyme (U.S. Biochemicals) and the dye-terminator method with an Applied Biosystems (Foster City, CA) DNA sequencer.

cDNA library.

5 A cDNA library was generated from polyadenylated RNA extracted from PAV-3 infected ST cells at 12 h and 24 h post infection. Double stranded cDNAs were made with reagents from Stratagene and cloned into Lambda ZAP vector. Plaques which hybridized to specific restriction enzyme fragments of PAV-3 DNA were plaque purified twice. Plasmids containing cDNAs were excised from 10 the Lambda ZAP vector according to the manufacturer's protocol. The resulting plasmid clones were characterized by restriction endonuclease analysis and by sequencing of both ends of the cDNA insert with T3- and T7-specific primers. Selected clones were sequenced with internal primers. cDNA sequences were aligned with genomic sequences to determine the transcription map.

15

Viral transcript mapping by nuclease protection

Transcript mapping was conducted according to the method of Berk *et al.* (1977) *Cell* 12:721-732.

20

**Example 1: Development of an E1-complementing helper cell line
(VIDO R1)**

Primary cultures of porcine embryonic retina cells were transfected with 10 µg of plasmid pTG 4671 (Transgene, Strasbourg, France) by the calcium phosphate technique. The pTG 4671 plasmid contains the entire E1A and E1B 25 sequences (nts 505-4034) of HAV-5, along with the puromycin acetyltransferase gene as a selectable marker. In this plasmid, the E1 region is under the control of the constitutive promoter from the mouse phosphoglycerate kinase gene, and the puromycin acetyltransferase gene is controlled by the constitutive SV40 early promoter. Transformed cells were selected by three passages in medium 30 containing 7 µg/ml puromycin, identified based on change in their morphology

from single foci (*i.e.*, loss of contact inhibition), and subjected to single cell cloning. The established cell line was first tested for its ability to support the growth of E1 deletion mutants of HAV-5. Subsequently the cell line was further investigated for the presence of E1 sequences in the genome by PCR, expression of the E1A and E1B proteins by Western blot, and doubling time under cell culture conditions. E1 sequences were detected, and production of E1A and E1B proteins was demonstrated by immunoprecipitation (Figure 3). Doubling time was shorter, when compared to that of the parent cell line. Example 3, *infra*, shows that this cell line is capable of complementing a PAV E1A deletion mutant.

To assess the stability of E1 expression, VIDO R1 cells were cultured through more than 50 passages (split 1:3 twice weekly) and tested for their ability to support the replication of E1-deleted HAV-5. Expression of the E1A and E1B proteins at regular intervals was also monitored by Western blot. The results indicated that the VIDO R1 line retained the ability to support the growth of E1-deleted virus and expressed similar levels of E1 proteins during more than 50 passages in culture. Therefore, VIDO R1 can be considered to be an established cell line.

Example 2: Construction of a full-length infectious clone of PAV-3.

A plasmid clone containing a full-length copy of the PAV-3 genome (pPAV-200) was generated by first constructing a plasmid containing left- and right-end sequences of PAV-3, with the PAV-3 sequences bordered by *PacI* sites and separated by a *PstI* restriction site (pPAV-100), then allowing recombination between *PstI*-digested pPAV-100 and an intact PAV-3 genome. Left- and right-end sequences for insertion into pPAV-100 were produced by PCR amplification, as follows.

The plasmid p3SB (Reddy *et al.*, 1993, *Intervirology* 36:161-168), containing the left end of PAV-3 genome (position 1-8870) was used for amplification of the first 433 bp of the PAV-3 genome by PCR. Amplification primers were oligonucleotides 1

(5'-*GCGGATCCTTAATTAACATCATCAATAATACCGCACACTTT*-3')

(SEQ ID NO.: 2) and 2

(5'-*CACCTGCAGATAACCCACACACGTCA*TCTG-3') **(SEQ ID NO.: 3)**.

In the sequences shown here, adenoviral sequences are shown in bold and
5 engineered restriction enzyme sites are italicized.

For amplification of sequences at the right end of the PAV-3 genome, the plasmid p3SA (Reddy *et al.*, 1993, *supra*) was used. This plasmid was used as template in PCR for amplification of the terminal 573 bp of the genome using oligonucleotide 1 (above) and oligonucleotide 3

10 (5'-*CACCTGCAGCCTCCTGAGTGTGAAGAGTGTCC*-3') **(SEQ ID NO.: 4)**.

4). The primers were designed based on the nucleotide sequence information described elsewhere (Reddy *et al.*, 1995c, *supra*; and Reddy *et al.*, 1997, *supra*).

For construction of pPAV-100, the PCR product obtained with oligonucleotides 1 and 2 was digested with *Bam*HI and *Pst*I restriction enzymes 15 and the PCR product obtained using primers 1 and 3 was digested with *Pst*I and *Pac*I enzymes. Modified bacterial plasmid pPolyIIsn14 was digested with *Bam*HI and *Pac*I enzymes. This plasmid was used based on its suitability for homologous recombination in *E. coli*. The two PCR products described above were cloned into pPolyIIsn14 by three way ligation to generate the plasmid pPAV-100 which 20 carries both termini of PAV-3, separated by a *Pst*I site and bordered by *Pac*I restriction enzyme sites.

Plasmid pPAV-200, which contains a full length PAV-3 genome, was generated by co-transformation of *E. coli* BJ 5183 *recBC sbcBC* (Hanahan, 1983, *J. Mol. Biol.* 166:557-580) with *Pst*I-linearized pPAV-100 and the genomic DNA 25 of PAV-3. Extensive restriction enzyme analysis of pPAV-200 indicated that it had the structure expected of a full-length PAV-3 insert, and that no unexpected rearrangements had occurred during recombination in *E. coli*.

The infectivity of pPAV-200 was demonstrated by lipofectin transfection (Life Technologies, Gaithersburg, MD) of ST cells following *Pac*I enzyme 30 digestion of the plasmid to release the viral genome from the plasmid. Viral

plaques were evident 7 days following transfection, and titers were equivalent to, or higher than, those obtained after infection with wild-type PAV. The plaques were amplified and the viral DNA was extracted and analyzed by restriction enzyme digestion. The viral DNA obtained by cleavage of pPAV-200 with *PacI* contained an extra 3 bases at each end; but these extra bases did not substantially reduce the infectivity of the PAV genome excised from pPAV-200. In addition, the bacterial-derived genomes lacked the 55-kDa terminal protein that is covalently linked to the 5' ends of adenoviral DNAs and which enhances infectivity of viral DNA.

10

Example 3: Generation of E1 deletion mutants of PAV-3.

A plasmid (pPAV-101) containing the left (nucleotides 1-2,130) and the right (nucleotides 32,660-34,094) terminal *NcoI* fragments of the PAV-3 genome was constructed by digesting pPAV-200 with the enzyme *NcoI* (which has no recognition sites in the vector backbone, but many sites in the PAV insert), gel-purifying the appropriate fragment and self-ligating the ends. See Figure 4. The E1A sequences of pPAV-101, between nucleotides 407 and 1270 (PAV genome numbering), were deleted by digestion of pPAV-101 with *NotI* (recognition site at nucleotide 407) and *AseI* (recognition site at 1270), generation of blunt ends, and insertion of a double-stranded oligonucleotide encoding a *XbaI* restriction site to create a plasmid, pPAV-102, containing PAV left- and right-end sequences, separated by a *NcoI* site, with a deletion of the E1A region and a *XbaI* site at the site of the deletion. See Figure 5. Plasmid pPAV-201, containing a full-length PAV-3 genome minus E1A sequences, was created by co-transformation of *E. coli* BJ 5183 with *NcoI* linearized pPAV-102 and genomic PAV-3 DNA. The resulting construct, when transfected into VIDO R1 cells following digestion with *PacI* restriction enzyme, produced a virus that had a deletion in the E1 region. In similar fashion, construction of a virus with deletions in E1 and E3 was accomplished by transformation of BJ 5183 cells with *NcoI* linearized pPAV-102 and genomic PAV-3 DNA containing an E3 deletion. These

ElA deletion mutants did not grow on either ST (swine testis) cells or fetal porcine retina cells and could only be grown in the VIDO R1 cell line.

Example 4: Generation of E3 inserts and deletion mutants.

5 To systematically examine the extent of the E3 region that could be deleted, a E3 transfer vector was constructed. The vector (pPAV-301) contained a PAV-3 segment from nucleotides 26,716 to 31,064 with a green fluorescent protein (GFP) gene inserted into the *SnaBI* site (located at nucleotide 28,702) in the same orientation as E3. The GFP gene was obtained from the plasmid pGreen 10 Lantern-1™ (Life Technologies), by *NotI* digestion followed by purification of a 732-nucleotide fragment. Similarly, another construct was made with GFP cloned into the *SacI* site located at nucleotide 27,789. *KpnI-BamHI* fragments encompassing the modified E3 regions were then isolated from these E3 transfer vectors and recombined in *E. coli* with pPAV-200 that had been linearized at 15 nucleotide position 28,702 by *SnaBI* digestion. Virus were obtained with a construct that had the GFP gene cloned into the *SnaBI* site.

To delete the non-essential portion of E3 from the transfer vector, a PCR approach was used. In this approach, the region of the PAV genome between nucleotides 27,402 and 28,112 was amplified using the following primers:

20 5'-GACTGACGCCGGCATGCAAT-3' SEQ ID NO: 5
5'-CGGATCCTGACGCTACGAGCGGTTGTA-3' SEQ ID NO: 6

In a second PCR reaction, the portion of the PAV genome between nucleotides 28,709 and 29,859 was amplified using the following two primers:

25 5'-CGGATCCATACGTACAGATGAAGTAGC-3' SEQ ID NO: 7
5'- TCTGACTGAAGCCGACCTGC-3' SEQ ID NO: 8

In the oligonucleotides designated SEQ ID NO: 6 and SEQ ID NO: 7, a *BamHI* recognition sequence is indicated by underlining. The template for amplification was a *KpnI-BamHI* fragment encompassing nucleotides 26,716-31,063 of the PAV genome, inserted into the plasmid pGEM3Z (Promega), and 30 *Pfu* polymerase (Stratagene) was used for amplification. The first PCR product

(product of amplification with SEQ ID NO: 5 and SEQ ID NO: 6) was digested with *Bam*HI and gel-purified. The second PCR product (product of amplification with SEQ ID NO: 7 and SEQ ID NO: 8) was digested with *Bam*HI and *Spe*I and gel-purified. They were inserted into *Sma*I/*Spe*I-digested pBlueScript II SK(+) (Stratagene) in a three-way ligation reaction to generate pPAV-300. See Figure 6. pPAV-300 contains the portion of the PAV-3 genome extending from nucleotides 27,402 to 29,859, with 594 base pairs (bp) between nucleotides 28,113 and 28,707 deleted from the E3 region. A virus with such a deletion was constructed as follows. A *Sph*I-*Spe*I fragment from pPAV-300, containing part of the pVIII gene, a deleted E3 region, and part of the fiber gene was isolated (see Figure 6). This fragment was co-transfected, with *Sna*BI-digested pPAV-200 (which contains a full-length PAV-3 genome) into *E. coli*. Homologous recombination generated a plasmid, pFPAV-300, containing a full-length PAV genome with a deletion in the E3 region. pFPAV-300 was digested with *Pac*I and transfected into VIDO R1 cells (Example 1) to generate recombinant virus with a deletion in the E3 region of the genome.

Example 5: Construction of a PAV recombinant with an insertion of the PRV gp50 gene in the PAV E3 region and expression of the inserted gene

To construct a recombinant PAV expressing pseudorabies virus (PRV) gp50, the PRV gp50 gene was inserted at the *Sna*BI site of pPAV-300 to create plasmid pPAV-300-gp50. A *Sph*I-*Spe*I fragment from pPAV-300-gp50, containing part of the pVII gene, a deleted E3 region with the PRV gp50 gene inserted, and part of the fiber gene, was purified and co-transfected, along with *Sna*BI-digested pFPAV-300 (E3-deleted) into *E. coli*. In the bacterial cell, homologous recombination generated pFPAV-300-gp50, a plasmid containing a PAV genome with the PRV gp50 gene replacing a deleted E3 region. Recombinant virus particles were obtained as described in Example 4.

Expression of the inserted PRV gp50 was tested after infection of VIDO R1 cells with the recombinant virus, by 35 S labeling of infected cells (continuous

label), followed by immunoprecipitation with an anti-gp50 monoclonal antibody and gel electrophoresis of the immunoprecipitate. Figure 7 shows that large amounts of gp50 are present by 12 hours after infection, and expression of gp50 persists up to 24 hours after infection.

5

Example 6: Expression of the Chloramphenicol acetyltransferase gene from a region that lies between the promoter of the E4 region and the right ITR.

The right terminal fragment of the PAV genome (encompassing 10 nucleotides 31,054-34,094) was obtained by *Xba*I digestion of pPAV-200 and cloned between the *Xba*I and *Not*I sites of pPolyII λ n14. A Chloramphenicol acetyltransferase (CAT) gene expression cassette, in which the CAT gene was flanked by the SV40 early promoter and the SV40 polyadenylation signal, was inserted, in both orientations, into a unique *Hpa*I site located between the E4 15 region promoter and the right ITR, to generate plasmids pPAV-400A and pPAV-400B. The modified terminal fragments were transferred into a plasmid containing a full-length PAV-3 genome by homologous recombination in *E coli* between the isolated terminal fragments and *Hpa*I-digested pPAV-200. Recombinant viruses expressing CAT were obtained following transfection of 20 VIDO R1 cells with the plasmids. PAV-CAT2 contained the CAT gene cassette in a leftward transcriptional orientation (*i.e.*, the same orientation as E4 region transcription), while, in PAV-CAT6, the CAT gene cassette was in the rightward transcriptional orientation.

These recombinant viruses were tested for expression of CAT, after 25 infection of VIDO R1 cells, using a CAT Enzyme Assay System from Promega, following the instructions provided by the supplier. See, Cullen (1987) *Meth. Enzymology* 43:737; and Gorman *et al.*, (1982) *Mol. Cell. Biol.* 2:1044. The results are shown in Table 3.

30

Table 3: CAT activity expressed by recombinant PAV viruses

Sample	³ H cpm
Mock-infected	458
CAT positive control*	199,962
PAV-CAT2	153,444
PAV-CAT6	63,386

* - the positive control sample contained 0.1 Units of purified CAT.

These results show that recombinant PAV viruses, containing an inserted
5 gene, are viable and are capable of expressing the inserted gene.

Example 7: Construction of replication defective PAV-3 expressing GFP

A 2.3 kb fragment containing the CMV immediate early promoter, the
10 green fluorescent protein (GFP) gene and the bovine growth hormone poly(A)
signal was isolated by digesting pQBI 25 (Quantum Biotechnology) with *Bgl*II
and *Dra*III followed by filling the ends with T4 DNA polymerase. This fragment
was inserted into the *Srf*I site of pPAV-102 in both orientations to generate
pPAV-102GFP (Figure 8). This plasmid, digested with *Pac*I and *Sma*I enzymes,
15 and the fragment containing part of the E1 sequence and the GFP gene was gel
purified. This fragment and the *Srf*I digested pFPAV-201 were used to transform
E. coli BJ 5183 to generate the full-length clone containing GFP in the E1 region
(pFPAV-201-GFP) by homologous recombination. The recombinant virus,
PAV3delE1E3.GFP was generated following transfection of VIDO R1 cells with
20 *Pac*I restricted pFPAV-201-GFP that had the GFP transcription unit in the
opposite orientation to the E1. A similar virus with the GFP in the same
orientation as E1 could not be rescued from transfected cells. Presence of the
GFP gene in the viral genome was confirmed by restriction enzyme analysis. The
recombinant virus replicated in VIDO R1 cells two logs less efficiently than the
25 wild type PAV-3.

Example 8: Virus entry and replication of PAV-3 in human and animal cells.

To initially characterize the host species restriction of PAV *in vitro*, monolayers of 11 cell types from 6 different mammalian species were infected 5 with wild type PAV-3 or PAV3del.E1E3.GFP. ST, VIDO R1 (porcine), 293, A549 (human), MDBK, VIDO R2 (bovine), C3HA (mouse), COS, VERO (monkey), sheep skin fibroblasts or cotton rat lung cells were incubated with 1 pfu/cell of wild type PAV-3 or helper-dependent PAV-3 expressing GFP. The cells infected with wild type PAV were harvested at 2 h and 3 days post-infection, 10 subjected to two cycles of freeze-thaw, and virus titers were determined on VIDO R1 cells. Cells that were infected with the recombinant virus expressing GFP were observed with the aid of a fluorescent microscope for green fluorescence.

A ten-fold increase in virus titers in Vero and COS cells, and a hundred-fold increase in cotton rat lung fibroblasts and VIDO R2 cells, was noticed. No 15 increase in the virus titers was observed with 293, A549, MDBK, sheep skin fibroblasts, dog kidney and C3HA cells. All of these cell types showed bright green fluorescence when infected with PAV3delE1E3.GFP except human cells, which showed a weak fluorescence. In addition, low levels of GFP expression were achieved in human cells with recombinant PAV-3. These observations 20 suggest that virus entry into human cells is limited and/or the human cells are non-permissive for the replication of the virus. These results also demonstrated that GFP was expressed by the PAV-3 vector in cells which are semi-permissive (VERO, COS, Cotton rat lung fibroblasts and VIDO R2), or non-permissive (Sheep skin fibroblasts, MDBK and human cells) for virus replication.

25

Example 9: Insertions in the regions of the PAV-3 genome defined by nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,573-27,088; and 31,149-34,094

Insertions are made by art-recognized techniques including, but not limited 30 to, restriction digestion, nuclease digestion, ligation, kinase and phosphatase

treatment, DNA polymerase treatment, reverse transcriptase treatment, and chemical oligonucleotide synthesis. Heterologous nucleic acid sequences of interest are cloned into plasmid vectors containing portions of the PAV genome (which may or may not contain deletions of PAV sequences) such that the foreign
5 sequences are flanked by sequences having substantial homology to a region of the PAV genome into which insertion is to be directed. Substantial homology refers to homology sufficient to support homologous recombination. These constructs are then introduced into host cells that are co-transfected with PAV-3 DNA or a cloned PAV genome. During infection, homologous recombination
10 between these constructs and PAV genomes will occur to generate recombinant PAV genome-containing plasmids. Recombinant virus are obtained by transfecting the recombinant PAV genome-containing plasmids into a suitable mammalian host cell line. If the insertion occurs in an essential region of the PAV genome, the recombinant PAV virus is propagated in a helper cell line
15 which supplies the viral function that was lost due to the insertion.

Deposit of Biological Materials

The following materials were deposited and are maintained with the Veterinary Infectious Disease Organization (VIDO), Saskatoon, Saskatchewan, Canada.

5 The nucleotide sequences of the deposited materials are incorporated by reference herein, as well as the sequences of the polypeptides encoded thereby. In the event of any discrepancy between a sequence expressly disclosed herein and a deposited sequence, the deposited sequence is controlling.

10	<u>Material</u>	<u>Internal Accession No.</u>	<u>Deposit Date</u>
Recombinant plasmids			
	pPAV-101	VIDO 98-1	April 10, 1998
	pPAV-102	VIDO 98-2	April 10, 1998
	pPAV-200	VIDO 98-3	April 10, 1998
15	pPAV-300	VIDO 98-4	April 10, 1998
	pPAV-400A	VIDO 98-5	April 10, 1998
	pPAV-400B	VIDO 98-6	April 10, 1998
Recombinant cell lines			
20	Porcine embryonic retinal cells transformed with HAV-5 E1 sequences:		
	VIDO R1	VIDOO 98C-1	April 10 1998

While the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications may be practiced without departing from the spirit of the invention. Therefore the foregoing descriptions and examples should not be construed as limiting the scope of the invention.

CLAIMS

What is claimed is:

1. A nucleotide sequence that is substantially homologous to the genome of porcine adenovirus type 3 (PAV-3), or a fragment thereof.
- 5 2. A nucleotide sequence that is substantially homologous to a portion of the genome of porcine adenovirus type 3, said portion selected from the group consisting of nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,5732-27,088; and 31,149-34,094 of the PAV-3 genome, or a fragment thereof.
- 10 3. A nucleotide sequence that is substantially homologous to a PAV-3 gene or fragment thereof, wherein the gene is selected from the group consisting of E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K.
- 15 4. A nucleotide sequence according to claim 3 comprising a PAV-3 coding sequence from a region of the PAV-3 genome selected from the group consisting of E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K, and fragments thereof.
5. A nucleotide sequence that is substantially homologous to the nucleotide sequence of claim 4.
- 20 6. A nucleotide sequence comprising an intergenic region of the PAV-3 genome.
7. A nucleotide sequence that is substantially homologous to the nucleotide sequence of claim 6.
- 25 8. A nucleotide sequence encoding a PAV-3 regulatory sequence.
9. The nucleotide sequence of claim 8, wherein the regulatory sequence is selected from the group consisting of a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.
- 30 10. A vector comprising the nucleotide sequence of claim 1.

11. A vector comprising the nucleotide sequence of claim 2.
12. A vector comprising the nucleotide sequence of claim 3.
13. A vector comprising the nucleotide sequence of claim 8.
14. A defective recombinant PAV vector, comprising ITR sequences, packaging sequences, and at least one heterologous nucleotide sequence, wherein the PAV vector lacks E1 function.
5
15. A defective recombinant PAV vector according to claim 14, wherein the vector is deleted in the E1 region.
16. A defective recombinant PAV vector according to claim 15, 10 wherein the vector is additionally deleted in a region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right end of the genome.
17. A defective recombinant PAV vector according to claim 16, wherein the vector is additionally deleted in more than one region selected from 15 the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right end of the genome.
18. A defective recombinant PAV vector according to claim 14, wherein the heterologous nucleotide sequence encodes a therapeutic polypeptide.
19. A defective recombinant PAV vector according to claim 18, 20 wherein the therapeutic polypeptide is selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.
25. A recombinant PAV vector comprising a PAV genome and at least one heterologous nucleotide sequence, wherein the heterologous sequence is inserted in a region selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.
30. The recombinant PAV vector of claim 20, comprising two or more heterologous nucleotide sequences.

22. The recombinant PAV vector of claim 21, wherein the two or more heterologous nucleotide sequences are inserted at different sites.

23. The recombinant PAV vector of claim 20, wherein the heterologous nucleotide sequence encodes a therapeutic polypeptide.

5 24. The recombinant PAV vector of claim 23, wherein the therapeutic polypeptide is selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

10 25. A method for obtaining a recombinant PAV comprising a heterologous nucleotide sequence inserted into an insertion site, the method comprising the steps of:

(a) providing a PAV genome;

15 (b) providing a heterologous nucleotide sequence;

(c) linking the heterologous nucleotide sequence to guide sequences, the guide sequences being substantially homologous to PAV sequences flanking the insertion site, such that guide sequences are present at both ends of the heterologous sequence;

20 (d) introducing the construct from step (c) into a cell together with the PAV genome;

(e) allowing homologous recombination to occur between the two sequences from step (d) to generate a recombinant PAV genome;

(f) purifying the recombinant PAV genome;

25 (g) inserting the recombinant PAV genome into a mammalian cell;

(h) culturing the mammalian cell under conditions wherein the recombinant PAV genome is replicated and packaged; and

30 (i) collecting the recombinant PAV from the cell or the culture medium.

26. The method according to claim 25 wherein the insertion site is located in a region of the PAV genome selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

5 27. The method according to claim 26 wherein the PAV genome is deleted in a region selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

10 28. A method for producing a recombinant PAV that comprises introducing the PAV vector of claim 14 into an appropriate helper cell line and recovering virus from the infected cells.

29. The method according to claim 28 wherein the helper cell line provides E1 function.

30. A host cell comprising the vector of claim 10.

31. A host cell comprising the vector of claim 11.

15 32. A host cell comprising the vector of claim 12.

33. A host cell comprising the vector of claim 13.

34. A host cell comprising the vector of claim 14.

35. A host cell comprising the vector of claim 20.

20 36. A recombinant porcine cell line comprising an adenovirus E1 gene region, said recombinant cell line thereby providing E1 function and allowing replication of a PAV vector having a deletion in the E1 region.

37. A method for producing a recombinant PAV, the method comprising:

25 (a) introducing, into the cell line of claim 36, a vector comprising ITR sequences, PAV packaging sequences, and at least one heterologous nucleotide sequence, wherein the vector is deleted in the E1 region and the vector is additionally deleted in one or more regions selected from the group consisting of the E2 region, the E3 region, the E4 region, and the region between E4 and the right end of the genome;

(b) culturing the cell line under conditions whereby virus replication and packaging occurs; and

(c) recovering virus from the infected cells.

38. A method for producing a recombinant PAV polypeptide, the
5 method comprising:

(a) providing a population of host cells according to claim 31;
and

(b) growing said population of cells under conditions whereby
the PAV polypeptide is expressed.

10 39. A method for producing a recombinant PAV polypeptide, the
method comprising:

(a) providing a population of host cells according to claim 32;
and

(b) growing said population of cells under conditions whereby
15 the PAV polypeptide is expressed.

40. A method for producing a recombinant polypeptide, the method
comprising:

(a) providing a population of host cells according to claim 33,
and

20 (b) growing said population of cells under conditions whereby
the polypeptide is expressed.

41. A method for producing a recombinant polypeptide, the method
comprising:

(a) providing a population of host cells according to claim 34,
25 and

(b) growing said population of cells under conditions whereby
the polypeptide is expressed.

42. A method for producing a recombinant polypeptide, the method comprising:

(a) providing a population of host cells according to claim 35, and

5 (b) growing said population of cells under conditions whereby the polypeptide is expressed.

43. A PAV polypeptide encoded by the nucleotide sequence of claim 2.

10 44. A PAV polypeptide encoded by the nucleotide sequence of claim 3.

45. A PAV polypeptide produced by the method of claim 38.

46. A PAV polypeptide produced by the method of claim 39.

47. A recombinant polypeptide produced by the method of claim 40.

48. A recombinant polypeptide produced by the method of claim 41.

15 49. A recombinant polypeptide produced by the method of claim 42.

50. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

(a) providing a biological sample; and

(b) subjecting the sample to hybridization using a labeled probe

20 comprising at least ten continuous nucleotides of the sequence according to claim 1.

51. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

(a) providing a biological sample; and

25 (b) subjecting the sample to hybridization using a labeled probe comprising at least ten continuous nucleotides of the sequence according to claim 3.

52. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to a polymerase chain reaction using

5 primers comprising at least ten continuous nucleotides of the sequence according to claim 1.

53. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

- (a) providing a biological sample; and

10 (b) subjecting the sample to a polymerase chain reaction using primers comprising at least ten continuous nucleotides of the sequence according to claim 3.

15 54. A kit for detecting the presence of PAV nucleotide sequences in a biological sample comprising one or more probes, said probes comprising at least ten continuous nucleotides of the sequence according to claim 1.

55. A kit for detecting the presence of PAV nucleotide sequences in a biological sample comprising one or more probes, said probes comprising at least ten continuous nucleotides of the sequence according to claim 3.

20 56. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 43.

25 57. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 44.

58. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

5 polypeptide of claim 45.

59. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

10 polypeptide of claim 46.

60. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 43.

61. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 44.

15 62. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 45.

63. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 46.

64. A method for obtaining antibodies to PAV, the method comprising:

20 (a) providing a PAV polypeptide according to claim 43;

(b) immunizing a mammalian host with the polypeptide; and

(c) collecting antibody from the immunized host.

65. A method for obtaining antibodies to PAV, the method comprising:

(a) providing a PAV polypeptide according to claim 44;

25 (b) immunizing a mammalian host with the polypeptide; and

(c) collecting antibody from the immunized host.

66. A method for obtaining antibodies to PAV, the method comprising:

(a) providing a PAV polypeptide according to claim 45;

(b) immunizing a mammalian host with the polypeptide; and

30 (c) collecting antibody from the immunized host.

67. A method for obtaining antibodies to PAV, the method comprising:

- (a) providing a PAV polypeptide according to claim 46;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

5 68. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 64.

10 69. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 65.

15 70. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 66.

20 71. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 67.

25 72. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 47.

73. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

5 polypeptide of claim 48.

74. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

10 polypeptide of claim 49.

75. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 47.

76. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 48.

15 77. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 49.

78. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a nucleotide sequence according to claim 2.

20 79. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a nucleotide sequence according to claim 3.

80. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 43.

25 81. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 44.

82. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 45.

5 83. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 46.

84. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 47.

10 85. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 48.

15 86. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 49.

87. A pharmaceutical composition comprising the defective recombinant PAV vector of claim 14.

20 88. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a defective recombinant PAV vector according to claim 87, wherein the vector encodes an immunogenic polypeptide.

89. A pharmaceutical composition comprising the vector of claim 10.

90. A pharmaceutical composition comprising the vector of claim 11.

91. A pharmaceutical composition comprising the vector of claim 12.

25 92. A pharmaceutical composition comprising the vector of claim 13.

93. A pharmaceutical composition comprising the vector of claim 20.

94. A pharmaceutical composition comprising a recombinant PAV obtained according to the method of claim 25.

30 95. A pharmaceutical composition comprising a recombinant PAV obtained according to the method of claim 37.

96. A pharmaceutical composition comprising the host cell of claim 30.
97. A pharmaceutical composition comprising the host cell of claim 31.
- 5 98. A pharmaceutical composition comprising the host cell of claim 33.
99. A method for eliciting an immune response in a mammalian host to protect against an infection comprising administering a pharmaceutical composition comprising a recombinant PAV vector capable of expressing a protective antigen.
- 10 100. A method of gene therapy in a mammalian host comprising administering to the host the vector of claim 11.
101. A method of gene therapy in a mammalian host comprising administering to the host the vector of claim 13.
- 15 102. A method of gene therapy in a mammalian host comprising administering to the host the defective recombinant PAV vector of claim 14.
103. A method of gene therapy in a mammalian host comprising administering to the host the recombinant PAV vector of claim 20.
- 20 104. A method of gene therapy in a mammalian host comprising administering to the host a recombinant PAV vector obtained according to the method of claim 25.
105. A method of gene therapy in a mammalian host comprising administering to the host a recombinant PAV obtained according to the method of claim 37.
- 25 106. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 31.
107. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 32.
- 30 108. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 33.

109. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 34.

110. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 35.

5 111. An antibody that specifically binds the polypeptide of claim 43.

112. An antibody that specifically binds the polypeptide of claim 44.

113. An antibody that specifically binds the polypeptide of claim 45.

114. An antibody that specifically binds the polypeptide of claim 46.

10 115. A composition comprising a full-length genomic clone of a PAV genome.

116. The composition of claim 115 wherein the PAV genome is the genome of PAV-3.

117. A method for obtaining a full-length genomic clone of a PAV genome, the method comprising:

15 (a) providing two or more cloned segments of the PAV genome, wherein the cloned segments of the PAV genome, taken together, represent the entire PAV genome;

(b) introducing the two or more cloned segments of the PAV genome into a cell;

20 (c) allowing homologous recombination to occur within the cell between the two or more cloned segments of the PAV genome to generate a full-length PAV genome; and

(d) purifying the full-length PAV genome from the cell.

118. A full-length PAV genome produced by the method of claim 117.

1 / 14

CATCATCAATAATACCGCACACTTTATTGCCCTTGTGGCGTGGTATTGGCGGAGAGGGT
TGGGGCGCGGGCGGTGATTGGTGGAGAGGGTGTGACGTAGCGTGGAACGTGACGTGGCGTGG
GAAAATGACGTGTGATGACGTCCCCTGGGAACGGGTCAAAGTCCAAGGGGAAGGGTGGAGGCCCTG
GGCGGTCTCCGCGGGGGCGGGCGAGCGCGGAAATTCCGCACAGGTGGAGAGTACCGCGGGA
TTTGTCGCCCTCTGGACCGGACCTTCCGCCTCGGTGTGGCATTCCGCACACGTCCGCGGCC
CGGTATTCCCCACCTGACGACGGTGACACCACACCTGAGCGGGGTGTCCCTCGCGCTGAGAGGT
CCGCGGCGGCCGCCGAGATGACGTGTGGGTGATTTCAGTGATATAGTCGC
AGCAGGGAGAGTCAGTACTCTGAGTCCGAAGGGAGTAGAGTTCTCTCAGCGGAACAGACCC
CGACATGGCGAACAGACTCACCTGGACTGGGACGGAAACCCCGAGGTGGTGCCTGAGAG
GGACCCGGTGGATCTGCGGACCCCTCTCGGGGGATGAGGGCTCTGTGAGCGTGTGGAGAG
TCTGGTCATGGACTGCCGGACGAGTGGCTGGACAGTGTGGACGAGGTGGAGGTGATTGTGACTGA
GGGGGGTGGAGTCAGAGGACAGTGGTGGAGTGGCCTGGTACTCAGGTGGCTCTCAGGGGGTCTT
TGAGATGGACCCCCCAGAAGAGGGGACAGTAATGAGGAGGATATCAGCGCGTGGCTGGAGG
GCTGTCGAACTGGCTGATGTGGTTTGAGGACCCACTGCGCCACCCCTCTCGTGTGGAG
CTGCCCCGAGGTACCTGGTGTGAACTGCCGCTTGTGATTACCATCGCTTCACTCCAAGGACCC
CAATCTGAAGTGCAGTGTGCTACATGAGGATGCATGCCCTGCTGTCTATGGTGGAGTTTG
GACATTGTGGATTATGTGAAAAAAAGGAAAAAGTGTGTAAGAAATCTCATGTGCTATTCC
CATTGGTCTTTAGAAGCTGTTCTCCAGCACCTCACAGGTGGGTTCCCAGGACTTGGAG
ACCTGCCAGGACGCAAGAGGAAGTACTGCTATGACTCATGCAGCGAACACCTTGGACCTGTCTA
TGAAGCGCCCCCGGATAATCATTAACCTCAATAACAGCATGTGATGATGACTGATTGTCTGTG
TCTCTGCTATATACCTGTGGTTGCAGGGAAAGGGATGTGGTACTGAGCTATTCCCTAGCA
TCATCATCGCTCTGCTTTCTACTGCAGGTATTCTGCTAGCTCGCTGTCCCTTTCTTT
CTGTGGGATGGACTATCAACTCTGGCCAAGCTACTAACGTGAACTACCTTAGGAAGGTGATAG
TACAGGGTCTCAGAACACTGCCCTGGTGGAAAAAGATTTTCGGACAGGTTATCAAGGTAGTAG
CAGAGGCCAGGAGGCAGTACGGCAAGAGTTGAGATTGGAGGGTGGAGAGGGCTTG
GTCCTGAGTTCTGCCGGAAAGGGGACTGTACGAAGAGGCCGTTCTGAAAGAGTTGGATTTCAGCA
CCTTGGGACGCCACCGTAGCTAGTGTGGCTCTGGTCTGCTTCTTTGAGAAGCTCAGAACACA
GCGGGTGGACTGACGAGGGTATTAAAGTCTCTGGTGGCCACTATGTTCCCTGCTGGAGGGCG
GAATGATGGCGGAGCAGGTGCGGCAGGGCTGTGCATCATCAGGATGCCGAGCGCGGAGCGGGAGA
TGCTGTTGCCAGTGGGTGATCCGGCAGTGGCAGCGGGCCGGATGCCGGACCAGGTGGTCCCA
AGCAGGGCGGGAGCAGGAAGAGGAGGAGGAGCAGGATGGGATGGAAGCGAGCGGGCGCAGGC
TCGAAGGGCCGGATCTGGTTAGATGCCGCCGGGGAGCGGGTGGAGAGGGAGCGGGGA
GGAGGCGGGGGGCTTCCATGGTAGCTATCAGCAGGTGCTTCTGAGTATCTGGAGAGTCCTCT
GGAGATGCATGAGCGCTACAGCTTGAGCAGATTAGGCCCTATGCTTCAGCCGGGGATGATCT
GGGGGAGATGATAGCCCAGCACGCCAACGGTGGAGTTGAGCCGGGACCGGTGTACGAGCTGAGGCG
CCCGATCACCATCCGCAGCATGTGTTACATCATCGGAACGGGCAAGATCAAGATTGGGGAA
TTACACGGAGTACATCAACATAGAGCGCTAACACATGTGTTCTGAGTATCTGGAGAGTCCTCT
GACTATCACGGATGTGGTTTGATCGGGAGCTACCGGGGGGGTGGTCTGATTTAGCCAACAC
GCACTTCATCCTGCACGGCTGCAACTTCTGGCTTCTGGCTCGTACAAGGCCTGGACCCGG
GGGGGGTGGTGCAGGGGATGCTACTTTCTGCCCTGCTACAAGGCCTGGACCCGGGGGGGGCTGTG
GCTGACGGTGAACGAGAACACGTTGAAAAGTGTGTGAGCGGGTGGTCTGAGGAGTGGCAG
GATCAAGTACAACCTCCCTGTCCACCTCTGCTCTGACATGAGCTACGGGCAAGATAGT
GGGAACAGCATGAGCCCTACAGTTCAGCGACGACCCCTACGTGGACCTGGTGTGCTGCCA
GAGCGGGATGGTGTGATGCCCTGAGCACGGTGCACATCGCTCCCTCGTCTGCCCTACCG
GTTCCGCAAGAATGTGCTCTCCGAGCACCATGTTGGGGCGCCGCTGGGAGCTCAGGCC
CAGCCGCTGCTCTACAGCTACAGCTCCCTGGTGGAGCAGCAGTCTACCGGGGCTGTGAGTGT
GACCTGCTGTTGATGACACTGTGAGATGTACAAGCTGCTGAGCGTACGGAGGCGAGAGAT
GGAGACGGATACCTCTCAGCAGTACGCCCTGCTGAGGGGACAATACCCCTGGCGCAGGTGCG
GCAGATGAAAGTGAACGAGCACGCCGCTGCCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
CAGCGATGAGCAGTGAAGGAGTGGAGTACGAGTACCCCCCTCCCTCTGAGGTACGTGGGCC
AGTGGGATGGCTTGGATGGGGAGGGGGTGTCCCTATAAAAGGGGGATGGGGGTGGAGGCATGC
AGCCCCACGGGGAGCTTGTGTGGAGGATGTCTCCGAGGGTGGAGATCCGGACCTGCTTCAATTCA

FIG._ 1-1

SUBSTITUTE SHEET (Rule 26)

2 / 14

GCTCGTCTTCCCAGCTGGGCCGGCGTCGCTCAGGGAGTGGCCGGACGAATGTGAACGGCGGAGTG
 GTGGGCAGCCCCCTGCCAGAGCGGGGTGCTGGCCTACTCCCGCTTCGTTCAAGCAACAGCAGCAG
 CGGGGACGGCGGCGACGGGGTCTGTGTTCCGGGGGTGTTCCATCGTGGATCTGAGCGCGGAG
 GTGGGCATGATGCGGCAGGCCTGGCGAGCTGCGGAGCTGAGGAGCTGCGGGAGGTGGTG
 GAGATAACAGCTGCGGGCACGGCCTCGGAGGCGCCGAGGAGGAAGAGGAGGAGGAGATTGTGGTG
 GACGAGGAGGTGGCGCCCGGCGCTGGAGCGAACACCATGGAAGAGGAGGAGGATGAGATGGCCTG
 ACGATGACTGTGGTGGGGGACCTGAGCCTGCTGGAGTGGAAAGCCCAGCCACCAACCAACCCACC
 CCGGAGAGCAGCCCTGCGGTGCGCTGACTACCAACTACCCCGAAGCGGCTCAGCTACGGCGCGAGC
 AAGAGGAGCGGTCCATGCGCGAGGACAACGTACGCGGACTGTGGGGGAAGAAGGGGAGGAGGA
 AAGAACCATGGAGACGGGTGTTGTCTTTCCAGCCAACTTATTGAGAATAATAAAAGC
 TTATGGATGTTGAAACGATAATAGCGTGTCCAGCGTTCTGTCTGCTTCAGGGCTTGTGATCTT
 CTCGAGGCACCGTAGACCTGGTGTGGACGTTGAAATACATGGGCATGACTCCCTCGGCGGGGTG
 CAGGTAAGGCACTGGAGGGCTGGGTGCGGGGGCAGGTGCAAGTAGATGATCCAGTCAGGCCT
 CTGGTGCCTGGTGGTGGTAAAATGTCCTTGAGGAGCAGGCTGATGGCGTGGCAGACCCCTGGT
 GTAGGCATTGATGAACGGGTTGACCTGGCGGGCTGCATGAGGGGGACATGATGTGGTACTTGGC
 CTGGATCTTGAGGTTGGAGATGTTGCCGCTCTGGTCGCGGCGGGGTTCATGTTGTGGAGGACGAC
 GAGGACGGCGTAGCCGGTGCAGCGGGGAAGCGGGCGTGCAGCTGGAGGGGAAGGCGTGGAAAGAA
 CTTGGCACCCCTTGTGTCGCCGAGGTCTCCATGCACTCGTCAAGGACGATGGCGATGGGTCC
 GCAGGGCGCGCGCGCGGGCGAAGACGTTGCGTAGTGCAGTCAGTGCACATCATAGTTGTGCTCTGCATGAG
 GTCTGGTAGCTCATGCGGACAAAGTCTGGCATGAGGGTGGCGGTCTGGGGGATTAGGGTGTGGTC
 CGGACCGCTGCGGTAGTTGCCCTCGCAGATCTGGGTCTCCAGGCCACTACCTCCTCGGGGGGAT
 CATGTCACCTGCGGGGTGATGAAGAAAACAGTCTCGGGGGGGAGAGGAGTTGGGAGGAGAT
 GAGGTTGCGGAGCAGCTGGACTTGCCGGAGCGTGGGACCGTAGATGACAGCGATGACTGGCTG
 GACCTGGTAGTTGAGGGAGCGCAGGTGCCAGCCGGGTGAGGAAGGGCATGCAGGCCTGGGAGGGT
 GTCGCAGGGTTGCGGTCTCTGGACGAGGTCTGCAGGAGGTGTCGGCCTCCAGGGAGAGGAG
 GTGGGAGAGGGAGGCAGGGCTTGAGGGGCTTGAGGCCCTCGGGTAGGGCATGTCCTGCAGGGC
 CTGGTGGAGCACCGCATGCGCTCCAGAGCTCGGTTACATGTCACCGGTATGTCCTCCAGCAG
 GTCTGGTTGTTCTCGGGTTGGGGTGTGCGTAGTACGGAACGAGGCGGTGGCGTCAAGGGG
 TGGAGGGTCCGGTCTTCCAGGGCCGGAGGGCCCGCGTGGGGTGTGACGGTGAAGGGG
 GCGGTCTGGGGCTGCTCGGTGGCCAGGGTCTTGTGAGGCTGAGGCGCTGGTGTGAAGGTGGC
 CTTCCGAGCTGCGCTCGTTAGGTAGCACTGGCGAGGGAGGTGAGGCGCTGGTGTGAAGGTGGC
 TGGCCCTTGGCGCGAGCTTGCCTGGGGGGCGCGTGGCCAGGAGCTGGCGTGGTGTGAAGGTGGC
 GCGTAGAGCTGGGGGAGCAGGACCGTCTGGAGCTGTGGCGTGGTGTGAAGGTGGCAGCGCTCG
 TGGGTCTCGCACTCGACAGCCAGGTGAGCTGGGGTTCTGGGGATCGAAGACGAGGGGGCCCCG
 TTCCGTTGAGGGCGGTGTTACCTTGGTCTCCATGAGCTCGCTCCGGCGGGGTGAGGAAGAGG
 CTGCGGTGTCCTCGTGAAGGGAGCTGGCGAGGGAGGTGAGGAGCTGGCGTGGTGTGAAGGTGGC
 TAGAGGATGAGGGCCCACTCGGAGATGAAGGGACCGCAGGGAGGTGAGCTGGCGTGGTGTGA
 GAGGGTAGCGGTGTTGGCACTAATGGCGAGGCTGCTCGAGCGTGTGGAGACAGAGGTCTCG
 TCGCCGCTCCAGGAAGTGGATTGGTGCCTGGAGTGTGAGTCCACGTGACCGGCTTGCCTCG
 GGTATAAAAGCGCGGGCGGGGTGCGTAGGGCGTGGCGTACGGCTCGCAGGGCTCGTACCG
 GCGTCTCCGGCGTCTCGCGTGCCTGCACTGTGGTCCCGAGTCTCAGGTGGTACGCTACG
 ACAAAAGTCCGGGTGACCTCAGCGCTGAGGTGTCAGTGTGTTCTATGAAGGGCGGAGGCGGACGGAG
 AGGTCGCCGCCGCGATGGCTTCGGTGGTGCCTGGCGTCCATCTGGCTGGCGAAGACCACTTCTTA
 TTGTCGAGGGCGTGTGGCGAAACTGCCGTAGAGGGCGTGGAGAGAAGCTTGGCGATGCTGCGGAGC
 GTTTGGTTCTGTCCCGGTGGCCCTTCTGGCAGCGATGTTGAGCTGCACGTAGTCTCGGGCG
 AGGCAGGCCACTGGGGAAAGATGCTGTTGCCTCGCCAGGAGGCGCACGGCCAGGCCACGG
 TTGTGGAGGGTGACCACGTCCACGGAGGTGGCTACCTCGCCCGGGAGGGCTCGTTGGTCCAGCAG
 AGGCGGCCGCCCTGCGGGAGCAGTAGGGGGCAGGACGTCAGCTGGTCCCTCGTGGGGGGT
 GCGTCGATGGTGAAGAGGGCGGGCAGGAGGTGGGGTCAAGTAGCTGAGGGGCTGGGGCGT
 AGGGCGTCTGCCAGGGCGGGCAGGGCGGGTCAAGGGGGTTGGCCGGCGGG
 AAGGGGTGGGTAGGGCGCTGGCATACATGCCAGATGTCATAGACGTAGAGGGGCTCCCGCAGG
 AGGCCGATGAAGTGGGTAGCAGCGGCCGCCAGGCTTCCAGGAGCTGGCGACGAGTCACTACAGCTC
 GTGGGAGGGCGCGAGGAGGTGGCCGAGGTGCGCGCCTGGGGCGGCTGGCGCGGTAGAGGAGC
 TGCTTGAAGATGGCGTGGAGTGGAGCTGATGGTGGGCTCTGGAGACATTGAAGGCGGTGG
 GGAAGGCCGGCTGCGTGTGGAGCAAGGCCGGTAGGACTCTTGCAAGCTTGCAGGCTGGGACCAGACGGCG
 GTGACGACGACGTCTGGCGCAGTAGCGCAGGGTGGCCTGGAGGATGTCGTAAGCGTCCCCCTGG

FIG._1-2

SUBSTITUTE SHEET (Rule 26)

3 / 14

CTCTCCTTCTCCACAGGTCTTGTGAGGAGGTACTCTGATCGCTGTCCCAGTACTTGGCGTGT
 GGGAAAGCCGTCCTGATCGCGTAAGTAGTCCCCGTGCGGTAGAACCTCGTTACGGCATCGTAGGGG
 CAGTGTCCCTGTCCACGGCCAGCTCGTAGGCCGGCGGCCCTGCGGAGGCTGGTGTGCGTGAGG
 GCGAAGGTGTCCCAGGACATGAACCTGACGTACTGGTGTGGGGTCTCGGGGCATGACGCC
 TCCTCCCAGTCCCGTAGTCGCGGCCGGAGGCGGGGTGGGAGGTTGAAGCTGATGTCA
 TTGAAGAGGATGCGGCCGTGCGCCGATGAAGGTGCGGGTGAACAGGAAGGAGGGGGCACCTCG
 CGCGGTGGCGAGCACCTGCGCGCCAGGACGATCTCATCGAAGGCCAGATGTTGTGGCCACG
 ATGTAGACCTCCAGGAAGAGGGGCCGCGCAGGCGGCCGCGCAGCTGGGCATAGGCCAGG
 GGGTCCCTCGGGTGTGCGCCAGGCCGGGGCCCGCTCTGCGCCAGCTGGCGAGGTCTGGGTG
 TGGGCCAGCAGGTGCTGCCAGAGGTGTCGGTGAGGCGGGCTGCAAGGGCGTCCGCAGGGCCTTG
 AAGGCAGGCCGATGGCGCTTCTGCGGGCAGACATGAGAAGGTGTTGGCTGGGTCTCCAGC
 GCTGAGGGGGCTCTGGACGGCCACCACCTGCAAGCGGCCGTCCAGCAGCTCCTCGTCCCCGAG
 AGGTGGAAGACCAGCAGGAAGGGCACGAGCTGCTTCCGAAGCGGCCGTGCCAGGTGAGGTCTCC
 AGGTCAAGGTGAGGAAGAGGCGGGTGCCTCGGGGAGGCCATGGGCGGAAGGCCATGGTC
 TGCAACCAGTCGGCGCTTGTGCGCTGAACGTGGTGAAGTAGAACGATCCCAGGCCACGGAGCAG
 GTGTGGCGGTCTGGAAGATGCGGCCAGTGCTCGACTTCTGGGCCTCTGGATGCTCTTGATG
 AGGTGGCAGCGGCCCTGGGTGAAGAGCAGGCGGAGGGGAAGGGGAGGCGGGCGGCCCTCG
 GGCGGGGGTCCCAGCGCACGTGGTGCAGGTGGTGTGCTGGCGGGTACCACTGGACGAAGGTG
 GGCGCGCGCAGCTCCACCGCGCTGGGGTAGCTGCAGGAGGTGGCGACGGAGGTGGGGCGGG
 CGCAGGAGGTGCAAGAGGTGGCCAGGGCGCTGCTCCAGTGGCGGTGAGGTGATGCTC
 CAGCTCTCCCCCTGGTGGTGGCCCTGGAGGCGGAGGGTGGCGGGCGCTCGAGCAGGAGCCCC
 CGCGTGGCGGCCCTCGCGGCCCTGGCGGGCGCGGGTCTCAGGGGGCAGCTGGGCCAGGGGCA
 CGGGCGCGTTGAGCTGGCAGCGGGAGGTGGTGCAGGGCGAGACGCAGGGCGTGGCGATGACGC
 GGCGGTTGATGTTCTGGATCTGCGGTTCCCGAGAACGACACGGGCCGGTACTCGAACCTGA
 AAGAGAGTTCCACGGAATCAATGTCGGCATCGTGGTGGCCACCTGGCGCAGGATCTGGACACGT
 CCCCGCTGTTTCCGGTAGGCGATGTCCTGCATGAACGTGCTCGAGCTCGTCTCGTCCAGGTCCC
 CGTGGCGCGCCTCACGGTGGGCCAGGTGACGGTATGGTTCTCGTCCACAGCGACTGTAGACCAG
 CGTTCTCTCGTTCTCGTCCACAGCGACTGTAGACCAGCTGGCGTGGCGTCCCGCGCGCA
 TGACTACCTGGCCAGGGTGGAGCGCCACCAGGGCGTTGAAGGGCGCTGCAAGGGCGTGGT
 GCAGGTAGTTGAGGGTGGTGGCGATGTGCTCCAGAGGAAGAAGTTATGACCCAGCGGGCGAGGG
 TCAGCTCGTTGATGTCGCCAGGTGGCCAGGGCGCTGACGGTATGGTTCTCGTCCACAGGGG
 GAAAAAAACTCGTGTGGCGGGCCAGACCGTGAAGCTCTTCCAGGGCGGCGATGGCTCGGCCA
 CCGCCTGCCGCACCTCCCTCTAAGGAGGGGGGGCGTGTGGTCCGGGCCACCGCCCTCTT
 CTTCCCTCTCCCTCACGGGTGGCATCTCTCGTCTTCTCTGCTGCTGCTGCCCTCGCGG
 GGACGGGGGCGCAGGCCGGGGACGGCGCCGGCGCAAGGGCAGCCGGTCCAGGAAGCGCTCGATGA
 CCTCGCCCCGCATGCGCGCATGGTCTCGGTGACGGCGGCCGGCCCTCCGGCGCAGCTCGA
 AGGCCTCCCCCGCGCAGCGCGGTGCCGTGCAAGAGGGCAGGCTGAGCGCACTGATGCA
 TCAACTCTCTCGTAGGTACCTCTGCTGTTGCAAGCGCTCGGCAAACACTCGGCCACCTGCTCTCG
 ACCCGCGAAGCGTTCAGAAGCGCTAGCCAGCAACAGTCGAAGGTAAAGTTGAGCGCGGTGT
 GCGTCGGGAGCCGGAGGTGGCGCTGACGAGGAAGTGAAGTAGGCCGCTTGAGCTGCCGGATGG
 CGCGCAGGAGGGTGAGGTCTTGGCGCCGGCGCTGCAAGGGCGATGCCGTGGCGTCCAGG
 CCTCGTGGCAGCGCCGATGCTTGAGCTGCTCTGCAAGCAGATGTGCCACGGCACCGTCCC
 GGTGGCGTCCAGGTGGTGCAGCGTAGCCAGGGCGCAGCAGCGCCAGGTGGCGAC
 CGCGCTCGGCCAGGATGGCCTGCTGCATGCGCTGCAAGGGAGTCTGAGAAGTCATCCAGGTCCAGGA
 ACCGGTGGTAGGCGCCGTGTTGATGGTGTAGGAGCAGTTGCCACCGGACCGAGTTGACCCACCT
 GGTAGTGGGGCTGGATGACCTCGTGTAGCCAGTCAGTCAGTGGCGCGTGTCAAAGATGTAAT
 CGTTGCAGAGGCAGCAGCGAGGTGCTGGTAGCCACAGGAGGTGGGGCGAGGGTAGAGGTAGAGGG
 GCCAGTGTCCGTGGCGGTGGCGGGGGAGAGGTTCATGAGCATGAGGCCGTGGTAGCGGTAGA
 TGAAGCGGGACATCCAGGCAGTGGCAGCGCGAGACGGAGGCGGGTCCACTGGTGGCGCGGT
 TCCAAATGTGCGCACCGGGCGGAAGAGCTCCACGGTAAATGATTGCCCGTGAAGCGGGCGC
 AGTCGAGGGCGCTCTGTCAAAAGAACGGGTGTGGTTGGTGTGTAGCGATCTATCTT
 CTTGTGATCTGGTAGTGAAGCTGCCAGGCTCCAGCAGGGGGCGTCCGCGTCTTCCCT
 CCCTATCTGGAGGTGTGCTCTGTTCTCTTTTATTCACTGAGCCATGCATCCGTTCTGCGGC
 AGATGAAGCCGCCGGCGCCCTGGCGGGAGGGGGAGGGCGACCGCGCTCGGTGCGCCCTCGCCGT
 CGCTGACCGGCCGCGCAGGAGGGGGAGGGCGTGGCGCGCTGCGGGCGGGCGGCCCGAGC
 GGCACCCACGGGTGCAAGCGAGAGGCCATGGAGGGCTATGTGCCAGGGCAGAATGCGTCC

FIG._ 1-3

SUBSTITUTE SHEET (Rule 26)

4 / 14

GCGAGCGACCGGGGGAGGGGGGAGGGAGGAGATGAGGGACCTGCGGTCCCGCGGGGGCGGGAGATGC
 AGCTGGACCAGGGAGCGAGTGCTCCAGCCCAGGGACTTGAAGGGCGCTGGAGGGAGGCGGGGGAG
 TGAGCGCGCGCGGGCCACATGAGCGCGCAGCCTGCCAGGCCACTACGAGCAGACGGTACCGC
 AGGAGGTCAACTTCAAAGACCTCAACAACAACGTGCGCACCCCTGGTGAAGGGAGGCGGGAGGTGA
 CCATGGGACTGATGCACCTGTGGACTTTGTGGAGGCCCTCCTGCAGCACCCCCGGTCCCGCGC
 TGACCGCGCAGCTGCTGATCGCGCAGCACTGCCGGACGAGGGCATGGTAAGGAGGCCTGC
 TGAGCCTGGCGCGCCAGAGGCCCTGGCTGGACTGGTGAACCTGCTCCAGACCAATTGTGG
 TGCAGGAGCGGTCCATGAGCTGAGCGAGAAGGTGGCGCCATCAACTACTCGGTGGCGACCCCTGG
 CCAAGCACTACCGCGCAAGATCTCACCTACATGCGCGCGGTGGTGAAGCTGCTGGTCTGG
 CCGACAACTGGGATGTACCGCAACAAGCGCTGGAGCGCGTGGTCAAGCACCTCGCGCGCG
 AGCTCAATGACAAGGAAGCTATGTTGGCTCCGCCGGCGCTGCCGGGGAGGGCGAGGAGGAC
 CTGGAGGAGGAGGAGGACCTGGAGGAGGCGAGGAGGAGGAGCTGAAAGAGGAGGAGTTCGGTCC
 CGGGGACCGCGCGCGTGAAGGTGGCAGTCCCCGCTGACTGCGAGCGATGAGGTGATGTGTACTG
 ATGGCAACCATCCCCCTTTTAACAACAACAGCAGCATGGCGCGAGCTCTGAAGCTGGCG
 GCAGCGGGGTGAGCGCGCCCTCCCTGGCGCCAGCGGGGAGCGGGATGCAGGCCTGCCCTCC
 CTGGACGAGCCTTGGGAGCAGGCTCTGCGCGCATATGGCCTGACGCCGACGGGTCTCGCGC
 TTGCGAGCCAGCCCTGGCCAACCGCATGGGCCATCTGGAGGCGGTGGTGCCTCCGCGCAG
 AACCCGACGCAAGAGAAGGTGCTGACCGTGGTGAACCGCTGCTGGAGACCTGGCCATCCGCC
 GACGAGGCCGAGTGGTACGATGCGCTGCTGGAGCGGGCTCCCGTACAACAGCGGAACCGT
 CAGACCAACCTGGACGGCTGCCCCAGGACGTGCGGAGGTGATGCCAGCGCGCTCGAGC
 GCCAACACCTGGCAGCCTGGCGCTGAATGCTTACATGCCCTCGTGCCTCCGCAACGGTGGAG
 CGGGGCCAGGAGAGCTACCTGGGTTCTCAGCGCGCTGCGGCTGCTGGTGAAGCGAGGTGGCG
 ACGGAGGTGTCGCTGGGGCCACACCTTCTGCAAGCGGCCGGAACGGTTCAAGACGGT
 AACCTCAACCAGGCCATGGAGAACCTGCGGCCCTGTGGGGCTGCAAGGCCCGCTGGGAGCGC
 GGGCACGTGTCCTCCCTGCTGACGCCAACACCCGGCTGCTGCTCCCTGGTGGCTCCCTCG
 GAGGAGATGAACGTCAAGCGGAGCTCCTACATTGGCACCTGCTGACACTCTACCGCGAGCG
 GCCAACTTGCATGTGGACGAGCGCACGTAACAGGAGATCACAGCGTCAGCCGGCGTGGCG
 GAGGACGACCGCGGGCTGCAAGGCCAACGGCCCTGGACGAGGAGCGCATCGCAGGCC
 CCGCGCGTATGCCCTGACGCCAACACCCGGCTGCTGCTCCCTGGTGGCTCCCTCG
 CTGTAACCTGATGCAAGGACGGGGGACGGCCACGGCCACGGGCCCTGGACGAGGCC
 CCCAGCTTCTACCGCGGCCACCGGACTTCATCAACCCGCTGATGGACTACTTCCATCGCG
 CGGGTGGCGCCCAACTACTTATGAATGCCCTCTGAACCCCGCTGGTGCCTGCCCTGG
 TTCACCGCGTGTATGACTTCCGGAGCAGACGAGGGGGAGGAGCGGGCCCTGGACGCC
 AGCGACGAGGAGGGCCCTCATGCTGCGGCTCGCAGGCCCTCTCAGAGCCCTCCTCC
 CCCCTGCCCTGACCGAGGAGGCCCTCGCGGCCCTCCACCCGCCCTCTCGCGCGTCC
 CGGCATCCCTCGCTCTCTGGCCTCTCTGGAAAGCGGGAGGGAGCTCGCTCG
 TCGCCGGCACGCCAACCTATGGCTCTCGTGGGCTCGCGCCCTGGACGAGGCC
 GACAGCCTGGAGTGGGACGCGCTGCTGGCCCTCCAGGATGTAACGAGCACCCAG
 GCCGGCCGCCGCCGCCCTCCGCTCTCCCTGGAGGAGGACATCGACGCCATCAGCAGCG
 CTGTTACCTGGCGCACGCGCGCCAGGAGATGGCCTGCCGTGGCAGCTCTCC
 CAGCCGCGCCCCGGGCCCTCGAAGACGACGAGGAGGAAGACTGGCGCAGGAC
 CGGGTGGCTTCGCTACGGAGCCTTTATGTGCCCGCGGTACTGGGCCACCGAG
 ACAGCATCCGTTATTACAGCTCCGCGCTACGATACCACAAAGATCTATCTG
 AGTCGGCGGATATGCCAGTCTGAACCTACCAAAACAACCACAGTGACTTCTC
 AGAACAGCGACTTCACGCCATGGAGGCGAGCACGAGACCATCAACCTGG
 AGGAGGAGCATCGGGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
 ACAGCTCCGGGTGCGCCCTGATGAGCGCGCGATAAAAGAGACAATGCC
 TCACCCCTGACCCCTGCCAGGGCAACTCTCGGACATCGCGGTAC
 TCGTGGAGAACTACCTGGCGGTGGGCGCAGCAGGGGTCAGGGAGGAG
 TCGACACCGCGCAACTTCCGCTGGCTATGACCCGGAGACCAAGCTGG
 CCAACATGGCCTTCACCCGACGTGGTGTGGCACCGGGCTGCC
 GCCTAAACAACCTGCTGGGATCCGCAAGCGCTACCCCTACCAG
 AGGACCTGGCGGGGCAACATCCCCGCGCTGGACCTCACCA
 CACCTATGATCAGGAGAACTCCA

FIG._ 1-4

SUBSTITUTE SHEET (Rule 26)

5 / 14

GCACCATCAAGCCCCCTGAAGCAGGACAGCAAGGGTCGCAGCTACCACGTGGGCCAGGACCCCGAGG
 CGGGGGACACCTTCACCTACTACCGCAGCTGGTACCTGGCTACAACATACGGGACCCGGCACGG
 GCACCGCCTCCCAGACGCTGCTGGTCTCCCGGACGTAACCTGCAGCTGGACAGGTCTACTGG
 GCCTGCGGGACTGATGCAGGACCCGGTGACCTTCCGGCCAGCCAGACGCCAGCAACTACCCGG
 TGGTAGCCACGGAGCTACTGCCGCTGCCCTCCGGGCTCTACAACACCCAGGCCGTGTACTCCC
 AGCTCCTGCAGCAGGCCACCAACAACACCCCTGGTCTTAACCGTCTCCGGAGAACAGATCCTCC
 TGCGCCGCCAGAGTCCACCATCACCTCCATCAGCGAGAACGTGCCCTCGTACGGACCCACGGCA
 CGCTGCCGCTCGTAACAGCATCCCGGGGTGAGCAGGGTAACCGTACCGAGCGCGGCCCGCG
 TGTGTCCCTATGTGTACAAGAGTCTGGGGTGGTACCCCGAGGGTGTCAAGCAGCCGAACCTTCT
 AACCGACAGCCCTACCCGTACAGGGGAGACAGAGAAAAGACAGCCAGCCGCATGGCATCCT
 CGTCTCGCCCAAGCAACAACTTGGCTGGGACTGGGCTGCCTCATGTACGGGGCGCCCGCCG
 CCTGTCCCCGGATCACCCCGTGATCGTCCGACGCCACTACCGGGCAACTGGGCACTGTGAAGGG
 ACGCGTGGCCCCCAGCACCATAAGCAGACAAACGGATGACCTGTGGCCACGTGGTCAACGCGATCG
 CGGCCGCCACCCGCCGCCGCCATCGTGCAGCTGGAGGGCCGCGCGTCTCCCTCGTGG
 CGTACCCGGGACCCGGTGGCGATGTGGTCAACCGGGTGGAGGCGTAGCCCGCGCCGCCGCG
 CGGGCGCCGTTCTCGCGATGCAGACCACGGGGACCCCGTGGCGATGTGGTGGCGGGTGG
 AGCGGTGGCGCGCCGGAGGGAGCACCCGGGGCGCGCAGGGCCTCCCGCGCCATCCTGG
 GGTGCGCCGAGCCGCCCTCGCAAACGCACCTCGTCTGAGATTGGTTTTGTTTCT
 GCCTCCCGTGGGTGAACAAGTCCATCCATCCAACATCCGTGGCTGCTGTGTTGTTCT
 CTTTGC GTTGC GCCCAGTTGAGCCGGCACCGACGCCCTCGGCCATGCCATCTCGCGCCGTGA
 AAAAGGAGCTGCTGCAGGGCTGGCGCCGAGGTGTACGGGGCGCTAAGAAGGAGGAGAACG
 TCAAAGAGGAGTCAAAGCTGACCTAAACCGCTGAAGAACGGCGCAAGGCCAACGGGGTTGA
 GCGACAGCGACGGAGTGTGGTGCTGGCACCGCCCGAGCGCCGCTGGACGGGGCGCGCTGC
 GCGCCACCTACCGCCGGTGCCAGCCTCGCTACGCCCGGGTCTCGGAGGTGAGCGCCACCA
 AGCGCTCTCGGGACGAGTTGATCGGACACGGACATCGTGCAGCAGGGTCCAGCGCTGAACG
 AATTGCTTATGGCAAGAGAGGCCGGCAGCGGGGGCCCTCGCCGACCCCCCGCGTCCC
 CGGGCCGGACCAAGCGCTTTATGACGAGGTGTGGCAGACAGTACATCCTGCAGCAACTTG
 GATCCGGGGACCGCTCCAATGAGTTCTCCTATGGCAAGCGGTGCTGCTGGGGAGTCAGGAGACA
 CCGTCCCCTGTTGGCCCGTCCCGTGGAGGAAGGAGCACACACCCAGCCTGCAGCCGCTCA
 CCGAGCCCATGCCCTGGTGTCCCCCTCGCACGGCGTCAAGCGGGGGCGCCGCCGAGGAGCCA
 CGGCCACTGGTCCCCACCGTGCAAGGTCTGGCCCCCAAGCGTGTCTGCAGGAGGTGGTGG
 AGCCGCCGCTCCAGCACCCACGCCCGCCCTAGCCCCCGGGTCCAGCGGCCGATCATCTGG
 CTCCCGCGCCGGGGCGGGCCGGCCAGGGCGTGTGGCGCCAGCTCAGCGCCGCCGCGCTGG
 AGCGGGCGGGGGCGGGCCGGCCAGGGTGTGCCCCCTGCCACCCGACACGGAGGACGACCTGG
 CTGGAGATGGCAGAGGCTGGCCGCTGAGGAGGAGCACACCCAGCCTGGGAGGAGGAGG
 CTGTGCGCCGCCCCGAGGTGTGCCCAGCCTCCCGTCTCCATCATGCCGCCACCGCCACGGAGG
 TGGCCCTGCCCCGTACAGACCCACTGCCGCCGTGGCGTGGCCAAGAGCTCCTGACCCCCGG
 TCCCGCGCTGATGGGACCGAGGGGTGCCCCCTCCAGTCTGGAGGCGCCCTGGTGGCCATGC
 CCGTGTCCGGCCACCGAGCCGGTGGTGCAGTCCATCACGGTCAAGCGGTCAAAGCGCTGACCA
 ACATCCCAGGCCAGGCAGCCCCGACGGTATCCCTGCCCGTGTCTCACGGAGCCGGCCACCGT
 CGGTGCGCTCCGTGCGCGCCGAGCCCAAGTCTGCAGGCGCCCCCGCCGACCGCCACCGT
 CCGTGGGGGGTGGCACCGAGCCGGTGGTGCAGTCCATCACGGTCAAGCGGTCAAAGCGCTGACCA
 AGCACCATCGGGGTGAGGAGGACCATCGACGTACCGTGCCACCGTCCGACTGTCAAGCGTGG
 AACACGCCCGCTGAGGAGGCGCTCGGTGGCGTCCAGACCGCTCCCGAGACCCGCTCCAGGG
 GTGCAGGTGGCTTCCAACCGCGTGTAGCCACCGCACACCCAGGAGGGTGCAGGCTGACGGCG
 TGGTGGCCCCCACCCCGCGGCCCGGTGGTCTGGTGGCCGGCGCCGCCGCGGGTCCGG
 TCCCCCAGCCCTCCAGCCCCGCGCGCGCGTGCAGCGCTCGGCCCGCCCGAGAGCGCCCTCG
 CGGCCGTACCCGGTGGCGGTGGCAGCGCCGCCCGCCAGCGGGCGTCCCCCGCCCTCG
 CGAGGGCGGCCATCGTGTGCTGCCGGGTGCGCTATCATCCAGTCAGGCCATGGCTCCCACCG
 AACCGCTATCTGGCGTGTGATTATTTGGAGACCTGACTGTGTGTTCTTAAATT
 CCTCTCCTCTGCTGAAGCCAGACGATGCTGACCTACCGTTGGCGCTGCCCGTGGGATGCC
 GAGACCGAGACTCCCGGGTGGGTTCCCGTGGCGCTCGCGCAGCGGGCGAGGGCGGGTACCG
 CGGGGGCCGATGAGGGGTGGCATCTCGCCGGCGTGGGCCATCATCGCGGCATCCATCTGG
 CATCCCCGGCATCGCCTCGGTGGCGATGAGTGTAGACAACGCAATTAAACGGCGCTGCTGT
 TGTGTCTTCCATGTGCCCTCTCTCGTCCAAACGGAACAGCAGCACCCTCCATGGAGGAC
 CTAAGCTTCCCGCTGGCTCCACGCTTGGCACGCCGGTCACTGGGACTTGGAGCGAAATC
 GGCACGAGTCAGATGAACGGCGGCCGCTCAGCTGGAGCAATATCTGGAGCGGGCTGAAGAGCTT

FIG._ 1-5

SUBSTITUTE SHEET (Rule 26)

6 / 14

GGTAGTTCTTGGCCTCCACGGCCAACAAGGCCTGGAACAGCGGGACGGTGACGAGCGTGCAC
 AAGTTGAAGGATGCCGACGTGCAGGGGAAGATAGGTGAGGTCAATTGGCTCCGGGTCCACGGTGCC
 CTGGACGTGGCCAACCAGGCCGTCTCCCACGCCGTGGACGCCGGTCAACAGCAGCAGCTGCC
 AGCAGCAGCTCCTCCGCCAGCAGCAACAGATGGCCTCGTGGAACCCCTCATGAGATGGAGA
 CAGACGAGCTGCCCTCCCTCCCCCAGGGACCTCTGCCTCTCCCTCCGCCGCCCTGCC
 CCACTCCCGCGGCCAATCCCGGGACGCCAGCAGGCCGCCGCCAGGAGATCATCA
 TCCGCTCCGACGAGCCCCCTCCCATGAAGAGCTGTATCCGACAAGGCCGGATCCCCGCCACCT
 TGGAGCTGCCGTCCCAGAACAAACTGCCGCCGTGGCCCACAATAAGATGCGCCCCCGCCGCC
 TCACCACCACCACTCCCGCTGCCGCCGCCGCCGCCGCCGCCGCCGCC
 GCGTCCGGCCGGCTCCGGCGCGCTCCGGCGAGTCCAAAGGCCGGAGGTGGGGTCCGC
 GCGCGGGTGGCAAACAAACTCAACACCATTGGAGCTGGGTGTCCGCACATGCAAGGCC
 CGTTGTTACTGAGAGAGACAGCATGGAGAACAAACAATGCTGGATCAAATAAGACACGCC
 TCTTCACGGTGTCCCGCTGTGTATTTCAACGGGCTGTTCCCTTTGCATCTGTGCC
 GCGCCACGGGAATTCCCGAGGATGGCGACGCCGTGATGATGCCGAGTGGTCTATATGCAC
 CTCCGGCAGCGCTCCGAGTACCTGTCTCCGGCTGGTGAGTCTCCAGGCAGGGAGAC
 CTACTTAACCTGAACAACAAGTTAGGAACCCCACCGTCGCCACCCACGATGTGACGAGGA
 GCGCTCGCAGGGCTGAGCTGCCGTCCGGACAAGGAGGACACTCAGTACACATACAA
 GACCCGCTTCAGCTGGGGTGCGACAACCGGTGTTGGACATGGCGAGCACCTTCTTGAC
 CCGGGGAACGCTGGACGGGGACCTCCTCAAACCGTACTCGGGCACCGCGTACAACATCATGGC
 TCCCAAGAGCGCTCCAAACAACTGTCAATATCTAGACCTAAAGGTGAAACTGAGGCTGCC
 TAATACCATGCTCAAGCAAGTTGTGGGTCTATTGATGAAACCAACGGGAGACATTAAATTAC
 AGAAGAAGAACGAGAACGAC
 CTCGTGGTCAGACAATATACCTCTCGACTAGCGGAGCTGGAGAGTTCTCAAACAGAC
 GCGTCAACCTGTACGGTTCTATGCCCTCCGACAAATATTCAACGGTGGGAAACGAAGGATGA
 CAAGGTTACACCATTGTACTTACAAACAATCCGCCACCGAAGCGAACGACTCGAAGAAAATGG
 ATTAAAGCCAATGTCAACCTATACTCAGAGGATGTTGACCTAAAGCACCAGATACTCATCTGG
 CTATGCTGTGAATCAAACCCAGGAATTGCTCAATATGACTTGGACAACAGGCCCTCAAACAG
 GCGCAATTACATCGGCTTCAGGGACAACCTTATCGGGCTGTTGACTACACAGCAATGCC
 GGGCATGCTAGCGGTCAAGGCCACTCAGCTCAACCGGGTGGTCACCTGCAGGACAGGAATCACCG
 AACTAGCTACCGCTCTCCTCGATAGCCTCTATGACAGGTGAGGTACTTTAGCCTGTGG
 GCCATCGATTCTTATGACAAGGATGTGCGTGTGGAAAACAATGGCTGGAGGACGAGATGCC
 CAACTTTGCTTCCCATCGGCCATCGAGACCAACATGACATTACACAGCTCAAAAGAGTGA
 GAATGGTGGCTCAAGAGGCCACAACCTGGACAAAGGAGAATGGGATGATGGGGAAACGGAGCGGA
 GCACCTACCTGGCATTGGCAACCTCAACGCCATGGAGATCAATCTACGGCAACCTCTGGCG
 CTTCTCTACAGCAACGTGGCGTGTACCTGCCGTACAAGTACAAGTTTCCCGCCACGTCCC
 CATCGACCCCAACACGCACTCCTATGACTACATCAACAAGCGCCTGCCCTCAACAACCTATTGA
 TACCTTGCTCAACATGGGGCGCGCTGGTCCCCGGATGTCATGGACAACGTCACCCCTCAACCA
 CCACCGCAACTACGCCCTGCGTACCGCTCCCGAGCTCTGGCAACGCCGCTACTGCAAGTTCA
 CATCCAGGTGCCGCAAAGTTCTTGCCCTCAAGAGCCTGCTGCTCTGCCGGGGCAGCTACAC
 CTACGAGTGGCTTCCGCAAGGACGTCAACATGATCCTCCAGTCCACGCTGGCAACGAC
 CGGGACGGGCCAAATCAACATCGAGAGCGTCAACCTCTACGCCAGCTTCCCATGGCCA
 CAACACCGCTCCACCCCTGGAGGCCATGTCGCAACGACACCAACAACCAACCTTATTGACTT
 CCTCTCTCCGCCAACATGCTCTACCCATCCGCCAACGTCAACCTGCCATCTCCATTCC
 CAGCCGCAACTGGGCCCTCCGGCTGGAGCTTCAGCGGCTGAAGCACAACGAGAACCCCCGC
 CCTGGGCTGCCCTTCGACCCCTACTTACCTACTCGGGCTCCATCCCTACCCGACGGGACCTT
 CTACCTGGGCCACACCTCCGCCATCAGCATCCAGTTGACTCCTCCGTGGCTGGGGCAA
 TGACCGCCTGTCACTCCAAACGAGTTGAGGTCAAGCGCACCCTGGACGGGGAGGGCTACACGGT
 GGGCCAGACCAACATGACCAAAAGACTGGTTCTGGTGAGATGCTGCCCACTACAACATGCC
 CCAGGGGATACCAACCTGCCAGAGGGCTACCGCGACCGCACCTACTCCTCTGCGCAACTTGAGCC
 CATGTGCCGCCAGGTGGCCGACTACGCCAACCAAAAGATGAGTACCTGGAGGTGCCACCCAC
 CCAGTTCAACAGCAGCGGCTTGTATCCGCCCTTCACCGCCGGCATGCCGAGGGGACCCATA
 CCCCGCCAACCTGGCCCTACCGCTCATCGGCCAGACGCCGTGCAAGACCGTGACCCAGCG
 CCTCTGCGACCGCACGCTCTGGCGATCCCTCAACTCATGTCATGGGCCACCCCTCAC
 CGACCTGGGCCAGAACCTCCTACGCCAACGCCCTGACATGACCTTGAGGTCTTGAC
 CGCCATGGATGAACCCACCCCTTGTATGTTGAGGTCTTGACGTCATGCCGCGTGCACCA
 GCCGCACCGAGGCATCGAGGCCGCTACCTGCCACGCCCTCTCCGCCGGAACGCCAC

FIG._ 1-6

SUBSTITUTE SHEET (Rule 26)

7 / 14

CTAAGGCGGAGCCGCGCAGGCATGGGCAGCACCGAGGACAGCTCCAGGCCATGGCGCGACCTC
 CAGCTGCCCGCTTCTGGCACCTTGACAAGTCCTCCGGGCTCTTGCAAGAGTCCCAGCGC
 TGCTGCCTCGCAACACGGCCGCCAACCGGAGGCCACTGGCTGGCGCTGCCCTGG
 GAGCCCGCTCGCACCCTACTTGTACCCCTTCTGGCTCTCGGACTCCGACCGGGAGCTGCCAG
 GTCTATGACTTGTGAGTACCGCGCTGCTGCGAAGAGGCCATCCAGAGCACCAGGCCACTGC
 CTCACGCTCGTAAGAGCACCCAGAGCGTGCAGGGACCACAGCGCCCTGGGACTCTCTGC
 CTCCCTTCTCGCCCTTGCCCCATGCCAGGCCATGGCTACAATCCCGTCATGGAC
 CTGGTGGAGGGCGTGGACAACGAGCGGCTCTGACGCCAGTCAGGCCATCTCCGCGCCAAC
 CAGGAGGCCTGCTACCGCTCTCGCTGCCACTCCGCTACTTCCGCGCCACCGCCACGCCATC
 ATGGAACAGACACACCTGCACAAAGCGCTCGATATGCAATAAAGGCTTTTATTGTAAGTCAAAA
 GGCCTTTTATCCTCCCGCTGGGGGTGTATGTAGATGGGGGACTAGGTGAACCCGACCCG
 CGCTGGCTCCCTCATCCCCCTCTCTCAAACAGGCTCTCATGTCGTCTCCGTTCCCACG
 GGGAAAGATGGTGTCTGACCTGGAACTGGGGCCCCACTTGAACCTGGGACCGTCAGTGGAGGC
 CGCGTCTGCATCAGGGCGGCCACATCTGTTGGTCAGCTGCAGGGCAGCATCACATGGGGCG
 CTGATCTGAAATACAATTCTCTGGGGTTGCCGCACCGCGGTACACCGGGTTGTAGCAC
 TGGAAACACCAGCACCGGGGGTGGGTACGCTGCCAGAATCTTGGGGTCTTCCACCAGCTGGGG
 TTCAGCGCCGCCGACCCGCTCAGCGCAAGGGGGTGTCTGAGGTCTGCCGCCAGCAGGGC
 ACCTGGCGCAGCCCCAGCCGAGTCGACACCAGCGGATCAGCAGGTGCGTCTCCGCGTTGCC
 ATCCGGGGTAGCAGGCTTCTGAAAGCCTTGAGCTGCTGAAGGCCTGTCGCCCTGGAGCC
 TCCGAGTAGAAGAGGCCAGGACCGCGGAGAAGGTGTTGGGGCCACCCACGTCGTGGCTG
 CAACACATGGCCCCGTGTTGCGCAGCTGCACCCACGTTGCCGCCAGCGGTTGGTGTATCTG
 GCCGCTCGGGGTCTCGCGCAGGGCGCTGCCGTTCTGCTGTTGAGATCCATCTCACCAGC
 TGCTCCTTGTGATCATGGCAGCCGTGAGGAGTCAGGAGTCAGCCCTCCGAGCCGCTGCCG
 CAGATCACGCAACCGCAGGGGTTCACTCGGGCTCTCAGACCCGCCCTCACACAAAGTCC
 AGCAGGAAGCGGGCATCACTGTCAGCAGGCTTTGCGTGTGAAGGTCAAGCTGGCAGCTGATC
 TTGCGCTCGTCAAGCCAGGCTTGGCCCCCGCCGGAAAGCACTCCAGGGTCTGCCGCCAGC
 AGCGTCAAGGCCCTGACATCCACCTCAGGGGACCGCATCTGCAAGCCAGATCCATGCCCG
 TGCCACTTCTGCTCCTGAGCATCCAGCTGCAGCAGGCCGGCCACGCCGGCTCGGGTCACC
 GGGCGGGGGGGCGGGGCCCCCTCTCCTCCCTCGCTGCCCTCGCTGCCCTCGGCC
 GTCGCCGCTGCCGTCTTCAGCCCTGCTCCCTCGACGGCGAGAGGGCGCGCTTGCGGCC
 CGCTTCCGCCCTCTGCAACGGCGAGAGGGCGCGCTTGCGGCCCTCCCGCGCCGGCTGGGG
 GTCGCGACAGGAGCGTCCACAATCAGCACCCCTTCCCGCTGTCAAGTCAAGACACGTC
 GAATAGCGCGACTCATTTGCTTCCCTAGATGGAAGACCAGCACGCGAGCCAGTGAGCTGG
 GTCCCTCCGCCGCCGACCCCTTCCGCCGCCACCCAGCCACCTCCGCCACGTCACGCCACC
 TTCACTGCAAGCGGAGCGAGGAGGCCACCGAAACGATGACGGAGGACACCTGCTCCTCGTC
 CTCCCTGCTCTCCGCCCTCCAGCGAGTGTCTCGCGCTGGAGACACGAGCTCCGAGGACTC
 GGCAGACACGGTGCTCCCTCGAGGCCGGGAGCGAGGAGGAGCAGGAGGAGGACTGCCGA
 CCGCTACATGGACGCGACGTGCTGCAGGCCACCTGCTGCCAGAGTACCATCCTGCCAGGT
 CCTGCAGGAGGCCGCCCGCGCAGCCGGAGGGCGAGGCCGCCAGAGTACCATCCTGCCAGGT
 CGGCCGCCCTGGAAGCGCCCTCTCTCCCCCGCACGCCGCCAGGCCAGGAGAACGGAACCTG
 CGCCCCGGACCCCCGCTCAACTCTACCCGGTCTTCATGCCAGGCCAGGCCACCTACCT
 CCTCTTCTCCACAACAAAAGATCCCCGTCACTGCCGCCAACGCCAGGCCAGGCCAGCGCA
 CTGGCGGCTGCCAGTGGACCCCTTACCTGACTATCCAACCAACCGACGAGGTTTACAAGATCTT
 TGAGGGCCTGGGGACGAGGAGCCGCTGCCAACCCAGGACCTGAAAGAGCGCAGCGTGT
 AGTCGAGCTCAAGCTGACAACCCCGCTGGCGGTGTCAGCAGTGCATGCCGTACCCACTT
 CGGCCCTACCCGGCCCTGGCGTGCACCCAGGTCACTGAGCACGCTCATGCCAGGCCAGCG
 CGCGCGAGGCCACTCCCCGACGAGGGCGAGACGCCCTCGAGGACCTCTGGTGGTCAAGCG
 GCAGCTGGCCCGCTGGATGCACACCTCGGACCCCAAGGTCTGGAGGAGCGGCCAGGAGAACG
 CGCCGCTGCACTGGTCACTGCCAGCTCCACTGCATGCCACCTCCCTCACCTCCGCCAG
 GCGCCGCTCGGAGAGTGCCTCAACTACATGTTCCGCCAGGGCTACGTCAAGCTAGCTAG
 CGCCAATATGGAACTCTCAACCTGGTCTCTACTTGGCATGCTGCACGAAAACAGGCTCGGT
 GCACGTGCTCCACCACCCCTCAAGCATGAGGCGAGACCGCAGACTACGTCCTGGGACACC
 ATACCTGGTCTATACCTGGCAGACCGCATGGGGTCTGGCAGCGAGTGCCTCGAGGCCAG
 GCGCGCCCTGGAACGCTCTGGCTCGCGCTGCCAGAGCCTGTTGAGCGCAGGCCAC
 TATCGCGCAGGACCTGCCCGTCTCCCTTCCCCACCAAGCTGAGAGACCTGCAGCGCTCG
 CCCCCACTTGCAGGCCAGAGCATGATGCATGCCCTCGCTCGAGCGCTCCGGCAT

FIG._ 1-7

SUBSTITUTE SHEET (Rule 26)

8 / 14

CCTGCCCGCCGCTGCAACCGCCTCCCTCTGACTTTGTGCCCACCGTCTACCGCGAGTGGCCGCC
 GCCCTCTGGGCTCACTGCTACCTCTGCGCTGCCAACCTCCTCATGTACCGTGCACCTCGC
 CGAGGACACCTCCGGCAGGGCCTCTTGAGTGTACTGCCGCTGCAACCTCTGCGCACCGCACCG
 CTGCTCGCCACCAACACCGCCCTCTCAACGAGGTGCAAGCCATCAACACCTTGAGCTCCAGCG
 GCCCCCAAGCCGACGGCACCCGCCCTCAAGCTGACCCCGGTCTCTGGACCTCCGC
 CTTCTCCGCCACTTGTCTCCGAGGAATCACCACCGACCGCATCTCTTACAGAGGACGTGTC
 CCGCCCCCCCAGGGTGGAGCCCTCCGCTGCGTACAGCACTGCCATTCTCGCGCAATTGCA
 TGACATCAAAAGGCCAGGGAAAGAGTTTGCTGACCAAAGGCCACGGCGTACCTAGACCCCCA
 CACCGGAGAGGAGCTCAACACCGCCGCCCTGCCACCGGCCACCATGCCGCCCTCCGGAGGAAGC
 CCATCCGACGACGACCAAGCAGCAGCAGCGAGCCACCGGCCACCGCTCCAGCTA
 CGCAGACCGTGTCCGAAGCGAGCTCACGCCAACGGCGTGCACCGGTTCCCTCCGCGACCCCTGT
 CTCTGGCGGATGCTCTGCCAGAGGAACCCACTCCCGCGATGCTGCTGAGAAGAGGCTCTCAGCA
 GCGAGACCAAGGGCAGCTCGAAGGCAGTTGCTCAGTACCCCTCAGGAACGGAGGAGGAGG
 AACCGTCACACCGACGAGGCCATCCAAGCCCTCTACACCAACAGCAGCAGCAAGAGCATCA
 GCCAGCGAGGAACCTCGCTCCCCAGCGAGGCTCGTAGATGGAATCAGACATCCATCCACCGGA
 GTAGCCAGCCAGGTAGGACACCTCCGCCCTGGCCCGACGCTCTGGCGCGCTACCGCCACG
 ACATCCTCTGGCCCTGGAGTACTGCGCCGGAGACGGACGCTCGTGCACGGGTACCTACTCTACC
 ACCAACATCAACATCCCTTCAAGATCATCCGTTACTACAAATCCTCTTCCGTTCCAGCGATC
 TCCAGGAAGGCCAGCGAGCGCCAGCAGAACCCAGCAGCTCAGCCAGCTGAGAGCTAAGATC
 TTCCCCACGCTGTACGCCATCTTCCAGCAGAGCCGCGCCAGGACGCCCTCAAAATCAGGAAC
 CGCACCCCTGCCCTCCCTACCAAGAGCTGTCTGATCACCGCAGGGAGGCCAGCTGGAAACGCACG
 CTCTCGGACGACAGAACGCTCTTCCAGAGACTGCTGCGCTCGGACGCCGGTATTTA
 AGGAGCGGACCCCTGCGTGCAGCACCATGAGCAAACAAATCCCCACCCGTCAGATGCGTCTTA
 TCAGCCACAATCTGGGCGTGCAGGCCGGTGCCTCCGTCGATTACTCCACCCGATGAATTGGCTCAG
 TGCCGGGCTTCCATGATTGGCAGGTCAATGACATCCGACACACCAGGAACCAAGATTCTCATTG
 CCAGGCCCTATCACCGAGACGCCAGGCCGGTCCAAAATCCCCCGTCTGGCCCGCAGCCTGTT
 GCCTCAGATGACGCAACGCCAACCCACCTGACCTGCCGCTAACGAAATTGGAGGAGACT
 GACTGACGCCGCATGCAATTAGCCGGGGGGAGCCCTCGCACCCAGAGACTTATATGCCCTGAC
 CCTCCGCGGAGGGCATCCAGCTAACGAGACCTACCCCTCTCCGCGAGCAGTCTCCGGCCGGA
 CGGCATCTTCAGCTGGAGGCCGGCTCTCTCTCACCCCCACCGACGCCCTACCTGACGCT
 GCAGAACTCCAGCTCCCTCCCCGAGCGCCGGCATCGCAGCGAGCAATTGTCGAGGCTCGT
 GCCACGGCTACATCAACCCCTCTCCGGACCGGCCGGACCTACCCCGACCGAGACT
 CTACAACATCTAACGGACTCTGAGCAGGCTATGACTGACGGTCCCCAGGGTCAGCAGGGCTGC
 GGGAGCTCCTCGACCAGCACGCCAGTGCCATAACCGCTGCTTCGCCAGGGAAAGGGATT
 ACCCGGAGTACTTTGCATCACCGCGAGCACTTGAGGCCAGTGCATCCCCGACTCTGCAAG
 AAGGCCACGGTCTGCGCTTCAGCTCCCCACGCGCTACAGCAGGCCACCGCGATGGAGACC
 GCACCATCCTACTTCGTAACGAGACATCGGGCCAAGACCTGGGCTGGGATACTTTATGCCG
 CTGCTCTCACCCCTCTTCTCGACCTCTGAGCTGACAAACCGCTCGTAGGGCTCAGCCCC
 TACACCTCCCCCTCGCTCCAATTCTGTCGACATAGAACCGAGACTCTGACTCTACTCGGGCTCT
 GGCTCTGGGAGCATGAAGATTATGAATATGAGCTGGCTACCAACACACCGAACGACATTCTA
 GGCAGCATAGTCATCAACAAACAGATCGGGCCAAGACCTGGGCTGGGATACTTTATGCCG
 ATGCAAGTTGTTACTACACCACCTCCGTCTTACGCCCCGGCTACGTGCTG
 GCCACCGCCCTCATCGTCAGCGCCAGATGTGGCTCTCGAGGCCGCTCGGGAAAACCTTCTCG
 GCCACCGTTGGTTACTCCCCAAAACAAGTCACCCCTGCAACTGCTCTGCCGCTTCGAGGAG
 ATGGTGTACTACACCACCTCCGTCTTACGCCCCGGCTACCTCTGCTCACCGCCA
 TGGTCCGCTGGCCAAGTGGATAGTGGATCAGATGCCAGCAGGAACCGCGCCGGCTGCCAC
 CGCCCTCACCTATGTGGACCCCTGCGCCAGGACCACATCTACGATGAGCCAACCGTAGGGCAAT
 ACGTACAGATGAAGTAGCTCCCCCTTTCCATTCCCCATTCTTCTTACTCAATAAGTTGCT
 TACCTGAGTTCATCCACACTCGGTCTGCCAGTGCAGTCTATCCATGCCGCTTTCCATACTCACA
 TAGCGCAGCCGCGCACCCCTGCCAGGTGACGAAACTGTCGAAATGTAACATTGCGCTTCTGTC
 AGCAGCACCCGTTATAGACCAAGTCCACCATGGGACCGAAGAACGAGCAGCGAGCTACCCGAG
 GACTTCGATCCAGTCTACCCCTATGACGCTCCGAGCTGCGAGATCAATCCACCCCTGTCAGCGG
 GACGGATTCAACCAATCCGTGGACGGGGTGTGTCCTGACATCGCACCGGCCCTGTTTGAC
 AACACCAGGGCCCTACCCCTGGCCTCGGGGAGGTACAGCTCAGGCAAGCAGCTCGTCT
 GCCACCGAGGGCTCGGGCTAACCAACCCGAGGCCAGCTGGTCTCAAAGTCAAGTCCCC
 ATCACCCCTGACCGCCAGGGCATCTCCCTGGGCTCCGGTCTTCTAACTCAGAGACCGGC

FIG._1-8

SUBSTITUTE SHEET (Rule 26)

9 / 14

CTCAGTCTGCAAGTCACAGCTCCCTGCAGTCCAGGGCAACGCCCTCACTCTCCCCCTCGCCGCC
 GGTCTCCAAAACACCGATGGTGAATGGGTGTCAAACTGGGGAGCGGTCTCACACGGACAACAGT
 CAGGGGGTACCGTTCAAGTGGAAATGGACTTCAGCTAACGCGAAGGACAACACTCACCGTCCC
 GCCACGGCCCTTCTAGTCTCAGGGAGCGCAGGCATCTCTTCAACTACTCCAGCAATGACTTCGTC
 TTAGACAATGACAGTCTCAGTTGAGGCCAAAGGCCATCTGTCAACCCCTCCGCTGCAGTCCACA
 GAGGACACAATCTCCCTGAATTATTCTAACGACTTTCTGGACAATGGGCCCTCACCTGGCT
 CCAACTTCAAACCTACACGCTGGACTGGCCCTACCCACAGCAAATGTCATTCTAACAAAC
 ACCACCACTCCAACGGCACCTTTCTCATGGCTACACGTGTGGTAGTTGGTTCC
 TTTGCCCTGAATCATCCATCGACCTTAAGTATGACCAAAAAGGTCAATTATTGGATGGG
 GCAGGTGGCTTCAGTCAGACTCCACTTATAAAGGGAGATTGGATTAGATCCAACGACAGCGTA
 ATTGAACCCACAGCCGAGGACTCAGTCCAGCCTGGTTAATGCCAAGCACCTTATTATCCACGC
 AACACCTCCGGTTCTCCCTAACATCATTGTATACATTAATCAGACATATGTGCATGTGGACATC
 AAGGTAACACACTCTCTACAAACGGATATAGCTAGAATTAACTTCAAAACATGAGCTCTCC
 GCCCCCTCTCCACCTCTACGGGACCTCTGCTACGTGCCCGAAGGACAACCTACCCTCCC
 CACGGCCCTTCTAGTCTCAGGGAGCGCAGGCATCTTCAACTACTCCAGCAATGACTTCGCTT
 AGACAATGACAGTCTCAGTTGAGGCCAAAGGCCATCTGTCAACCCCTCCGCTGCAGTCCACAGA
 GGACACAATCTCCCTGAATTATTCTAACGACTTTCTGGACAATGGGCCCTCACCTGGCTCC
 AACTTCAAACCCCTACACGCTGTGGACTGGCCCTACCCACAGCAAATGTCATTCTAACAAACAC
 CACCACTCCAACGGCACCTTTCTATGCCGTACAGTGTGGTTAGTTGGGTTCT
 TGCCCTGAATCATCCATCGACCTTAAGTATGACCAAAAAGGTCAATTATTGGATGGG
 AGGTGGCTTCAGTCAGACTCCACTTATAAAGGGAGATTGGATTAGATCCAACGACAGCGTAAT
 TGAACCCACAGCCGAGGACTCAGTCCAGCCTGGTTAATGCCAAGCACCTTATTATCCACGCAA
 CACCTCCGGTTCTCCCTAACATCATTGTATACATTAATCAGACATATGTGCATGTGGACATCAA
 GGTAACACACTCTCTACAAACGGATATAGCTAGAATTAACTTCAAAACATGAGCTCTCC
 CCCCTCTCCACCTCTACGGGACCTCTGCTACGTGCCCGAGTGCTAGAGAACCTGGCGT
 CAGCCGGCTCCCCCTTCCCAGGCCACCCGGTACACCACCGCTCATGTTCTGTATGTGTTCTC
 CTCCCGCCGCTTGTGCAGCACCACTCCCGTCTCGAGCTGAGGATCCGTGATGGACACAAAGCC
 AGGAAGACACATCCTCAGCTCCGGGGGGCTCCAACAACTGTTATGAAAGGAAATAAGACT
 CAGAGAAAATCCAAGTTATGATTTCTTATTGATTGGGAATTGATTCAAGTGGGTG
 GCATAATCACAAAATCACATCAGCAGGTACACACCTGAGACATCAGACAGGGTAAGGACAGCGC
 CTCAGCTTCTGGAACAGACATCAGAAAATATTAACTCTGCTGGTAGCTAACACTCCTCC
 ATACACTCCTGGAGGGCCCTCTGCTCTCCTCCCGTCCCGTCCCTCTGCGGGGACCAAC
 TCCCCCTCCGTGAACTGCTGTTCTCCCCCGCTGCGCCCCGATGGCCTCCGCGCAGCTC
 AGCCAGTGGCGAAGCGTGGCGAGGCCACCGCTCCGTCAGCTCGTGGCAGCGCCGG
 CACACCAGCACTATGTAATTGGCATAGTCCCCTCACAGTAGATGACCTCCCCCAGTGAACATG
 CGCAACAGCTTCAGATCACAGTACATGATCTTATGACATCAGGTGGCGCCTCGAAACATC
 ACAGTCCCCACGTACATCACGCGACTCACGCTGGCAGGTTCACCGCTCCCTGAACCAC
 AGACAGGAAATCTGAGTGGGAGGATGATCGCGCATCACGGGAGGCAATCACCAC
 ATGCGATTGTAUTCGCAGCCCCGGATGATCTCGCGCATCAGGGAGGCAATCACCAC
 CGGCACCTCAGACTGGACCTTCAAGACAGTGGCAATGAAAGTTCACAGCGTCCGG
 CGTCTCCGGGCTGAAACATATCTGCTCCAGCTAACCCCCCACACAGGCTACTGCA
 CCATTCTGATGGGAAAGGATGATCGGCCAGGGACCAATCTCAAACAGGGAAACAAACATAC
 CGCGGCCCCGGCTGTTGCGCACGGCCCCACCGGATGCAACGTGCTCACGGAGCAG
 ACAGCGGCCACGTCTCATAGCAAGTCAAGTCCGGAAAGTGGCACGGGGTCCGCC
 ACTGCTGCGCTGCGCCACCAAGCTCCATCGGCTCCATCCTCTGTTCCATCGGCT
 GCCTCCTCCCTCTGCGCTGCTCCATCATGCTCGTCTGCGGTATCAGGAGTCAA
 TTGGCCACCGCACGAGAGAACATGGAGCGCAGGGGCCAGGTGCCCCGGCGT
 AACTCCCCCAGCAGGTACTCATAGAGATGCTCCTCAAATCCACCGAAACCC
 AGGACATGCAAGAAC
 TCTTCCGTTGAGGACGCCACGGTAAAGACATAGCCCTCCGACCTTCACCG
 CGCTGCGCTGCGCCACCGGCTGGATGACTCCAGCACCTGATCGCTC
 AGCGCTCATGTCGCTGGAGTACACCCGGACCCGGCTGGATGACTCC
 AGACACCTCACAGAGATGCCAGCCTGAGCCAGCTCTCATAGAGAGGTGG
 AAGCAGCGAGCGGCTAGGCACCTCCCGCCCCCTTGGAAACAGGGCG
 CAGGCTACCTCACAAACATATCTGGCCATCGCCTGACCACGGTCACCAG
 GTAAAGGATGATGTCGTTGTCGAATGAGAATGCTCAGAGGTGACTCG
 GTAGCGTTATCAATCAC
 GTCCCCAAAGGTCCAAGGTCCCAGTTAGAAGTCAGGTGCTCAGGCC
 AGACACGCCCCATAGCA
 ACCAGTGGGAAAAGGCCAGCAAGAGATCCGTGGCACATGCA
 CACCAGTCCCCAGGAATCTCC
 CCACTCCGAGGCGTAGACCGTGTAAAGCTACACACCCCC
 CCCCCGAGTGGGAGCAGAAGCATTCTC

FIG._ 1-9


SUBSTITUTE SHEET (Rule 26)

10 / 14

GCTCAGCCGAAAGAACCTCAGGGTGGCCTGCATATCCTTTACTCACTTGTTAGCAGCTCCACA
CAGACCAGGGTTGTGTTGGCGGGAAATTAGGCAGCAGGGGTACGTCCCCAGTGAGGGACACCTGGATG
GGGGCAGAGGATTGATGCCAGGAAGCAGCAGGTACTGGGAAACAGAGACCAAGATCCCTCCCTGA
AAAATCTCGCTCAGTCGGACAAACACAGCAAACCCAGTGGGCACGTAGACTAGCACATTAAAAGG
ATCACGCTGGGTGTTCTGACGTCAAGCACCAGATGTCGGACGTGCCAGATGAATGCGGTTCTGA
TGAATTACCGGAGGCCTCTCACCCGAGCCAACAGCAGACCCGGCTGCTGATGCGGTCCCCAGAC
ATATATGAGTTCAATGTGTGCTTTCTAAACGTCTAGTGAGTGCTCGTCCTGCTCCTGCCA
ATCAAAATCCGGGCAACCAGGGCTGGGGTGGACCCGATGAAGAAGCGAGGAGAGGCGGCCCTG
AGTGTGAAGAGTGTCCCAGTCCTGCCACGCGAGGTAGGCGAAGTACAGATAGAGCACGGCGAGAAC
AGTCAGCACCGCGGCCAGCAGCAGTCGGTCGTCGGGATGAGAGGGGCTGATGGGAAGATGGCCG
GTGACTCCTCTCGCCCCGCTTCGGTTCTCCTCGTCGCTCTCAGTGTCTCTCTGTGTCAGC
GCCGAGACGAGTGTGAGCGAACACCGCGAGCGGGCGGTGATATAACCCACAGGGATGTGCCACG
CCTGCGGTGCGGTTAATCAGTACCCCATCGTCCGATCGGAATTCCCCCGCTCCGCGTTAACGATTA
ACCCGCCAGAAGTCCCGGAATTCCCGCCAGCGGCTCCGCCGACCTGCGACTTTGACCCCGC
CCCTCGGACTTTGACCGTTCCACGCCACGTCAATTCCACCGCGACGTACGTTCCACGCTACG
TCACACCCCTCTCCACCAATACCGCCCGCCCCAACCCCTCTCCGCAATACCAACGCCACAA
AAGGGGCAATAAAAGTGTGCGGTATATTATTGATGATG

FIG._ 1-10

11 / 14

**FIG. 2**

12 / 14

1 2 3 4




FIG._3A

1 2 3 4




FIG._3B

1 2 3 4 5 6








FIG._7
SUBSTITUTE SHEET (RULE 26)

13 / 14

**FIG.-4****FIG.-5**

**FIG._6****FIG._8**

SEQUENCE LISTING

<110> Reddy, P. Seshidhar
 Tikoo, Suresh
 Babiuk, Lorne

<120> PORCINE ADENOVIRUS TYPE 3 GENOME

<130> 293102002440

<140> Unassigned
 <141> Unassigned

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1
 <211> 34094
 <212> DNA
 <213> Porcine Adenovirus Type 3

<220>

<400> 1

catcatcaat	aatataccgc	acacttttat	tgcccctttt	gtggcggtgt	gattggcgga	60
gagggttggg	ggccggcgccc	ggtgatttgt	ggagaggggt	gtgacgtac	gtgggaacgt	120
gacgtcgcgt	ggaaaaatga	cgtgtatga	cgtccctgtgg	gaacgggtca	aagtccaagg	180
ggaagggtg	gagccctggg	cggttcctcc	gcggggcgccc	gccgagccgc	ggaaattccc	240
gcacaggtgg	agagtaccgc	gggattttgt	gccctctggg	ccggacccctc	gccctccgggt	300
gtggcacttc	cgcacccacac	gtcccgccgc	cggtattttcc	cacctgacga	cggtgacacc	360
actcacctga	gccccgtgtc	cttcgcgtg	agaggtccgc	ggcgccgcgc	cgagatgacg	420
tgtgtgggtg	tatttttcc	cctcagtgt	tatagtccgc	gcagcgcccg	agagtcacta	480
ctctttagtc	cgaagggagt	agagttttct	ctcagcgaaa	cagaccctcg	acatggcgaa	540
cagacttcac	ctggactggg	acggaaaccc	cgaggtgggt	ccgggtctgg	aatgggaccc	600
ggtggatctg	cgcgaccctc	ctccggggga	tgagggcttc	tgtgagccgt	gctgggagag	660
tctggtcgt	ggactgcccgg	acgagttggct	ggacagtgtg	gacgagggtgg	aggtgattgt	720
gactgagggg	ggtgagtcag	aggacagtgg	tggagtgccc	gctgggtact	caggtggctc	780
tcagggggtc	tttgagatgg	accccccaga	agagggggac	agtaatgagg	aggatatcag	840
cgcgggtggct	gcccgggtgc	tgtctgaact	ggctgatgtg	gtgtttgagg	acccacttgc	900
gccaccctct	ccgtttgtgt	tggactgccc	cgaggtaccc	ggtgtgaact	gccgcctttg	960
tgattaccat	cgttttcaact	ccaaggaccc	caatctgaag	tgcagtctgt	gctacatgag	1020
gatgcattcc	tttgcgtct	atggtgatgt	ttttggaca	tttggggat	tatgtggaaa	1080
aaaagaaaaa	atgtctgt	agaaaatctca	tgtcttattt	cccatttttt	gtcttttag	1140
aagcttttc	tccagcacct	cacaggtcgg	gttccccggg	acttggagac	ctgcaggac	1200
gcaagaggaa	gtactgtat	gactcatgca	gcgaacaacc	tttggacccgt	tctatgaagc	1260
gccccccgca	ttaatcatta	acctcaataaa	acagcatgtg	atgatgactg	attgtctgt	1320
tctctgccta	tatataccct	tgtggtttgc	agggaaaggga	tgtgggtact	gagctattcc	1380
tcagcatcat	catcgctctg	ctttttctta	ctcaggctta	tttcttgcata	gctcgctgtc	1440
ccttttctt	ttctgtgggc	atggactatc	aacttctggc	caagcttact	aacgtgaact	1500
accttaggaa	ggtgatagta	caggggtctc	agaactgccc	ttgggtggaaa	aagatttttt	1560
cggacaggtt	tatcaaggta	gtacgaggagg	ccaggaggca	gtacggccaa	gagttgattg	1620
agatttttgt	ggaggggtgag	aggggctttg	gtcttgatgtt	cctgcggaa	gggggactgt	1680
acgaagaggc	cgttctgaaa	gagtttgatt	tcagcacctt	gggacgcacc	gtagctagtg	1740
tggctctgtt	ctgcttcatt	tttgagaagc	tccagaagca	cagcgggtgg	actgacgagg	1800
gtattnaaag	tcttctgtgt	ccgcccactat	gttccctgtc	ggaggcgcga	atgatggcgg	1860
agcagggtgcg	gcaggggctg	tgcattatca	ggatgcccgg	cgcggagccg	gagatgtctgt	1920
tgcccagtgg	gtcatccggc	agtggcagcg	ggcccgggat	gcgggaccag	gtggtgccca	1980
agccccccgcg	ggagcaggaa	gaggaggagg	aggacgagga	tggatggaa	gcgagcgggc	2040

gcaggctcgaa	aggccggat	ctggttaga	tcggccgg	cccggggag	cgggtggaga	2100
ggggagcggg	gaggaggcgg	gggggtcttc	catggtagc	tatcgcgg	tgcttctga	2160
gtatctggag	agtccctctgg	agatgcata	gcgtacacgc	tttggcaga	ttaggccta	2220
tatgcttcag	ccggggatg	atctgggg	gatgatagcc	cagcaccca	aggtggagtt	2280
gcagccggc	acggtgtacg	agctgaggcg	cccgatcacc	atccgcagca	tgtgttacat	2340
catcggaac	ggggcaaga	tcaagattcg	gggaattac	acggagta	tcaacataga	2400
gccgcgtaac	cacatgtgtt	ccattgcggg	catgtggctcg	gtgactatca	cggatgtgg	2460
ttttatcg	gagctaccgg	ccgggggtgg	tctgatTTTA	gccaacacgc	acttcatcct	2520
gcacggctgc	aacttccctgg	gctttctggg	ctcggtaata	acggcgaac	ccgggggggt	2580
ggtgcgggga	tgctactttt	tcgctctga	caaggcgctg	gaccaccggg	ggcgctgtg	2640
gctgacggtg	aacgagaaca	cgtttggaaa	gtgtgttac	gccccgttct	ctgcggggcg	2700
ttgcaggatc	aagtacaact	cctccctgtc	cacccatctgc	ttcttgacca	tgagctatac	2760
ggcagata	gtggggaa	gcatcatgag	cccttacacg	ttcagcga	acccctacgt	2820
ggacctgg	tgtgtccaga	gccccatgg	gatggccctg	agcagggtgc	acatcgctcc	2880
ctcgctcgc	ctgccttacc	ctgagttccg	caagaatgtg	ctccctccga	gcacccatgtt	2940
tgtggccgc	cgcctgggc	gcttcagccc	cagccgctgc	tcctacagct	acagctccct	3000
ggtggggac	gagcagtcc	accggggct	gagtgtgacc	tgctgttgc	atcagacactg	3060
tgagatgtac	aaatgtgc	agtgtacgg	ggggcggag	atggagacgg	ataaccttca	3120
gcagtacgc	tgcctgtgc	gggacaatca	cccttggccg	cagggtggc	agatgaaagt	3180
gacagacgc	ctgcggggcc	cccggtccct	ggtgagctgc	aactggggg	agttcagcga	3240
tgacatgac	tgaggatgag	tcacccctc	cccttccctt	gcaggta	ggcccccggcc	3300
agtggggatgg	gctttggatg	ggggagggg	gttccctata	aaagggggat	gggggtggag	3360
gcatgcac	ccacggggaa	gcttggatgg	aggatgttt	ccgagggtga	gatccggacc	3420
tgcttcattt	cagctcg	tcccagctgg	gccccgtgc	gtcagggt	ggccgggacg	3480
aatgtgaac	gcccggatgg	ggggccct	gcccagacg	gggtgctgc	ctactccgc	3540
ttcggtcagc	agcaacacg	gcaagccggg	acggcggcga	cggggtctgt	gttccggg	3600
gtgtttccat	cgtggatct	gagcgggag	gtgggcatga	tgccggcagg	gctggcggag	3660
ctgcggcagc	agctgcagga	gctgcggag	gtggtggaga	tacagctgc	ggccacggcc	3720
tcggaggcgg	ccgaggagga	agaggaggag	gagattgtgg	tggacgagga	ggtggcggcc	3780
ggcgctgg	cgaacaccat	ggaagaggag	gagatgaga	tggctctgac	gatgactgtg	3840
gtgggggacc	ctgagcctgc	tggagtgaa	gcccagccgc	caccaccacc	caccccgag	3900
agcgaccctg	cgtgcctgc	tactaccact	accccgaa	ggctcagcta	cgccgcgagc	3960
aagaggagcg	gtccatgcgc	ggaggacaac	tgacgcggac	tgtggggg	agaagggg	4020
ggaggaaa	agaccatgga	gacgggtt	tgtttttt	cagcccaact	ttattgagaa	4080
taataataaa	gcttatggat	gtttggacg	ataatagct	gtccagcgtt	ctctgtctt	4140
cagggtctt	tgtatcttct	cgaggcacc	gtagacctgg	tgtggacgt	tgaaatacat	4200
gggcatgact	ccctcgccgg	ggtgcaggta	aagccactgg	agggctgggt	gcggggggca	4260
ggtgcagtag	atgatccat	cataggcgtt	ctgggtgcgg	tgggtgtt	aatgtcctt	4320
gaggagcagg	ctgatggcgg	tgggcagacc	cttgggtgt	gcattgtt	accgggttac	4380
ctggggggc	tgcgtgg	gggacatgt	gtggactt	gcctggatct	tgaggttgg	4440
gatgttgc	ctctgttgc	ggcgggggtt	catgttgc	aggacgacg	ggacggcgt	4500
gccggcgc	cggggaa	ggcgtgcag	cttggagggg	aaggcgtt	agaacttgc	4560
gacccttgc	tgcggccg	ggtcctccat	gcactcgtc	aggacgatgg	cgatgggtcc	4620
gcggggggc	gcgcggggc	agacgttgc	ttagtgc	acatcatgt	tgtgttgc	4680
catgagg	tgttagtca	tgcggacaaa	gtctggc	agggtggc	tctgggggat	4740
taggggtt	tccggaccgc	tgcgttagt	ccctcg	atctgggt	cccaggcgcac	4800
tacctcctgc	gggggatca	tgtccac	cggggtgt	aagaaaacag	tctccggcgg	4860
gggggagagg	agtggggagg	agatgagg	gcccggc	tggacttgc	cgggccgg	4920
gggaccgt	atgacacgc	tgactgc	gacctgg	ttagggg	ggcagggtgc	4980
agccgggt	aggaagg	tgcaggcgtt	gagggtgt	cgcagg	gttcttctt	5040
gacgagg	tgcagg	gtcggc	caggagagg	agggtgg	gggaggcga	5100
ggccttgc	ggcttgc	cctcg	ggccatgt	ggcagg	ggcagg	5160
gcccgc	tcccag	cggtt	ccacgg	tcgtt	ccagg	5220
ttgttctc	ggttgg	gtcgt	gttgc	gttct	gttgc	5280
tggagg	gttgc	ggcc	ggccgt	gggtt	ggcgtt	5340
aaggggc	tctgg	ctcg	ggcc	gggtt	ggcgtt	5400
ctgaagg	cgttcc	ctgc	ggcc	gggtt	ggcgtt	5460
gagagg	gggtt	gttgc	ggcc	gggtt	ggcgtt	5520
gcatcg	cgtgtcg	cagg	ggcc	gggtt	ggcgtt	5580
ctgtgg	cgttcc	ctgc	ggcc	gggtt	ggcgtt	5640
tggtt	gggtt	gttgc	ggcc	gggtt	ggcgtt	5700

tggtctcca tgagtcgcg tccggcgcgg gtgaggaaga ggctgtcggt gtccccgtag 5760
acggagcgca gggggccggtc ggcgatgggg gtgccgcgt cgtcggcgt aaggatgagg 5820
gcccactcgg agatgaaggc acgcgcggc gcgaggacga agctggcgcac ctgcgagggg 5880
tagcggtcg tggcactaa tggcagggcc tgctcgagcg tgtggagaca gaggtctcg 5940
tcgtccgcgt ccaggaagtg gattggtcg cagtggtagt ccacgtgacc ggcttcggg 6000
tcgggggtaaaaaggcgc gggccggggt gcgtggccgt cagttcttc gcagggctcg 6060
tcacccggactcgctcc ggcgtctcg cgtggggctg catctgttgtt cccggagtct 6120
tcaggtgggt acgtacgac aaagtccggg gtgacccatcg cgctgaggtt gtctgtttct 6180
atgaaggcgg aggagcggac ggagaggctg cgcggggcga tggcttcggg ggtgcggg 6240
tccatctggc tggcgaagac caccttctta ttgtcgagggc gtgtggcga actgcccgt 6300
agggcgttgg agagaagctt ggcgtatctg cggagcgtt gtttctgtc cggctcgcc 6360
tttccttgg cagcgatgtt gagctgcacg tagtctcg gaggcagcg ccactcg 6420
aagatgtgt tgcgtctgc cggcaggagg cgacggccc agccacgggtt gtggagggtg 6480
accacgtcca cggagggtgg tacctcgccg cggaggggtc cttggtcca gcagaggcgg 6540
ccgccttgc gggagcagta gggggggcagg acgtccagct gtcctcgctc ggggggg 6600
gcgtcgatgg tgaagagggc gggcaggagg tcgggtcgaa agtagctgag gggctcg 6660
ccgtcgagggc ggtcctgcca gccggcggcg gccaggcgc ggtcaagggtt gtggagggt 6720
tggccggcg ggaagggtg ggtgaggggcg ctggcataca tggcccgat gtcataagacg 6780
tagagggctt ccccgaggag gccgtatgaag ttgggttagc acggccgc ggcggc 6840
ttcgcggacg tagtcataca gtcgtggga gggcgcgagg aggttccggc gaggtcg 6900
gcctggggcc ggctggcgcg gtagaggagc tgctgaaga tggcgtggg gttggagctg 6960
atggtgggccc tcttggaaagac attgaaggcg gctggggaa gcccggcctg cgtgtgg 7020
aaggcgcgtt aggactcttgc cagcttgcgg accagacggg cgtgacgac gacgtctgg 7080
gcgcagtagc gcagggtggc ctggacgatg tcgtaagcgt ccccttggtt ctcccttcc 7140
cacaggcttct tggaggag gtaactctga tcgctgtccc agtacttggc gtgtggaaag 7200
ccgtcctgtat cgcgtaaatgat gtcggccctg cgttagaact ctttcacggc atcgtaggg 7260
cagtgtccct tggccacggc cagctcgtag gccggcggc gcttgcggag gctgggtgc 7320
gtgagggcga aggttgcctc gaccatgaac ttgacgtact ggtgtggg gtcctcg 7380
gccatgacgc cctcccttcca gtccgcgtag tcgcccgcg ggcggaaaggc ggggttggc 7440
aggttgaagc tgatgtcatt gaagaggatg cggccgttgc gggcatgaa ggtgcgggt 7500
accaggaagg agggggcgc ctcgcggcg tggcggagca ctcgcgcgc caggacgatc 7560
tcatcgaaagc ccgagatgtt gtggcccacg atgtagaccc caggaagag gggcggcc 7620
ccgcaggcggc ggcgcgcgcg cttggcatacg gccagggggtt ctcgggggtc gtccggcagg 7680
ccggggccccc gctctcgcc cagctcgccg aggtctgggt tggggccag cagggtctgc 7740
cagagggtgt cggtgaggcg ggcctgcagg gcgtgcgc gggccttggaa ggcgcggcc 7800
atggcgcgtt tctcg 7860
ggcggggtct ggacggccac cacctgcage gggcgttca gagctcttc gtccccggag 7920
aggttggaaagc ccacgaggaa gggcacgac tgcttccga acggccctgtt ccagggttag 7980
gtctccaggat cataggttaga gaagaggccg cgggtccctt cggggggac gatggggcgg 8040
aaggcgatgg tctggccacca gtcggccgtc tgccgtgaa cgtgggtggaa gtagaagtcc 8100
ccgcggcgcga cggcaggatgtt gttgggggtc tggaaagatgc gggcgcaigt ctcgcaactt 8160
tgggcctctt ggtatgttgc gatgggtgg cagcccccgtt ggtgaagag caggcggagg 8220
gggaaggggg ggcggggcg cggggccctcg ggcgggggggtt cccagcgcac gtgggtcagg 8280
tgggttgtct ggccgggtac cacctggacg aagggtggcc cggcggcgcg ggccagctcc 8340
accgcgttct ggggggtac gtcggggggcgtt gtcaggagg ggcgcaggag gtgcagctgg 8400
aagagggttg ccaggcgct gtcgggggtt cgggtgttagg tgatgtctca gtcctcccg 8460
tcctgggtgg tggccctggag gcgagggtt ggcggccgtc cagacggag ccccccgtt 8520
ccggcctcccg cggcctcgcc ggcggcgcgc ggtctcaggc gggcagctgg gcaaggggc 8580
ccggcgcgtt gagctcg 8640
tgacgcggcg gttatgttc tggatctcg gtttcccgaa gaagaccacg gccccgtga 8700
ctcgaaacct gaaagagagt tccacggaat caatgtcgcc atcggtgggtt gcaaccctggc 8760
gcaggatctc ggacacgtcc cgcgttggg cgcgttaggc gatgtcttcg atgaactgt 8820
cgagctcgcc tctgtccagg tccccgttgc cggcgcgtc cacgtggcg gccaggtcg 8880
cggtatgtcg gttatgttc gccaccaggcg cgttctctcc gttctcggtt cacacgcgcac 8940
tgttagaccag ctggccgtcg ccgtcccg cgcgcgtt gatgtggcc aggttggagcg 9000
ccaccaggcg gttgaaggcc gctgtcaggc gcaggccgtg gtgcaggtag ttgagggtgg 9060
tggcgatgtg ctgcagagg aagaagttt tgaccaggcg ggcgcagggtc agctcg 9120
tgtcgcccg gtcctcgagg accgtgatgtt cccggtagaa ctcggggccg aagcgaaaaaa 9180
actcggtctg gcgccgcgacc cctttccag gcttcccg ggcggcgtat gtcctcgcca 9240
ccgcctcgcc cacccttccct tctaaggagg gcgccggcgt gtcgggtccg gcaaccggcc 9300
cctttttccct cttttccctc tccagggtt gcatctccctc gtccttcttct tctgtgtct 9360

ctgcctccgc	ggggacgggg	ggcgcaaggcc	ggggacggcg	ccggcgaag	ggcagccggt	9420
ccacgaagcg	ctcgatgacc	tgcggccga	tgcggcgcatt	gttctcggt	acggcgcggc	9480
cgcggcccg	gggcccgcgc	tgcggcgcgc	ccccgcgcag	cgcggcgcgc	ctgcagagg	9540
gcaggctgag	cgcactgatg	atgcagcgt	tcaactctct	cgttagtacc	tcctgctgtt	9600
gcagcgttc	ggcaaactcg	cgcacccgt	cttcggaccc	ggcgaagcgt	tgcacgaagg	9660
cgtctagcca	gcaacagtgc	caagtgaa	tgcgcgcgtt	gtgcgtcggg	agccggaggt	9720
gccggctgac	gaggaagtga	aagttaggccc	tcttgcgcgt	ccggatggcg	cgcaggaggg	9780
tgaggcttt	gcggccggcg	cgctgcaggc	ggatgcggtc	ggccatgccc	cagggctcct	9840
gctggcagcg	gccgatgtcc	ttgagctgt	cctgcagcag	atgtccacg	ggcacgtccc	9900
gtcggcgtc	cagggtgggt	cgaccgtac	cccgccagggg	gcccacgtcgg	gcccacgtcgg	9960
ccaccacgcg	ctcgccagg	atggcctgt	gcatgcgt	cagggagtct	gagaagtcat	10020
ccagggtccag	gaaccgggtg	taggcgcgg	tgttgcgtt	gtaggagcag	ttggccagca	10080
cggaccagg	gaccacctgg	tagtggggct	ggatgcaccc	ggtgtagcgc	agtcgactgt	10140
aggcgcgcgt	gtcaaagatg	taatcggtc	agaggcgcag	caggtgcgtt	tagggccacga	10200
gcaggtgggg	cggagggtag	aggttagaggg	gccagtgttc	cgtggccgg	ttgggggggg	10260
agaggttcat	gagcatgagg	cgggtggtagc	ggtagatgaa	gcgggacatc	caggcgtatc	10320
cgacggccga	gacggaggcg	cgggtccact	ggtggggcgcg	gttccaaatg	ttgcgcaccg	10380
ggcggaaagag	ctccacgggt	taaatggatt	gccccgtgag	gcccggcag	tcgagggcgc	10440
tctgtaaaaa	agaaccgggt	gtgggttgtt	ggtgtgttgtt	agcgtatctat	ctttctttgt	10500
gatctggta	gtgaagcctg	ccaggctcca	gcagggggcg	tccggcgtct	ttcccttcctt	10560
ccctatctgg	aggtgtgtct	ctgttcttctt	tttatttca	tgtagccatg	catcccggtt	10620
tgcggcagat	gaagccgccc	gcccggcccc	tggcgcggg	ggggggcagc	cgctctcggt	10680
cgccctcgcc	gtcgtcgacg	cggccgcgcg	aggagggggg	gggcctggcg	cggtgtcggt	10740
gcgcggccgc	ccccgagcgg	cacccacggg	tgcagctcaa	gcgagaggcc	atggaggcct	10800
atgtgccgag	gcagaatgcg	ttccgcgagc	gaccgggggg	ggagggggag	gagatgaggg	10860
acctgcgggt	ccgcgcgggg	cggagatgc	agctggaccg	ggagcgtatg	ctccagcccg	10920
aggacttga	ggggcgcgt	gaggaggcgg	ggggagttag	cgcggcgcgg	gcccacatga	10980
gcgcggccag	cctggccca	gcctacgagc	agacggatcg	cgaggaggtc	aacttccaaa	11040
agaccttcaa	caacaacgt	cgcacccctgg	tgagccggga	cgaggtgacc	atgggactga	11100
tgcacctgt	ggactttgt	gaggccttcc	tgcagcacc	ccggtccccg	gcgctgaccg	11160
cgcagctgt	gtgtatcgcg	cagcactgac	gggacgagggg	catgtgttgc	gaggcgtgc	11220
tgagcctggg	cgcgcggcg	agccgtggc	tgttggaccc	gttgaacctg	ctccagacca	11280
ttgtggtgca	ggagcgggtc	atgagcctg	gcgagaaggt	ggcggccatc	aactactcg	11340
tggcgaccct	ggccaagcac	tacgcgcga	agatctccac	tttctacatg	cgccgcgtgg	11400
tgaagctgt	gtgtctggcc	gacaacctgg	gcatgtacc	caacaagcgg	ctggagcgcg	11460
tggtcagcac	ctcgccggcg	cgcgagctca	atgacaagg	agctcatgtt	ttggctccgc	11520
cggggcgtgg	ccgggggggg	cgaggaggac	ctggaggagg	aggaggac	ggaggaggcg	11580
gaggaggagg	agctggaaag	aggaggagtt	cgtccccgg	ggaccgcggc	gcgtgagggt	11640
gcagttcccg	ctgactgcga	gcgtatgggg	tgtatgtgtac	tgtatggcaac	catcccccctt	11700
tttaacaaca	acagcagcat	ggcggcgagc	tctgaagctg	ggcggccggc	ggcgggggtg	11760
agcgcggcct	ccctggcgcc	cgagcggggcg	acgcggatgc	aggcgtgtcc	ctccctggac	11820
gagccttggg	agcaggctct	gcggcgtatc	atggcgttgc	cgggccacgg	gtctcgccgc	11880
ttcgcgagcc	agccccctggc	caaccgcac	ggggccatcc	tggaggcggt	gggtccctcg	11940
cgcacgaacc	cgacgcacga	gaagggtctg	accgtggtga	acgcgtgt	ggagacctcg	12000
gccatccgcc	cggacgaggc	cggcatgtt	tacgatgcgc	tgctggagcg	ggtctcccg	12060
tacaacagcg	gcaacgtgc	gaccaacctg	gaccggctgt	cccaggacgt	gcggcagggt	12120
atgccccacg	gcgagcgctc	gagcggcaac	aacctgggca	gcctggccgc	gtgtatgc	12180
ttcatacgct	cgctgcccgc	aacgggtggag	cggggccagg	agagctacc	gggttccct	12240
agcgcgtgc	ggctgtgtgt	gagcggatgt	ccgcagacgg	agggtgtcc	ctccggggccg	12300
cacaccccttcc	tgcaggcgcc	gccgaacgg	tccaagacgg	tgaacccat	ccaggccatg	12360
gagaacctgc	ggccccctgt	ggggctgcag	gccccctgt	gggagcgcgg	gcacgtgtcc	12420
tccctgtgt	cgcccaacac	ccggctgt	ctgtctctgg	tggctccctt	cgccggaggag	12480
atgaacgtca	gcccggagctc	ctacatggg	cacctgtgt	cactctacc	cgagacgtgt	12540
gccaacttgc	atgtggacga	gcccacgtac	caggagatca	ccagcgtac	ccggggcgtt	12600
ggcgacgggg	acgacgcggc	ggggctgcag	gcccacccctca	acttcttct	gaccaacccgg	12660
cagcggccggc	tgccggccggc	gtatggcttgc	accggccagg	aggagcgtat	cctcgctac	12720
gtgcagcagg	ccgtgagcc	gtacctgtat	caggacgggg	cgacggccac	ggggccctg	12780
gacgaggggca	ggcccaaccc	ggagccacgg	ttctacgcgg	cgacccggga	cttcatcaac	12840
cgcctgtatgg	actacttcca	tcgcggggcc	gggggtggcgc	ccaactact	tatgaatgc	12900
gtcctgaacc	cccgctggct	ggccctcgag	ggcttcttca	ccggcgtgt	tgacttcccg	12960
gaggcaggacg	agggggagga	ggggccctgg	gaccccttgc	acagcgtac	ggaggggccgc	13020

ctcatgctgc ggtccgcagc ctcctcagag ccctcctctt cttcacccc cctgccccgt	13080
accaggagc cgccctcgcg gcctccacc ccggccctct cgcgctcccc gtcccgccga	13140
tctccctgc tctctctggc ctctctggg aagcgggagg gaggggaaact gtcgcctac	13200
tcgcccccca cggccacta tggctctcg tggggctcgc gcccgtccag cctggccagc	13260
ggcgccgaca gctggagtgg aacgcgcgtg ctggcccttc ccaaggatgt gaacgagcac	13320
ccaggcccg ccggccggcg ccggccggcgc gctcccgct cttcccttgg ggaggacatc	13380
gacgcataca gcaagccggct gttcacctgg cgacacgcgc cccaggagat gggctgccc	13440
gtggccagct tctcccgccg ccaccagccg cgccccgggg ccctcgaaga cgacgaggag	13500
gaggaagact ggcggccagga ccggttctt cgttctgaag cgccccggga aaacccttc	13560
cggccacatcg cccccaagggg gctgtaatgc aaaaaagcaa aaaaaaaaaa ccctcccggt	13620
ccaaactcacc acggccatgg ttgtccctgt gtggccgtca gatgaggagg atgatgccag	13680
cagccgcgc geaggggagcg tcgcctccgc cgctctacga gatgtgttg gggcttcgc	13740
tcacgagcc ttcttatgtg ccggcccggt acctggggcc caccgagggg cggAACAGCA	13800
tccgttattc acagctccg ccgtctacg ataccacaaa gatctatctg atcgataaca	13860
atgcgcgga tategcgact ctgaactacc aaaacaacca cagtgacttt ctcaccagcg	13920
tggcgagaa cagcgacttc acgcccattgg aggcgagcac gcagaccatc aacctggatg	13980
agcgctcgcg ctggggcggg gagtttaaga gcatctgac cacaacatc cccaaacgtga	14040
cccaagatcat gtcagcaac agcttccggg tgccctgtat gagcgcgcgc gataaagaga	14100
caaatcccc cacctacgag tggttcaccc tgaccctgccc cgagggcaac ttctcgac	14160
tcgcgtcat cgacctgtat aacaacgcga tcgtggagaa ctacctggcg gtggggcgcc	14220
agcaggggt caaggaggag gacatcgggg tgaagatcga caccgcgcac ttccgcctgg	14280
gctatgaccc ggagaccaag ctggcatgc ccggcagcta cacaacatg gccttcacc	14340
ccgacgttgt gtcggaccc ggctgcgcac tcgacttac cttctcccgct ctaaacaaacc	14400
tgctggcat ccgcacgcg tacccctacc aggagggtt catgctgacc tacgaggacc	14460
tggcgggggg caacatcccc gcgcgtctgg acctcaccac ctatgatcag gagaactcca	14520
gcaccatcaa gcccctgaag caggacagca agggcgcag ctaccacgtg ggccaggacc	14580
ccgaggcggg ggacacccctt acctactacc gcagctggta cttggcttac aactacgggg	14640
acccggccac gggcaccgc tcccagacgc tgctggcttc cccggacgta acctgcggag	14700
tggagcagggt ctactggacg ctggcgacc tgatgcagga cccggtgacc ttccggccca	14760
gccagacgcg gagcaactac ccgggtgttag ccacggagct actggcgtg cgctcccggt	14820
ccttctacaa caccctaggcc gtgtacttcc acgttctgca gcagggccacc aacaacaccc	14880
tggctttaa cgccttcccg gagaaccaga tcctcctgca cccggccagag tccaccatca	14940
cctccatcg cgagaacgtg ccctcgctga cggaccacgg caccgtcgcc ctgcgtaa	15000
gcatccccgg ggtgcagcg gtaaccgtca ccgcgcgcgc gcgcgcgtg tgtccctatg	15060
tgtacaagag tctcggtgt tgaccccgaa ggtgctcag cagccgaacc ttctaacgaa	15120
cagccctacc cgtcacaggg gagacagaga aaagacagcc agccccgcca tggccatcct	15180
cgtctcgccc agcaacaact ttggctgggg actgggcctg cgctccatgt acgggggcgc	15240
ccgccccctg tccccggatc accccgtat cgtccgcacgc cactaccggg ccaactgggc	15300
cagtctgaag ggacgcgtgg ccccaagcac catacgacca acggatgacc ctgtggccga	15360
cgtggtaac cgcacgcgc ggcaccccg ccgcggcgcc cgccatcgcc gacgtcgag	15420
ggccgcgcgc gtctccctcg tggccgtcac cggggaccccg gtggccgatg tggtaacgc	15480
ggtggaggcg gtagccgcgc gccgcgcgcgc ggggcgcgt tcttcgcgc tgcagaccac	15540
gggggacccc gtggcggtat tggtggcgcc ggtggaaagcg gtggcgccgc ggaggcggag	15600
cacccggcg cggcgcaggc gctccgcgc ggcacccatctg ggggtgcgc gcagccgcgc	15660
cctccgcaaa cgcacccctgt cctgagattt ttgtgttttgc tctccgtggg	15720
tgaacaagtc catccatcca tccaacatcc tggtctgttg tgcgttttgc ttcttttgc	15780
gttgcgcctt agttgacccgc gcaccgcacgc gtcggccat ggcacatctcg cggccgtgt	15840
aaaaggagct gtcgacggcg ttggcgcccg aggtgtacgg ggcgcctaag aaggaggaga	15900
aggacgtcaa agaggaggcc aaagctgacc taaaaccgtt gaaagaagccg cgcaaggccca	15960
agcgggggtt gacgcacgc gacgagggtgc tggtgtctggg caccgcgcgc accgcgcgt	16020
ggacggggcg gcgcgtgcgc gcccacccat cggccgggtgc caccgtcgcc tacgtcccg	16080
gtcttcggag gtcgacggcc accaagcgct ctgcggacga ttgtatgcg gacacggaca	16140
tcctgcagca ggcgtccctcg cgcctgaacg aatttgcata tgcaagaga gcccggcgcc	16200
agcgggggc ccccccctcg ccgacccccc cgtcccgccg cccggaccacc aacgcgtctt	16260
atgacgagggt cgtggcagac agtgcacatcc tgacgtact tggatccggg gaccgcgttca	16320
atgaggcttc ctatggcaag cggtcgtctgc tggggggatc aggagacacc gtcggcgctg	16380
tggccgtccc gtcggaggaa ggcaggaaacc acacacccag cctgcagccg ctcaccgagc	16440
ccatccccctt ggtgtccccct cgcacggccg tcaacgcgcg ggcgcgcgc gacgagccca	16500
ccgcctcaact ggtccccacc gtcgggttcc tggcccccgg ggcgcgtctg caggaggtgg	16560
tggtgagcc gcccgttcca gcacccacgc cgccccctagc cccgcggccg tccagccggc	16620
gcatcattctt ggtccgcgc cggcggggcc ggcacccaggc cgtcggtggc cgcagctca	16680

gcgcggccgc ggcgctggag	cggcgccgg	ccggccgtgcc	cctgcccaccg	gacacggagg	16740
acgacacctgg	ggagatggca	gaggctgtcg	ccgcggccga	ggtgcgtccc	16800
tctccatcat	gcccggccacc	gccacggagg	tggccctgcc	cgtacagacc	16860
ccgtggcggt	ggccaagagc	tccctgaccc	ccggccctccg	cgcgctgtatg	16920
gggtggcggt	tccagtctg	gaggcgcccc	tggtgccat	gcccgtgtc	16980
ccggccctgc	cgagcccccg	cgccgcgtgc	cccgcagggc	cgtgcgggac	17040
ggcagccccg	cacggtatcc	ctgcccgtgc	tcacggagcc	cgccccggcc	17100
cctccgtgc	cgcggcagcc	caagtctgc	aggcgcccc	cgccccgaccg	17160
ccgtgggggt	gggcaccggag	ccgggtgtgc	agtccatcac	ggtcaagcg	17220
tgaccaagca	ccatcggggt	gcagaccatc	gacgtcaccg	tgcccacccgt	17280
agcgtggca	ccaacacgc	ccggctgagg	agcgcctcg	tggcgctcca	17340
gagaccgc	cccaaggggt	gcaggtggct	ttccaaccag	cgtgcgtaccc	17400
ccaggcagg	gcccgtgac	gccccgtgc	cccccccccc	gcccgcggcc	17460
tggccggcg	cccgccgg	ttccgtgccc	tcccccagcc	cctccagccc	17520
gcgtgcgc	cgcggccccc	gagcgcctcg	gcgtcgccg	cgtaccccg	17580
agcggccccc	gcccgcagcg	gcccccccc	gccccctggct	gcccggcc	17640
tggccgggt	gcgcatacat	cccaagtcc	ccatggctcc	caccgc	17700
ggcgttgatt	tattttgg	gacactgactg	tgttgtgttc	cttaaaat	17760
cctccatgc	tgaagccaga	cgatgcgtac	ctaccgggt	cggtgc	17820
gagaccgaga	ctccgcgg	ggttccgcgt	ggccgc	tggcgatgc	17880
gtaccgcgg	ggccgcatga	gggggtgc	cctgcggcg	ctgggtccca	17940
atccatctgg	gcccaccc	gcatgc	ggtggcgatg	agtgc	18000
acggcgctc	tgtgtatgt	tgtcttccat	gtgccttcc	tccttcgtt	18060
agcagaccg	tctccatgg	ggaccta	tttccgcgt	tggctccacg	18120
cggccgtca	tgggcactt	gagcgaatc	ggcac	ccatcg	18180
agctggagca	atatctgg	cgggctgaag	agcttggta	gttctctgg	18240
aacaaggc	ggaacacgc	gacggtgac	agcgtgc	ccgcgc	18300
gtgcagggg	agataggt	gttcat	tccgggt	acgg	18360
aaccaggcc	tctcccacgc	cgtggaccgc	cgtgca	gacg	18420
agctcctcc	ccagcagc	caacagatgg	gcctcgt	accct	18480
cagacgag	gcctc	cccgaggacc	tctgc	ccccc	18540
cctcgccac	tccgc	caatccc	ggacgt	ccag	18600
aggagatcat	cattcg	gacgag	ctcc	ccgaca	18660
ccgggatccc	cgccac	gagctgc	ccgag	actgc	18720
ataagatgc	cccccc	ccgct	ccca	ccgc	18780
ccgccccggc	cccccg	cctgt	ggcgt	ccgg	18840
cggcgagt	caaagg	ccagg	gtcc	gggt	18900
aacaccatt	tggact	tgtcc	caca	gtcg	18960
cagcatgg	aaacaaca	gtctgg	aaataa	tgtt	19020
ctccgc	tgtt	tttcc	aacgg	atct	19080
cgggaa	tttcc	tttgc	gttgc	ctgt	19140
ctccgg	tttgc	tttgc	at	catcg	19200
ggagac	tttgc	tttgc	at	ccagg	19260
tgtgac	tttgc	tttgc	at	gc	19320
ca	tttgc	tttgc	at	gg	19380
catggc	tttgc	tttgc	at	gtt	19440
gtactc	tttgc	tttgc	at	gtt	19500
accgc	tttgc	tttgc	at	gtt	19560
tttgc	tttgc	tttgc	at	gtt	19620
tttgc	tttgc	tttgc	at	gtt	19680
caatata	tttgc	tttgc	at	gtt	19740
tctgc	tttgc	tttgc	at	gtt	19800
accc	tttgc	tttgc	at	gtt	19860
tttgc	tttgc	tttgc	at	gtt	19920
aaatgg	tttgc	tttgc	at	gtt	19980
tactcat	tttgc	tttgc	at	gtt	20040
gtctat	tttgc	tttgc	at	gtt	20100
acagg	tttgc	tttgc	at	gtt	20160
gtactac	tttgc	tttgc	at	gtt	20220
ggtgg	tttgc	tttgc	at	gtt	20280
ctatg	tttgc	tttgc	at	gtt	20340

aagagccaca acctggacaa aggagaatgg ggatgatggc ggaaacggag cggagcacta	20400
cctggcata ggcacaccca acgcccata gataaatctc acggccaaacc tctggcgca	20460
cttccttac agcaacgtgg cgctgtaccc gcctgacaag tacaagttt ccccccccaa	20520
cgtccccatc gaccccaaca cgcactctta tgactacatc aacaagcgc tgccccta	20580
caacctatt gataccttg tcaacatcg ggcgcgtgg tccccgatg tcatggacaa	20640
cgtcaacccc ttcaaccacc accgcaacta cggcctgcgc taccgctccc agctctggg	20700
caacggccgc tactgcaagt tccacatcca ggtgcgcga aagttcttg ccctcaagag	20760
cctgctgctc ctggccgggg cgacctacac ctacgagtgg tccttccca aggacgtca	20820
catgatcctc cagtccacgc tgggcaacga cctccgcgcg gacggggca aaatcaacat	20880
cgagagcgtc aacctctacg ccagcttcc tcccatggcc cacaacaccg cctccaccct	20940
ggaggccatg ctgcgcaacg acaccaacaa ccaaaccctt attgacttcc tctccctccgc	21000
caacatgctc tacccttaccc cggccaaacgt caccaacctg cccatctcca ttcccagccg	21060
caactggcc gcctccgcg gctggagctt cacgcggctg aagcacaacg agaccccccgc	21120
cctggctcg ccttcgacc cctactttac ctactgggc tccatccct acctggacgg	21180
gacccctac ctggccaca ccttcccg catcagcatc cagttcgact cctccgtggc	21240
ctggccggc aatgaccgccc tgctcactcc caacgagttc gaggtcaagc gcaccgtgga	21300
cggggaggc tacacgggtgg cccagaccaa catgacccaa gactggttc tggtcagat	21360
gctccccac tacaacatcg gctaccaggg ataccacctg ccagagggtt accggcaccg	21420
cacctactcc ttcttcgca actttgagcc catgtccgc caggtcccg actacccaa	21480
ccacaaagat gagtacctgg aggtgcaccc cacaaccag ttcaacagca gcccgtttgt	21540
atcccgccgc ttaccggcc gcatgcgcga gggcacca taccggccca actggcccta	21600
cccgctcata ggcgaagacg cctgtcagac cgtgacccag cgcaagtcc tctgcgaccg	21660
cacgctctgg cgcataccct tctcccttca cttcatgtcc atgggcaccc tcaccgaccc	21720
ggccagaac ctcccttacg ccaactccgc ccacggccctc gacatgaccc tccgggtcg	21780
cgcacatggat gaacccaccc tcttgtatgt tctgttcgag gtcttgcacg tctgcggcg	21840
gcaccagccg caccggggc tcatcgaggc cgttctaccc cgacacccct tctccgggg	21900
gaacgccacc acctaaggcg gagccgcga ggcattggca gcacccgggca cgagctccga	21960
gccatggcgc ggcacccatcc gctgcccgc ttcttggca ctttgcaccc gtccttcccg	22020
ggcttcttc aagagtccca ggcgtctgc gccatctgc acacggccgc cggccacacc	22080
ggagggccgc actggctggc cgtgcctgg gagccggcct cgccgacccctt ctacttctt	22140
gacccttcg gcttctccga cccggagctc gcccaggctt atgacttta gtagccggc	22200
ctgctgcga agagcccat ccagagcacc cccggccgtc gcctcagct cgtcaagagc	22260
acccagagcg tgcaggacc gcacagccgc gcctgcccac tcttctgcct cctttccctc	22320
gcccctttg cccgctaccc cgacagcccc atggctaca atcccgtcat ggacctggtg	22380
gagggcgtgg acaacgagcg gctttcgac gcccacgtcc agcccattt ccgcgcacac	22440
caggaggct gctacgcgtt cctcgctcgc cactccgcct acttccgcgc ccaccgcac	22500
gccatcatgg aacaacacaa cctgcacaaa gcgtctcgata tgcaataaaag gcttttatt	22560
gtaagtcaaa aaggcttcc ttatcctccg tgcctgggg gtgtatgtat atggggggac	22620
taggtgaacc cggacccgcg gtcggctccc ctccatcccc tcttctotca aaacaggctc	22680
tcatcgctgt cttccgttcc cacggggaaat atgggttttgc acacccatggaa ctggggcccc	22740
cacttgaact cgggcaccgt cagtggaggc cgcgtctgc tcaaggccggc ccacatctgt	22800
ttggtcagct gcaaggccag catcacatcg gggcgctga tcttgaatc acaatttttc	22860
tgggggttgc cgcgcgaccc ggggtacacc ggggtttagc actggaaacac cagcaccgc	22920
gggtgggtca cgttggccag aatcttgggg tcttccacca gctgggggtt cagcggccgc	22980
gaccgcgtca ggcgcgaagg ggtgatcttgc caggtctgc gggccagcag gggcacctgg	23040
cgccagcccc accccgcagtc gcacaccagg ggcacacggc ggtgcgtctc cgcgttgc	23100
atccgggggtt agcaggccctt ctggaaagcc ttgagctgtc cgaaggccctg ctgcgcctt	23160
gagccctccg agtagaagag gcccacggac cgcgcggaga aggtgttggg ggcgcacccc	23220
acgtcggtgc tcaacacat ggcggccgtc ttgcgtcgact gcaccacgtt gcccggccag	23280
cgggttgggg ttagtcttgc ggcgtctgggg gtcgtctgc gggcgctg cccgttctcg	23340
ctgttggat ccacatctccac cagctgtcc ttgttgcata tggcgacccc gtcaggccag	23400
tgcaggccctt cccggccgtc ggggtgtcgc cagatcacgc accccgcagg gttccactcg	23460
ggcgcttca gacccgcgcgc cttcaccacaa aagtcccgac ggaaggccggc catcaactgtc	23520
agcaggctct tttgcgtgtc gaaggctcgc tggcgtctga tcttgcgtctc gttcaggccag	23580
gcttggccccc cggccggaa gcaactccagg gtgtgtccgt cccggcagcag cgtcaggcccc	23640
ttgacatcca ctttcagggg gaccggatc tgacacagcca gatccatggc cccgttgcac	23700
ttctgtctt gacatcccg ctgcaggcgc gggccggccca cccgggggtt cgggggtcacc	23760
gggcgcgggg ggcggggcccc cttctttcc tccccatctt ccccttccct cctcgccggc	23820
cgcgcgtcg cccgtgtccgt ctcttcagcc tgcgtctctt ccccttccgt gaccaggggc	23880
ttggcaccgcg cgcgttcccg cccgtctgc acggccggag aggccgcgcg cttgcggcc	23940
cccccgccgc ggctgggggt cgcgacagga gctgtccca caatcagac cccctttcc	24000

ccgctgtcat agtcagacac gtccgaatag cggcgactca ttttgcctcc cctagatgg 24060
 agaccagcac aegcgcagcca gtgagctggg gtccctcgcg gccccgaaaa ttccggcc 24120
 accaccggcg ccacacctcgcc ccacgtcacc gccaccttca ctgcagcagc ggcagcagg 24180
 gcccacccgaa accgatgacg cggaggacac ctgtctctcg tcctcctctg cctccgcctc 24240
 cagcgagtgc ttctgtctcgcc cgctggaaaga cacagactcc gaggactcgg cggacacgg 24300
 gtcctccctcc gageccccggc gggacgagga ggagcaggag gaggactcgg cggacccgcta 24360
 catggacgacg gacgtgtcgc agcgcacccct gtcgcggcg agtaccatcc tgccggcagg 24420
 cctgcaggag gcccggggccg ggcgcggccg ggaggccct cggggccct cgggtggcg 24480
 gtcagccgc cgccctggaaag cgccctctt ctccccggc acgcccgcgc ggcggccagg 24540
 gaacggaaacc tgccggccgg accccccctt caacttctac ccgtcttca tgctggcc 24600
 ggcctggcc acctacctcc tcttcttcca caacccaaaag atccccgtca gctggccgc 24660
 caaccggccca cgagccgacg cgcactggcg gtcgcggcgt gggacccct tacctgacta 24720
 tccaaaccacc gacgagggtt acaagatctt tgagggcctg ggggacgagg agccggcctg 24780
 cgccaaaccag gacctgaaag agcgcgacag cgtgttagtc gagtcagaagc tggacaaccc 24840
 cccgcctggcg gtggtaaagc agtgcattcgc cgtcaccac ttcgcctacc cggccctggc 24900
 gtcgcctccca aaggtcatga gcacgctcat gcagaccctg ctggtgccgc ggcgagccc 24960
 actccccgac gaggggcgaga cgccctcgaa ggacccctg gtggtcagcg acgagcagct 25020
 gggccgtgg atgcacaccc cgaccccaa ggtcctggag gagcggcgca agaccgtc 25080
 cggccgcctgc atggtaacgg tgcagcttca ctgcattgcac accttcttca cctccgcga 25140
 gatggtgccgc cgccctggag agtgccttca ctacatgttc cgccagggtc acgtaagct 25200
 agctagcaag atcgccataa tggaaacttca taacctggtc tcctacttgg gcatgtc 25260
 cgaaaacagg ctcggtcagc acgtgttca ccacaccctc aagcatgagg cgagacgcga 25320
 ctacgtccgg gacaccattt acctataacctt ggcttataacc tggcagaccc ccatgggggt 25380
 ctggcagcag tgccctcgagg accgaaacctt ggcgcggctg gaaacgttcc tggctcgcc 25440
 tcgcccagacg ctgtggacgg gctttagtgc ggcactatcc ggcgcaggacc tcgcccgtt 25500
 cctttttccc accaagctcg tagagaccctt gcaagcgtcg ctccccactt ttgcagcc 25560
 gagcatgatg catgccttcc gtccttcgt ctcgagcgc tccggcattcc tgccggccgt 25620
 ctgcaacgcg ctccccctcg actttgtgcc caccgtctac cgcgagtgc cggccggcc 25680
 ctgggctcact tgcctaccc tgcgcctcgca caacttccctc atgttaccact ggcacccgc 25740
 cgaggacacc tccggcgagg gcttcttgcgt gtcgtactgc cgctgcacc tctgcgcacc 25800
 gcaccgcgtc ctcggccacca acacccctt ctcacccggcgt gtcgaaggca tcaacaccc 25860
 tgagctccag cgccccccca agcccgacgg caccctgcca cccgccttca agctgacccc 25920
 cggtctctgg acctccgcct tcctccgcca ctttgtctcc gaggactacc actccggacc 25980
 catccttcc tacgaggacg tgcctccccc ccccaagggtt gageccctccg cctgcgtcat 26040
 cacgcactcg gccattctcg cgcaatttgc tgacatcaaa aaggccagg aagagtttt 26100
 gctgacccaa gcccacggcg tctacccatcc ccccaacacc ggagaggacg tcaacaccc 26160
 cggcccggtcc accggccacc atgcccggcc tccggaggaa gcccacccgc agcagcacc 26220
 gcaccagcag cagccggcc accggcccg ccaccacccgc tccagctacg cagaccgtgt 26280
 ccgaagcggcgtcc accggccgtgc gaccgggtcc tccggcacc ctgtctctgg 26340
 cggatgtct gccagaggaa cccactcccg cgatgtctgt cgaagaagag gcttcagca 26400
 gcgagaccag cgccagctcc gaaggcagggt tgctcagttac cctcggaggaa ctggaggagg 26460
 aggaggaacc ggtcaccccg acgaggccat ccaagccctc ctacaccaac agcagcagca 26520
 gcaagagcat cagccagcgc aggaactccg tcgtccccag cgaggctcg agatggaaatc 26580
 agacatccat ccacccggagt agccagccag gtggacacc tccggccctcg gcccggcc 26640
 gtcctggcg ccgttaccgc caccatcc tctccggccct ggagacttgc gccggaggacg 26700
 gagcctgcgt gccgggtac ctacttacc accacaacat caacatccct tccaagatca 26760
 tccgttacta caaatccctt tccgggttcca gcaatcttca ggaaggccgc agcagcggcg 26820
 gcagcagaac cagccacccgt cagccaggctg agagcttacg tcttccctcc gctgtacg 26880
 atcttccacg agagccggcg cggccaggac gccccttcaaaa tcagggaccc caccctgc 26940
 tccctccacca agagctgtct gtatcaccgc gaggaggcc acgtggaaacg cacgtctcg 27000
 gacgcagaag ctcttccgtcga gaagttactgc gtcggcaggc ggcagaccgg cccgtattta 27060
 aggagccggac cctgcgtgcg gacacaccat gggaaacaa atccccccccc cgtacatgt 27120
 gtcttatccatcc caacccatctg ggcgtggccgc cggcccttcc gtcgattact ccaccgc 27180
 gaattggctc agtgcggggc cttccatgtat tggccagggtc aatgacatcc gacacacc 27240
 gaaccagatt ctcatccgc accggcccttacccggacacg ccacccccc tccaaaatcc 27300
 cccgttccctgg cccggccaccc tggccgttcca gatggacccaa cccggccaccc acctgcaccc 27360
 gcccgttaac gaaattttgg aaggcagact gactgaccc ggcgttcaat tagccgggg 27420
 cggagcccttc gcaacccagag acttatatgc cctgaccctc cggccggagg gcatccagct 27480
 caacgaggac ctacccctct cggcgacac tctccggccg gacggcatct tccagctcgg 27540
 aggccggaggc cgcttccctcc tcaacccac ccacccctac ctgacgtgc agaactcc 27600
 ctcccttccc cgcacccggcg gcatccgtcg cggaccaattt gtcggcggagt tcgtggcc 27660

ggtctacatc aacccttct ccggaccgcc cgggacccatc cccgaccagt tcatcgccaa 27720
 ctacaacatc ctaacggact ctgttagcagg ctatgactga cggtecccag ggtcagcage 27780
 ggctgcggga gtcctcgac cagcacccgc gccagtgcgc taaccgctgc tgctcgcca 27840
 gggaaaggat tcacccggag tacttttgc tcacccgcga gcacttttag gccgagtgc 27900
 tccccgactc tctgcaagaa ggccacggtc tgccgttcag cctcccaacg cgctacagcg 27960
 accgcggcca cccgcgttgg gaccgcacca tcctcaactc gtactactgc ggcctgtt 28020
 ctttcaaagt tcgctgtctc tgccgcattc ctgctctca cccttttctt ctcgacccctc 28080
 tgtgtgagct gtacaaccgc tcgttagctc agccccata cctccctcg cgtccaattt 28140
 ctgtccgaca tagaaccaga ctctgactt tactcgggt ctggctctgg ggacgatgaa 28200
 gattatgaat atgagctggc taccaacaca cccgaaacgaa acattctagg cagcatagtc 28260
 atcaacaacc agatcgggcc caagacccctg gcccctggat acttttatgc cgccatgcag 28320
 tttgtcttct ttgcctcatc catcatcgtc ctcatctct actaccggcg ctacgtgt 28380
 gccaccggccc tcactgtgc gcccagatg tggccctcg aggccgttct gggaaaacc 28440
 ttctcgccca ccgttgggt tactccccca aaacaagtca cccctgttca ctgtctgtc 28500
 cgcttcgagg agatgggtt ctactacacc acctccgtct tcatgcccgt gtggccctca 28560
 tcctctgtc caccggccatg gtccgcctgg ccaactggat agtggatcag atgcccagca 28620
 ggaaccggc cccggccgtg ccaccggccc tcacctatgt gggaccctgc gccgaggacc 28680
 acatctacga ttagccaaacc gttagggcaat acgtacagat gaagtagctc ccccttttc 28740
 ccattcccccc atttttctct attcaataaa gttgttacc tgagttcatc cacactcggt 28800
 ctgccagtgc agtctatcca tgcgccttt tccataactca catagcgcag ccgcgcacgc 28860
 ctcgcagggt gacgaaactg tcgaaatgtt acatttcgcg cttctgtcag cagcaccccg 28920
 ttatagacca gtccaccat gggaccgaag aagcagaagg gcgagctacc cgaggacttc 28980
 gatccagtct acccctatga cgtcccgac ctgcagatca atccaccctt cgtcagcggg 29040
 gacggattca accaatccgt ggacgggtt ctgtccctgc acatcgaccc gcccctcg 29100
 tttgacaaca ccagggccct caccctggcc ttccggggag gtctacagct ctcgggcaag 29160
 cagctgtcg ttgcccaccga gggctgggg cttaaccacca acccgatgg caagctgg 29220
 ctcaaagtca agtccccat caccctgacc gccgagggca tctccctgtc cctgggtccc 29280
 ggtctttcta actcagagac cggcctcgt ctgcagatca cagctccctt gcagttccag 29340
 ggcaacgccc tcactcttcc cctcgccgc ggtctccaaa acaccgttgg tggaatgggt 29400
 gtcaaactgg ggagcggtct caccacggac aacagtccagg cggtgaccgt tcaggtgg 29460
 aatggacttca agtgcacgg cgaaggacaa ctacccgtcc cccgcacccgc ccctttagtc 29520
 tcagggagcg caggcatctc tttcaactac tccagcaatg acttcgttctt agacaatgac 29580
 agtctcgtt tgaggccaaa gcccattctt gtccaccctc cgctgcagtc cacagaggac 29640
 acaatctccc tgaattattt taacgacttt tctgtggaca atggccctt cacctggct 29700
 ccaacttca aaccctacac gctgtggact gggccctcac ccacagcaaa tgtcattcta 29760
 acaaacacca ccactccaa cggcacctt ttctatgcc tgacacgtgt ggggggtta 29820
 gttttgggtt ccttgcctt gaaatcatcc atcgaccctt ctatgtatgc caaaaagggtc 29880
 aattttattt ttgatggggc aggtcgctt cagtcagact ccacttataa agggagattt 29940
 ggatttagat ccaacgacag cgtatggaa cccacagccg caggactcag tccagcctgg 30000
 ttaatgccaa gcacccctt ttagccacgc aacaccctcg gttttccctt aacatcattt 30060
 gtatacatta atcagacata tgcgtatgt gacatcaagg taaacacact ctctacaaac 30120
 ggatatagcc tagaattttt ctttcaaaaat atgagttctt ccccccctt ctccacccctt 30180
 tacggaccc tctgctacgt gccccgaagg acaactcacc gtcccccaca cggcccccctt 30240
 agtctcaggc agcgcaggca tcttttcaa ctactccagc aatgacttcg tcttagacaa 30300
 tgacagtctc agtttgaggc caaaggccat ctotgtcacc cctccgtgc agtccacaga 30360
 ggacacaatc tccctgaattt attctaactca cttttctgt gacaatggcg ccctcacctt 30420
 ggctccaact tccaaaccctt acacgctgtg gactggccgc tcacccacag caaatgtcat 30480
 tctaacaac accaccactc ccaacgcac cttttctta tgccctgacac gtgtgggtgg 30540
 gttagtttg gttccctttt ccctgaaatc atccatcgac cttacttagta tgaccaaaaa 30600
 ggtcaattttt attttttagt gggcaggtcg gttcagtc gactccactt ataaaggagg 30660
 atttgattt agatccaaacg acagcgtaat tgaacccaca gcccgcaggac tcagtcacgc 30720
 ctggtaatg ccaagcacctt ttagttatcc acgcaacacc tccgggttctt cccttaacatc 30780
 atttgatacc attaatcaga catatgtca tgcgttccatc aaggtaaaca cacttcttac 30840
 aaacgatatac agccttagaat ttaacttca aaacatgagc ttctccggcc ccttctccac 30900
 ctcctacggg accttctgtc acgtgccttcc gagtgccctag agaaccctgg cccgtcagccg 30960
 gcctccccc tcccaaggccca cccggatcacac caccggctcc atgtttctgt atgtgttctc 31020
 ctcccgccgc ttgtgcagca ccacccctt ctcgtcgac tgaggatccg tgatggacac 31080
 aaagccagga agacacatcc tcagctccgtt gggggcgtcc aacaactgtt tatgtaaagg 31140
 aaaataaaga ctcagagaaa atccaagttc atatgatttt tcttttattt attgggggaa 31200
 ttgattcagg tgggggtgtgc ataatcaca aaatcacatc agcaggtaca cacctgagac 31260
 atcagacagg ggtaaaggaca ggcgcctcagc ttctggaaaca gacatcgaa atatttaatc 31320

tgcgttgttagc taacactctt tcccaacacc atacactctt ggaggggccct ctgcctctcc 31380
tcctcccgct ccgcgtcccc ctgcccggac caccactccc cttccgtgaa ctgtgtcttc 31440
ctccccccgc gctgcgcccc gatggcctcc gccgccagct tcagccagtg ccgcaagcgc 31500
tgggcgcaggcc gcccggccac cggtctcgctc agctctgtgc aqgcggccgca caccagcact 31560
atgttaattgg catagtcggcc gtcacagtag atgacctccc cccagtgaa catgcgaac 31620
agcttcagat cacagtata catgtatctt atgtacatca gttggccgccc tcgaaacatc 31680
acaactgccta cgtaacatcac gcgactcacc ctggccaggt tcacccgcctc cctgaaccac 31740
cagaagatgc gattgtactc gcagccccgg atgatctcg ccatcaggga ggcgtatcacc 31800
acctgcggcc cgccggactc cagactggac ctttcagac aqgtggcaatg aaagttccac 31860
agcgtcgcc cccgacagcg tctccgggt gaaacatata tgctccagct ccaacccccc 31920
acacaggctg tactgcggg aaatccattc ttgtatggaa aggatgttagc gccaggggac 31980
cacaatctcc aaacaggggaa caaaacatac cgccggccgg ctgttgcgca cggcccccac 32040
cgatgoaac gtgtcacgg agcagatacg ggtggacag cggccacgt ctcatagcaa 32100
gtcaagtccg gaagtggcac ggggttcgccc accactgcta ctgctccgccc tgccacca 32160
gctccatcg ctcctccatc ctccctctgt tccatcggtc gaggtgtctgc ctccctctcc 32220
tcctgcggct gtcctcatcat gtcgtctgc ggtcatcagg aqgtaaaaaaaa ttcatggcc 32280
accgcacgca gagagaacat ggagcgcagg ggcccagggt cccggcccg ggcgtcgctc 32340
aactccccca gcaggtactc atagagatgc tcctccaaat ccacccgcaaa ccaggcatgc 32400
agaaactctt ccgttcgagg accgcccacg gtaaagacat agccctcccc cacctcacc 32460
gctgccagct gcacgcgtcc atgtcgctgg gagtacaccc gacccgggac ctggatgtac 32520
tccagcacct gatcgcttag acacccatcaca gagatgccag cctgagccag cttctatag 32580
agaggtggct gaatctttag cttgaagcag cgagccgcta ggcactcccc gcccccttgg 32640
aacaggccgg cccggtcagc catggacttc ctctacatcc ggggtcttgg ccacccatcaca 32700
aactatctgg ccaatcgctt gaccacgggt caccaggtaa gatgtatgtc cgttggcgcg 32760
aatgagaatg ctcaagaggt actcggttagc gttatcaatc acgtccccaa aggtccaaag 32820
gtcccagtttta gaagtccggt gcttcagacc gcagacacgc ccatagcaac cagtggaaa 32880
agccagcaag agatccgtgg gcacatgcac cgaagctccc gcaggaatct ccacccactc 32940
cgaggcgttag accgtgtaa gtcacacaccc cgcctccgaa gtggagcag aacgttctc 33000
gctcagccga aagaacttca ggggtggctt catatccctt tttactcaact tgtagcagc 33060
tccacacaga ccagggttgg gttggcggga ataggcagca ggggtacgta cccagtgagg 33120
gacaccttgg tggggggcag aggattgtat ccaggaagca gcaggtactg ggaaacagag 33180
accagatccc tcctctgaaa aatctcgctc agtccggacaa acacagcaaa cccagtggc 33240
acgttagacta gcacattaaa cgggttctga tgaattaccg atgcgttccc gcagacatata 33300
cgggacgtgc gcagatgaat aacagcagac cggctgtctc tgcgtctc tgcgttccc acccgcagcc 33360
ttttctaaac gtcttagttag gggctgggtt ttggacccgaa tgaagaagcg aggagaggcg 33420
gtcccgtatcc tgccacgcga caccgcggcc agcagcgtc tgcgttccc tgcgttccc 33480
gtgactccctc tcgccccgtc ggtcggtggc catgagaggg ggtgtatggg aagatggccg 33540
gtcagcgcgg agacgagtgt gtagtggcca cggctgttccc tgcgttccc tgcgttccc 33600
cctccgcgtt aacgattaac cggcccgaggaa gtcccgggaa ttcccgccag ccggctccgc 33660
cgcgacctgc gactttgacc tccacacccct tcacaccctt ctccaccaat caccggccgc 33720
tcccacgcga cgtcacgttc ccacgcgtac tcacaccctt ctccaccaat caccggccgc 34020
cgcccccaac cctctccgccc aatcaccacg ccacaaaagg ggcaataaaaa gtgtgcggta 34080
tattattgtat gatg

<210> 2
<211> 44
<212> DNA
<213> Porcine Adenovirus Type 3

<400> 2
qcggatcc tt aattaacatc atcaataata taccgcacac tttt

44

<210> 3
<211> 32
<212> DNA

<213> Porcine Adenovirus Type 3
<400> 3
cacctgcaga tacacccaca cacgtcatct cg 32
<210> 4
<211> 32
<212> DNA
<213> Porcine Adenovirus Type 3
<400> 4
cacctgcagc ctccctgagtg tgaaggagtgt cc 32
<210> 5
<211> 20
<212> DNA
<213> Porcine Adenovirus Type 3
<400> 5
gactgacgccc ggcattgcaat 20
<210> 6
<211> 27
<212> DNA
<213> Porcine Adenovirus Type 3
<400> 6
cgatatcctga cgctacgagc ggttgta 27
<210> 7
<211> 27
<212> DNA
<213> Porcine Adenovirus Type 3
<400> 7
cgatatccata cgtacagatg aagttagc 27
<210> 8
<211> 20
<212> DNA
<213> Porcine Adenovirus Type 3
<400> 8
tctgactgaa gccgaccctgc 20